



OPERATIONS
MANUAL

**University of Michigan
Human Research
Protection Program**

November 2025

Table of Contents

Acronyms/Definitions	8
PART 1: Introduction, Purpose, and Ethical Principles	10
I. MISSION AND PURPOSE OF THE HRPP	10
II. SCOPE OF HUMAN RESEARCH AT THE UNIVERSITY	10
A. Types of Human Research Conducted.....	10
B. Categories of Participants	10
III. AUTHORITY UNDER WHICH THE HRPP OPERATES	11
A. Institutional Authority.....	11
B. Limitations on Institutional Authority	11
IV. ETHICAL PRINCIPLES.....	11
V. PROTECTION FROM UNDUE INFLUENCE	12
PART 2: Organization of the HRPP	14
I. KEY ORGANIZATIONAL REPRESENTATIVES	14
II. ORGANIZATIONAL ENTITIES THAT SUPPORT THE HRPP	14
A. The Office of the Vice President for Research (OVPR).....	14
B. The U-M Medical School (UMMS) Office of Research	18
C. The Academic Units.....	18
D. The Institutional Review Boards (IRBs).....	19
E. Other Research Review and Support Units	20
F. Independence of Research Review Units and Response to Undue Influence.....	23
G. Resources.....	23
PART 3: HRPP Policy.....	24
I. INTRODUCTION.....	24
II. HRPP OPERATIONS MANUAL	24
III. IRB STANDARD OPERATING POLICIES AND PROCEDURES	24
A. IRB Authority and Guiding Principles	25
B. IRB Organization and Personnel.....	26
C. IRB Review Policies and Procedures.....	29
D. IRB Administrative Functions	45

E.	Quality Assurance and Quality Improvement	48
IV.	OTHER REVIEW UNIT STANDARD OPERATING POLICIES AND PROCEDURES.....	48
PART 4: Activities Subject to the HRPP		49
I.	DETERMINING WHAT IS AND WHAT IS NOT HUMAN SUBJECTS RESEARCH.....	49
II.	DETERMINING WHETHER RESEARCH INVOLVES HUMAN SUBJECTS	50
III.	DETERMINING WHETHER THE UNIVERSITY IS RESPONSIBLE FOR IRB OVERSIGHT OF HUMAN SUBJECTS RESEARCH	51
IV.	DETERMINING WHEN RESEARCH BEGINS AND ENDS.....	52
V.	AUTHORITY TO MAKE REGULATED/NOT REGULATED DETERMINATIONS (PER THE COMMON RULE AND FDA) AND NOTIFICATION OF DECISIONS.....	53
A.	Authority to Make Regulated/Not Regulated Determinations.....	53
B.	Common Activities	53
C.	Student Practicums and Internships	60
D.	Notification of Decisions	62
VI.	POLICY ON EXEMPT RESEARCH	62
A.	Introduction	62
B.	Categories of Eligibility for Exempt Determination	63
C.	Authority to Grant Exempt Status	64
D.	Notification and Documentation of Exempt Status.....	64
Part 5: IRB Jurisdiction, Cooperative Research, and Reliance Agreements		66
I.	INTRODUCTION.....	66
II.	WHICH UNIVERSITY OF MICHIGAN IRB	66
A.	IRBMED	66
B.	IRB-Health Sciences and Behavioral Sciences.....	67
C.	General Exceptions	68
III.	COLLABORATIVE AND MULTI-SITE RESEARCH.....	68
A.	Engagement in Human Research	69
B.	Researcher and IRB Responsibilities Concerning Engaged Performance Sites	69
C.	Researcher and IRB Responsibilities Concerning Performance Sites not Engaged in Research.....	69
D.	University Responsibilities for Multi-Site Research in Which the University is Engaged	70
IV.	UNAFFILIATED INVESTIGATORS.....	75

V. COMMUNITY BASED PARTICIPATORY RESEARCH (CBPR)	75
VI. U-M HEALTH STATEWIDE CLINICAL RESEARCH PARTNERSHIPS	76
PART 6: Roles and Responsibilities of Researchers and Research Staff	77
I. ELIGIBILITY TO PERFORM RESEARCH AT THE UNIVERSITY OF MICHIGAN	77
A. Principal Investigator	77
B. Co-Investigator.....	77
C. Subinvestigator	77
D. Faculty Advisor	78
E. Other Study Team Members.....	78
F. Students/Trainees.....	78
II. ROLES AND RESPONSIBILITIES OF RESEARCHERS AND RESEARCH STAFF FOR THE PROTECTION OF RESEARCH PARTICIPANTS	80
A. Key Responsibilities for Principal Investigators.....	80
B. Key Responsibilities for Researchers.....	82
C. Studies Regulated by the Food and Drug Administration	91
D. Other	91
PART 7: Participant Protection	92
I. HRPP PROTECTION EXTENDS TO ALL PARTICIPANTS.....	92
II. VULNERABLE PARTICIPANTS	92
A. Research Involving Pregnant Women, Fetuses, and Neonates	93
B. Research Involving Prisoners.....	94
C. Research Involving Children	95
D. Research Involving Adults with Cognitive Impairment or Otherwise Impaired Decision-making Capacity	96
III. DATA AND SAFETY MONITORING PLANS AND BOARDS	98
IV. ADVERTISING AND RECRUITMENT MATERIALS.....	100
V. PAYMENT TO RESEARCH PARTICIPANTS	101
VI. COMPENSATION FOR INJURIES	101
PART 8: Studies Regulated by the FDA and Use of Investigational Articles	103
I. INTRODUCTION AND DEFINITIONS	103
II. RESEARCH INVOLVING INDs OR IDEs	105

A.	IND Requirements for Research Involving an Investigational Drug or Biologic	105
B.	IDE Requirements for Research Involving Investigational Devices	106
C.	Off-Label Use of an FDA-Approved Drug, Biologic or Device.....	110
III.	EXPANDED ACCESS TO INVESTIGATIONAL DRUGS, BIOLOGICS AND DEVICES.....	110
A.	Expanded Access as Research versus Clinical Treatment	110
B.	The Role of the IRB.....	111
C.	Clinician Responsibilities	111
D.	Expanded Access to Investigational Drugs and Biologics for Treatment Use	111
E.	Right to Try.....	112
F.	Expanded Access to Investigational Devices	112
IV.	Expanded Access: EMERGENCY USE OF INVESTIGATIONAL ARTICLES.....	113
A.	IRB Review	113
B.	Single Use.....	114
C.	Informed Consent	114
D.	Additional Guidance For Emergency Use of Investigational Articles	114
E.	Emergency Use of Investigational Drugs and Biologics	114
F.	Emergency Use of Investigational Device.....	116
V.	PLANNED EMERGENCY RESEARCH USING INVESTIGATIONAL ARTICLES	118
VI.	HUMANITARIAN USE DEVICES (HUD) AND HUMANITARIAN DEVICE EXEMPTIONS (HDE)	118
VII.	FDA SPONSORS AND SPONSOR-INVESTIGATORS	118
A.	University/University Employee as Sponsor/Holder	118
B.	Sponsor-Investigator Responsibilities	119
C.	Clinical Trials Registration	119
D.	Noncompliance	119
E.	Manufacturer of Investigational Articles.....	120
VIII.	INVESTIGATOR AND IRB RESPONSIBILITIES FOR FDA-REGULATED RESEARCH	120
A.	Ensuring Review by Appropriate IRB	120
B.	Verification of IND or IDE Acquisition Prior to Release of Final IRB Approval	120
C.	Oversight of FDA-Regulated Research	120
D.	Investigational Article Accountability.....	121
E.	Charging for Investigational Articles	121

F. Records and Documentation.....	121
G. Required Reporting.....	122
H. ICH-E6 and Good Clinical Practice (GCP)	122
I. FDA Inspections of FDA-Regulated Research and Related Activities	123
PART 9: Conflicts of Interest and Commitment	124
I. APPLICABLE POLICIES	124
II. CONFLICTS OF INTEREST OF INVESTIGATORS AND RESEARCH STAFF	125
A. Identification and Disclosure of Outside Interests Related to Human Research	125
B. Conflict of Interest Review and Management.....	126
C. IRB Risk/Benefit Analysis.....	127
III. CONFLICTS OF INTEREST OF IRB MEMBERS, CONSULTANTS AND STAFF	128
IV. INSTITUTIONAL CONFLICTS OF INTEREST.....	128
PART 10: Sponsored Research	131
I. ROLE OF THE OFFICE OF RESEARCH AND SPONSORED PROJECTS.....	131
II. AGREEMENTS WITH SPONSORS.....	131
A. Assurance of Compliance with Human Research Protection Requirements	131
B. Medical Care For Research-Related Injury	132
C. Communication of Findings that May Affect the Safety of Human Research Participants or Their Willingness to Participate, or Influence the Conduct of the Research	132
D. Dissemination of Findings from the Research.....	133
III. FINDER FEES AND BONUS PAYMENTS.....	135
IV. ADDITIONAL INFORMATION	135
A. General Contracting Principles.....	135
B. Human Use in Research	136
PART 11: Laws, Regulations, and Standards.....	137
I. FEDERAL, LAWS, REGULATIONS, AND REQUIREMENTS COMMONLY APPLICABLE TO RESEARCH.....	137
A. Federal Laws and Regulations Applicable to Research.....	137
B. Federal Agencies and Additional Federal Requirements Applicable to Human Research	144
II. MICHIGAN STATE LAWS, REGULATIONS, AND REQUIREMENTS COMMONLY APPLICABLE TO HUMAN RESEARCH	146
A. Informed Consent and Legally Authorized Representatives.....	146

B.	Confidentiality of and Access to Research Records and Other Information	149
C.	Mandatory Disclosure Requirements	151
D.	Additional Protections for Vulnerable Populations	153
E.	Human Stem Cell Research	153
F.	Document Control and Record Retention and Destruction.....	154
G.	State Professional Licensing Laws and Institutional Credentialing Policies	155
III.	INTERNATIONAL RESEARCH	155
A.	World Medical Association (WMA)	155
B.	International Council for Harmonisation Good Clinical Practice (ICH-GCP).....	156
C.	The General Data Protection Regulation (GDPR)	156
IV.	ACCESS TO LEGAL COUNSEL.....	156
PART 12: Quality Assurance, Quality Improvement, and Research Compliance		157
I.	QUALITY ASSURANCE AND IMPROVEMENT	157
A.	Performance Measurement and Quality Assurance.....	157
B.	Quality Improvement.....	157
C.	Research Compliance Review.....	158
II.	REPORTABLE EVENTS: ADVERSE EVENTS, UNANTICIPATED PROBLEMS, NONCOMPLIANCE, SUSPENSIONS, AND TERMINATIONS OF IRB APPROVAL	158
A.	Background	158
B.	Definitions.....	159
C.	Roles and Responsibilities for Required Reporting of Reportable Event	161
III.	COMPLIANCE OVERSIGHT	162
A.	Background	163
B.	Noncompliance Review Procedures.....	163
C.	How Compliance Concerns are Brought Forward	164
D.	Receipt and Initial Handling of Allegations of Noncompliance.....	164
E.	Chair and Board Considerations and Determinations	165
F.	Actions of the HRPP Director as Delegated by the IO.....	165
G.	Response to Determinations of Noncompliance.....	166
H.	Institutional Notification and Reporting Requirements	166
Part 13: Education and Training.....		168

I. EDUCATION IN GENERAL.....	168
A. Required Education.....	168
II. TRACKING AND COMMUNICATING NEW DEVELOPMENTS.....	168
III. IRB CHAIRS, MEMBERS, AND STAFF EDUCATION.....	169
IV. RESEARCHERS AND RESEARCH STAFF EDUCATION.....	169
A. IRB Educational Activities.....	169
B. MICHR Educational Activities.....	169
C. Additional Educational Activities.....	169
V. RESEARCH PARTICIPANTS AND THEIR COMMUNITIES: ENGAGEMENT, EDUCATION, AND OUTREACH ACTIVITIES.....	170
A. General Research Communications.....	170
B. Research-Specific Communications.....	170
C. MICHR’s Community Engagement Program.....	170
D. UMHealthResearch.org.....	171
E. Additional Community Engagement Initiatives.....	171
F. Evaluation of Community Outreach Programs.....	171
HRPP OM Revision Table.....	172

Acronyms/Definitions

AE	Adverse Events
AAHRPP	Association for the Accreditation of Human Research Protection Programs
AWD	Award Management
Co-I	Co-Investigators
CITI	Collaborative Institutional Training Initiative
COC	Certificates of Confidentiality
COI	Conflict of Interest
COI/COC	Conflict of Interest/Conflict of Commitment
CRAO	Clinical Research Calendar Review & Analysis Office
CTSO	Clinical Trials Support Office
DSMB	Data and Safety Monitoring Board
DSMP	Data and Safety Monitoring Plan
DOD	Department of Defense
ED	Department of Education
EHS	U-M Environment, Health and Safety
DOE	Department of Energy
DIO	Deputy Institutional Official
EPA	Environmental Protection Agency
eRPM	eResearch Proposal Management
eRRM	eResearch Regulatory Management
FERPA	Family Educational Rights and Privacy Act
FWA	Federalwide Assurance
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act
FD&C Act	Food, Drug and Cosmetic Act
GDPR	General Data Protection Regulation
GINA	Genetic Information Nondiscrimination Act
HIPAA	Health Insurance Portability and Accountability Act
HITECH	Health Information Technology for Economic and Clinical Health Act
HPSRO	Human Pluripotent Stem Cell Research Oversight
HRPP	Human Research Protection Program
IBC	Institutional Biosafety Committee
ICOI	Institutional Conflict of Interest
ITS	Information and Technology Services
IO	Institutional Official
IRB	Institutional Review Boards
ICH GCP	International Conference on Harmonisation-Good Clinical Practice
ICMJE	International Committee of Medical Journal Editors
IDS	Investigational Drug Service
IND	Investigational New Drug Application
IRB-HSBS	IRB-Health Sciences and Behavioral Sciences

IRBMED	Medical School Institutional Review Board
MICHR	Michigan Institute for Clinical and Health Research
MICHR MIAP	Michigan Institute for Clinical and Health Research Investigator IND/IDE Assistance
NIH	National Institutes of Health
OCR	Office for Civil Rights
OHRP	Office for Human Research Protections
ORCR	Office of Research Compliance Review
ORIO	Other Reportable Information or Occurrences
ORSP	Office of Research and Sponsored Projects
OSP	Office of Science Policy
O-CTSU	Oncology Clinical Trials Support Unit
OVPR	Office of the Vice President for Research
PI	Principal Investigator
PEERRS	Program for Education and Evaluation in Responsible Research and Scholarship
PAF	Proposal Approval Form
PRC	Protocol Review Committee
RAD	Research Associate Dean
RSS	Radiation Safety Services
sIRB	Single Institutional Review Board
SOP	Standard Operating Procedure
SPG	Standard Practice Guide
UaP	Unanticipated Problem
U-M	University of Michigan
UMMS	U-M Medical School
UMRCC	University of Michigan Rogel Cancer Center
VPR	Vice President for Research
WMA	World Medical Association

PART 1: Introduction, Purpose, and Ethical Principles

Describes the scope of human research conducted at the University of Michigan (U-M), the mission and purpose of the U-M Human Research Protection Program (HRPP), and the authority and ethical principles under which the HRPP operates. For a description of the roles and responsibilities of HRPP Leadership see [Part 2](#).

I. MISSION AND PURPOSE OF THE HRPP

The mission of the HRPP is to protect the rights and welfare of research participants in research under the U-M oversight. This includes research conducted at the U-M or elsewhere by University faculty, staff, students, trainees, and others when the U-M agrees to serve as the IRB of record for multi-site research. The HRPP's goals are to promote compliance with relevant legal requirements and ethical standards at all levels, while also addressing the needs and concerns of researchers and enhancing support for their endeavors.

The Vice President for Research (VPR), who serves as the Institutional Official (IO) for human research oversight, has established the HRPP as an integrated system of research leadership, administration, and oversight functions. The oversight component includes education and training; quality assurance and compliance; research review units, including institutional review boards (IRBs); and other organizations responsible for protecting research participants and promoting excellence in all aspects of human research. See [Part 4](#) of this OM for determining what is and what is not human research.

Ensuring the success of the HRPP is a joint responsibility. The program is directed by The Office of the Vice President for Research (OVPR), but its implementation requires the active participation and collaboration of many stakeholders including all of the University's executive officers, including the Provost, Chief Financial Officer, Executive Vice President for Medical Affairs, the Chancellors, and leadership of the schools and colleges whose faculty, staff, students, and trainees conduct human research.

II. SCOPE OF HUMAN RESEARCH AT THE UNIVERSITY

A. Types of Human Research Conducted

The U-M supports a broad range of human research including, but not limited to biomedical research and clinical trials, education and behavioral research, research with vulnerable populations, and genomic research.

B. Categories of Participants

Participants in research conducted by the faculty, staff, students, and trainees at the U-M include a diverse group of individuals from the local community, throughout the United States and the world. They reflect the communities in which research is conducted and include individuals who represent different racial, ethnic, and cultural backgrounds and who may speak languages other than English. Some participants are healthy adults or are individuals with disease and health conditions, while others are members of specifically identified and protected vulnerable research participant populations (such as children, pregnant

women, and prisoners) and other groups of individuals entitled to special safeguards (such as those who are decisionally impaired or economically or educationally disadvantaged).

III. AUTHORITY UNDER WHICH THE HRPP OPERATES

A. Institutional Authority

The [Bylaws of the Board of Regents of the University of Michigan](#) assign to the VPR general executive responsibility for the research programs of the University. As the University's IO, the VPR has established and maintains a [federalwide assurance](#) (FWA) between the University and the United States Department of Health and Human Services (HHS), through its [Office for Human Research Protections](#) (OHRP). Through that assurance, the University pledges to comply with federal regulations for all federally supported research. In addition, the VPR has established and maintains a Department of Defense (DoD) Addendum to the FWA. By signing this addendum, the University agrees to the special terms and conditions for IRB review of projects funded by the DoD.

The IO, on behalf of the University, has established IRBs and grants the IRBs authority to approve, require modifications to secure approval and disapprove all research activities overseen and conducted by the University. The University has established eight IRBs in two operational offices. See [Part 5](#) of this OM for IRB Jurisdiction. They function in coordination with University officials and other review committees but at all times maintain their independence. Individuals responsible for University business development are prohibited from serving as members or ex-officio members of the IRBs or carrying out day-to-day operations of the review process.

B. Limitations on Institutional Authority

All human research conducted by the University must be approved by an IRB or granted an exemption as specified in this Operations Manual and/or IRB standard operating procedures. Research reviewed and approved by a University IRB or external IRB may be subject to further review and disapproval by other review bodies or officials (including the IO); however, no person or organization may override an IRB's disapproval determination.

IV. ETHICAL PRINCIPLES

The VPR has issued [Standard Practice Guide \(SPG\) 303.05](#). This document establishes the University policy that all human research, regardless of funding source, will be guided by the ethical principles outlined in the report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research entitled *Ethical Principles and Guidelines for the Protection of Human Subjects Research* (the "[Belmont Report](#)") and will comply with applicable University policies and federal, state, and local laws and regulations.

The Belmont principles and their application to human research are summarized in the table below.

Table 1: Ethical principles guiding human research at the University of Michigan.

PRINCIPLE	APPLICATION
Respect for Persons	Respect for persons requires that protocols (including the informed consent process) be designed to promote personal capacity to consider alternatives, make choices, and act without undue influence or interference from others. The principle is reflected in federal regulations and University policy through requirements that legally effective informed consent be sought and obtained unless specific requirements for waiver of informed consent are met and appropriately documented; and that subjects with diminished capacity and others who are vulnerable to coercion or undue influence receive special protection or consideration.
Beneficence	Beneficence entails an obligation to protect individuals from harm. The principle can be expressed in two general rules: (1) do no harm; and (2) protect from harm by maximizing possible benefits and minimizing possible risks of harm. It is reflected in federal regulations and University policy through a requirement that principal investigators design and IRBs approve protocols only under circumstances where the benefits to the subjects and the importance of the knowledge to be gained justify the risks to the subjects sufficiently to warrant a decision to allow the subjects to accept those risks.
Justice	Justice requires fairness in the distribution of burdens and benefits. The principle is often expressed in terms of treating persons of similar circumstances or characteristics similarly. It is reflected in federal regulations and University policy through requirements that the selection of subjects is equitable and is representative of the group(s) that is intended to benefit from the research.

Additional ethical codes and guidelines, including ethical codes of professional societies, may also govern University research.

V. PROTECTION FROM UNDUE INFLUENCE

The University will investigate and resolve any reported attempt to inappropriately pressure (i.e., to exercise undue influence upon) an IRB or other HRPP unit administrator, member, or staff representative because of that individual’s role. “Undue influence” refers to interference with the normal functioning and decision-making of an IRB or other HRPP unit, or to influence an IRB or other HRPP faculty or staff member, outside of established processes or through normal and accepted methods, to secure a particular determination or outcome.

Any attempt to exercise undue influence over the IRB or any other HRPP unit should be reported as follows:

- An IRB or HRPP unit staff or faculty member who experiences undue influence should first report the occurrence to the IRB chair or HRPP unit director, who will attempt to mediate or resolve the

concern, in consultation with the HRPP Director, the Deputy Institutional Official (DIO) or the IO as necessary or appropriate.

- An IRB chair or unit director who experiences undue influence should first report the occurrence to the HRPP Director, who will attempt to mediate or resolve the concern, in consultation with the DIO and/or IO as necessary or appropriate.
- Any individual who believes that undue influence is being exerted by an official in one of the above reporting chains, or who believes that the undue influence has not been resolved in an appropriate or timely manner, should report to the next higher level in the reporting chain and ultimately to the OVPR and General Counsel.
- In addition, individuals who wish to report an incident of undue influence may report through the [Compliance Hotline](#), which allows the reporters to remain anonymous if they choose.

Resolution of incidents involving undue influence depends on the circumstances but may include disciplinary actions following University standard procedures addressing non-compliance with policy or procedures as described in the [Faculty Handbook](#) and [OM Part 12](#).

PART 2: Organization of the HRPP

Describes the organization of the U-M Human Research Protection Program (HRPP) and the roles and responsibilities of the various entities and units that guide and support the program. This section also describes the general allocation of resources to the various units in the HRPP.

I. KEY ORGANIZATIONAL REPRESENTATIVES

An [organizational chart](#) identifies key officials and units in the HRPP and illustrates their relationships with one another.

II. ORGANIZATIONAL ENTITIES THAT SUPPORT THE HRPP

Numerous organizational entities, listed below, contribute to the operation of the University's HRPP. In addition to these entities, other key executive and administrative offices – including the Provost, the Executive Vice President for Medical Affairs, the Chancellors of the Flint and Dearborn campuses, and the General Counsel – all help contribute to the operation of the HRPP. The decentralized organization and shared support system of the HRPP contributes to the program's success by promoting local review and accountability and expert analysis of research proposals and IRB applications. The inherent complexity is managed through several mechanisms, including convened standing coordinating committees, overlapping membership on local committees, and collaborative associations among individuals with HRPP responsibilities.

A. The Office of the Vice President for Research (OVPR)

The mission of [OVPR](#) is to catalyze, support, and safeguard U-M research and scholarship activity. OVPR promotes the integration of the research, education, and service missions of the University; facilitates the sharing of knowledge and expertise with the larger society; and promotes responsibility in the conduct and administration of these activities. To this end, OVPR establishes the institution's research policies, administers several freestanding research units, assists in the creation and incubation of new initiatives, and provides a voice for U-M scholars and scientists in communicating with the public, private industry, and government.

As the University's Institutional Official (IO), the Vice President for Research (VPR) sets the tone for an institutional culture of respect for research participants and bears ultimate accountability for the proper conduct of human research at the University. The VPR's primary activities as IO are described further below.

1. Policy Implementation, Communication, and Education

The IO reviews and approves (or delegates approval authority) all HRPP policies and represents the HRPP to internal and external stakeholders. In this capacity, the IO:

- Defines the scope of the [FWA](#) and obligates the University to comply with its terms;
- Retains authority to make exemption determinations in specific instances or for defined

categories of activities and to make categorical determinations of what does or does not constitute human research. See [Part 4](#) of this OM for additional details;

- Makes or delegates authority to make decisions on IRB reliance agreements, collaborating institution agreements, and individual investigator agreements;
- Is responsible for all budgets within OVPR, including its various administrative and research units; and
- Manages all OVPR units.

The IO promotes communication among research administrators, deans, department chairs, researchers, clinical care staff, research participants, and other stakeholders to maintain a high level of awareness regarding the ethical conduct of research and the safeguarding of the rights and welfare of participants. See [Part 13](#) of this OM for additional details.

Note substantive changes to the OM are approved by the IO in coordination with the DIO and HRPP Director. Minor or non-substantive changes to the OM, such as wording changes or updates, are approved by the DIO in coordination with the HRPP Director.

2. Recordkeeping and Reporting

The IO establishes policies and procedures requiring that IRB records are maintained as required by applicable laws and regulations and that they are accessible to authorized regulators and sponsors. Records for projects that rely on a non-U-M IRB for review and oversight are maintained by the non-U-M IRB in accordance with the [U-M IRB Authorization Agreement process](#).

The IO also directs the establishment of policies and procedures on reporting requirements. See [Part 6](#) of this OM for the Principal Investigator's (PIs) reporting responsibilities to the IRBs, University officials, federal regulators, and private sponsors of the PI. See [Part 12](#) of this OM for the written procedures regarding the reporting process for reportable events to the IRB, appropriate institutional officials, the head (or designee) of any federal department or agency conducting or supporting the research, and any applicable regulatory bodies.

3. Monitoring and Oversight

The IO designates IRBs to review research covered by the FWA, as well as other research subject to the HRPP, and delegates additional authority to the IRBs and other units to act on other related issues. In collaboration with other University executive officers, the IO provides sufficient resources, space, and staff to support the IRBs' review, monitoring, and recordkeeping duties.

The IO ensures that appropriate oversight mechanisms are implemented to promote compliance with applicable laws, regulations, and IRB determinations. For collaborative and multi-site research projects that include more than one performance site, the IO ensures that when sharing oversight with another organization, the rights and welfare of research participants are protected and that when applicable, IRB review arrangements are documented in writing consistent with OHRP, FDA, and other applicable regulations and guidance. See [Part 5](#) of this OM for additional information on , single IRB arrangements, when applicable, and the University's policy on non-U-M researchers collaborating on U-M projects.

4. Organization

Multiple individuals, units, and functions within OVPR assist in the development, implementation, and enforcement of University policies and procedures for the HRPP.

a. Leadership of the HRPP

Together, the Associate Vice President – Clinical and Human Subjects Research serving as the Deputy Institutional Official (DIO) and the Assistant Vice President for Research-Human Research Protection Program serving as the HRPP Director, advise the IO on all aspects of human research, including policy changes.

The DIO has been delegated the following responsibilities:

- Serving as the designated contact person for OHRP under the University's FWA;
- Working with the HRPP Director, the HRPP Associate Director, and the IRB Directors to draft institutional policies for effective and efficient administration of the HRPP;
- Coordinating policy implementation initiatives as necessary and appropriate;
- Promoting consistency and addressing identified inconsistencies among various University policies, procedures, and guidance affecting research with participants;
- Serving as a liaison between the HRPP and individual review units, organizations, and functions, including the IRBs, the Institutional Biosafety Committee, the Department of Environment, Health & Safety, the Conflict of Interest Review Committees, the Radiation Policy Committee, the General Counsel's Office, campus and health system compliance structures, and academic misconduct investigations and proceedings;
- Performing other tasks as delegated by the IO.

Reporting to the DIO, the HRPP Director oversees the HRPP administrative functions.

Responsibilities include oversight or delegation of the following:

- Coordinating and oversight of IRB functions;
- Signing Certificates of Confidentiality on behalf of the University;
- Signing or approving IRB reliance agreements, collaborating institution agreements, and individual investigator agreements;
- Assisting with the review and reporting of cases involving noncompliance;
- Developing and maintaining the U-M HRPP Operations Manual and the IRB Standard Operating procedures (SOPs);
- Facilitating appropriate content and functionality of the human research application system;
- Facilitating communication and education within the HRPP and to the research community including websites and newsletters; and
- Performing other tasks, as delegated by the IO or the DIO.

b. Office of Research and Sponsored Projects

The [Office of Research and Sponsored Projects \(ORSP\)](#) assists faculty and staff members in all aspects of externally sponsored research projects and other scholarly activities, which includes the identification of a potential sponsor, preparation of a proposal, identification, and resolution of various administrative, contractual, and regulatory compliance issues, negotiation of funding agreements, and submission of the documents required to close out the project.

ORSP submits sponsored research proposals to external funding entities, negotiates the terms of those agreements consistent with the mission and goals of the HRPP and law and policy applicable to the University, and arranges for the establishment of appropriate financial accounts when a project is awarded. ORSP obtains and records information about the proposal and project activity, including whether a research proposal involves human research and the status of the IRB approval, through the campus-wide [eResearch Proposal Management \(eRPM\) system](#) that utilizes a proposal approval form (PAF) and award management (AWD) functionality to provide a system level check for appropriate compliance approvals prior to award activation. See [Part 10](#) of this OM for more details on sponsored research.

ORSP project representatives monitor any proposal or award that is flagged for conflict of interest review and will not establish financial accounts without confirmation of review and approval by the appropriate [Conflict of Interest Review Committee](#) and by the [Board of Regents](#), if required. See [Part 9](#) of this OM for additional information on conflicts of interest procedures.

c. Office of Research Compliance Review

The mission of the [Office of Research Compliance Review \(ORCR\)](#) is to assess the conduct of research, including the protection of participants, by reviewing compliance with laws, regulations, and University policies. This mission is fulfilled by initiating and conducting routine (not-for-cause) reviews of research protocols, for-cause reviews of allegations and instances of noncompliance; initiating periodic reviews of HRPP subsystems, including the IRBs; and assisting with the coordination of the AAHRPP accreditation activities.

d. Coordinated Services and Practices

[Coordinated Services and Practices](#) is a unit housed within the HRPP. CSP provides support to the University IRBs in developing centrally coordinated services and practices including the oversight for the operations of single IRB activities and harmonization of IRB guidance and workflow procedures.

e. eResearch

To support the management of research information at the University, OVPR and Information and Technology Services (ITS) Enterprise Application Services maintain an electronic administrative system called [eResearch](#). eResearch supports efforts of faculty, staff, and students to comply with federal, state, and University requirements aimed at ensuring the safety and privacy of persons who volunteer to participate in research studies. eResearch also supports the administrative functions involved with conflict of interest management, grants, and sponsored projects. Updates are made to eResearch with input from the leadership and administrative and academic units that support the HRPP. Requested changes are prioritized and approved via eResearch governing

committees. Final authority to implement changes for the Regulatory Management system of eResearch belongs to the Assistant Vice President for Research — Regulatory and Compliance Oversight and operationalization is delegated to the ITS Product Manager for eResearch Regulatory Management.

f. Research Associate Deans

The [Research Associate Deans \(RADs\)](#) of the schools and colleges generally gather monthly at meetings convened by the Vice President for Research. The meetings facilitate communication between central administration and faculty through their RADs as well as providing a forum for RADs to share initiatives and experiences in the development, conduct, and administration of research in their own units. The RADs may review and provide feedback concerning HRPP policy and procedure initiatives.

B. The U-M Medical School (UMMS) Office of Research

The Medical School Office of Research works to facilitate and impact key research functions and processes at the Medical School. The units of the UMMS Office of Research include the:

- Biomedical Research Core Facilities
- Central Biorepository
- Calendar Review & Analysis Office
- Clinical Trials Support Office
- Data Office for Clinical & Translational Research
- Fast Forward Medical Innovation
- Grant Services & Analysis
- IRBMED
- Michigan Institute for Clinical & Health Research
- Unit for Laboratory Animal Medicine

C. The Academic Units

The University's schools, colleges, departments, and other academic units whose appointed faculty and staff conduct research with participants are responsible for ensuring that sufficient resources (including facilities and equipment, personnel, regulatory support, and other financial and non-financial support) are allocated to sponsored and non-sponsored research activities to protect participants engaging in those activities. For sponsored activities, the academic units certify compliance with this requirement through eRPM.

In addition, the academic units are permitted and encouraged to develop, implement, and enforce local policies and procedures governing University research, so long as those policies are consistent with the requirements of this OM and applicable University policies. Academic unit policies and procedures may address issues such as the following:

- Mentoring programs for new faculty and continuing education for experienced faculty, to ensure familiarity with best research practices and with applicable regulatory and institutional requirements;
- Administrative requirements designed to ensure that limited financial, facility, staff, and participant resources are appropriately allocated to individual projects or groups of projects; and
- Substantive peer review requirements designed to promote sound research design and scientific integrity in any University research.

D. The Institutional Review Boards (IRBs)

All sponsored projects must be approved both at the local academic unit level and through ORSP and this is accomplished through [eResearch](#). In addition, through eResearch, the academic units may require that any individual projects or categories of projects, regardless of sponsorship, be approved at the unit level before they are initiated.

IRBs may withhold approvals pending confirmation of approval or receipt of additional information (or both) from the academic unit and from other review units at the University or at other performance sites.

Each of the University's IRBs sits within an administrative structure that provides the resources for and oversees the general operation of the IRB. The Medical School provides resources and administrative support for [IRBMED](#). OVPR, UM-Flint, and UM-Dearborn provide resources and administrative support for the [IRB Health Sciences and Behavioral Sciences](#).

The business functions of the IRBs are separated from the ethics review function to avoid conflicts of interest and competing business interests. Individuals or offices responsible for administrative, business development, or financial oversight in support of the research enterprise are not involved in the day-to-day operations of the IRB review process and these individuals are not permitted to serve as members of the IRB.

1. Authority of the University of Michigan Institutional Review Boards

Except for research that is specifically exempted in accordance with applicable laws and regulations and [Part 4](#) of this OM, the University's IRBs review and monitor all University research involving participants, regardless of funding source, including cooperative research as delineated by IRB reliance agreements. The specific types of research with participants that must also be reviewed and approved by other departments, divisions, or units of the University are described in section E below. Depending on the nature and scope of a project, a University IRB may withhold its approval pending confirmation of approval by, or receipt of additional information from, any of these units or from review units at other performance sites. Further, the University IRBs have the right to observe or have a third party observe the consent process and the conduct of research.

Each University IRB also has the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to participants or others. Any suspension or termination of approval must be imposed in compliance with the IRB's SOPs and, at a minimum, include a statement of the reasons

for the IRB's action. Promptly following any such suspension or termination, the IRB must report its action to the IO or DIO, or their designee, who then follows the procedures outlined in [Part 12, Section III](#) of this OM.

2. Primary Responsibility to Human Participants

Each IRB's first and most important function is to protect the rights and welfare of human research participants. The safeguarding of participant rights and welfare must at all times take precedence over the goals and requirements of any research endeavor overseen by the IRB. IRB members and staff, as well as researchers submitting applications to the IRB, all must be informed of and understand this obligation.

3. Standard Operating Procedures (SOPs) and Guidance

The University's IRBs have developed and documented a set of SOPs, together with related guidance, that are consistent with the requirements of [Part 3](#) of this OM. When necessary, each IRB tailors its activities to the specific type of research it oversees and provides targeted training and education for IRB members and staff, and the research community.

IRB and HRPP leadership are responsible for the development, maintenance, review, and updating of IRB SOPs. IRB SOPs and any substantive amendments may be implemented only upon the approval as outlined in the IRB SOPs.

E. Other Research Review and Support Units

1. Michigan Institute for Clinical and Health Research

The [Michigan Institute for Clinical and Health Research \(MICHR\)](#) is an institution-wide institute providing education, resources, infrastructure, consultation, and guidance in the development and conduct of clinical and translational research at the University of Michigan. MICHR is the recipient of the NIH-funded Clinical and Translational Sciences Award (CTSA).

2. Clinical Trials Support Office (CTSO)

The [Clinical Trials Support Office \(CTSO\)](#) is part of the Medical School Office of Research and supports all NIH-defined clinical trials and clinical research studies that have a billing calendar, as required by Michigan Medicine.

3. Rogel Cancer Center

a. Oncology Clinical Trials Support Unit (O-CTSU)

The [Oncology Clinical Trials Support Unit \(O-CTSU\)](#), a dedicated unit of the CTSO, serves as the centralized core facility of all clinical research trials conducted by researchers at the University of Michigan Rogel Cancer Center (UMRCC). The O-CTSU offers a broad range of support services including regulatory and data management services.

b. Protocol Review Committee

The [Protocol Review Committee \(PRC\)](#) is a multidisciplinary committee that provides peer review of

the scientific merit, prioritization, and progress of all cancer clinical research.

c. Tissue Procurement Service

The [Tissue Procurement Service](#) ensures that relevant ethical and administrative guidelines are followed in the procurement and distribution of human tissue for research purposes.

4. Conflict of Interest Committees

The [OVPR Conflict of Interest Committee](#) addresses potential conflicts of interest in research performed by faculty, staff, and trainees affiliated with non UMMS schools or colleges.

The [UMMS Conflict of Interest Review Board](#) (U-M login required for link) addresses potential conflicts of interest in research performed by Medical School faculty, staff, and trainees, and their affiliated co-investigators in other schools and colleges as appropriate.

The [Institutional Conflict of Interest Committee](#) reviews potential conflicts of interest in research involving financial interests of the University (e.g., investments held by the University in a company) or an executive officer, dean, or an institute or center director with day-to-day responsibility for the supervision of faculty and staff participating in research conducted at or under the auspices of the University.

5. Clinical Engineering (CE)

Clinical Engineering is responsible for the maintenance and care of all medical equipment used in the patient care and clinical setting at Michigan Medicine, with certain exceptions for specialized devices.

6. Institutional Biosafety Committee

The [Institutional Biosafety Committee \(IBC\)](#) oversees all recombinant DNA and synthetic nucleic acid molecule research at the University of Michigan, including human gene transfer clinical trials. The IBC also oversees research with other potentially hazardous biological agents including infectious agents (e.g., viruses, bacteria), biological toxins, human-derived materials, and certain animal-derived materials. The BSL3 subcommittee of the IBC reviews research with select agents and toxins regulated by HHS and the U.S. Department of Agriculture (USDA), and serves as the Institutional Review Entity required for identification and review of life sciences Dual Use Research of Concern (DURC).

7. Michigan Medicine Research Pharmacy

All investigational drug protocols conducted by Medical School faculty or using Michigan Medicine facilities must be reviewed by the [Michigan Medicine Research Pharmacy](#) (U-M level 2 login required for link) before submission to IRBMED. The Research Pharmacy is responsible for:

- a. ensuring proper storage, handling, and dispensing of all investigational drugs in compliance with institutional policies and regulations;
- b. maintaining accurate investigational drug accountability records, including receipt, dispensation, and final disposition;
- c. dispensing investigational drugs only for protocols approved by IRBMED and in accordance

with protocol requirements; and

- d. providing relevant information on investigational drugs to healthcare personnel responsible for patient care.

Requests for a waiver of Research Pharmacy oversight should be made only for patient safety or if research or drug integrity will be compromised by adherence to policy, or when studies involve an investigational agent from a class of drugs not routinely managed by the Department of Pharmacy Services (e.g., certain cellular therapies). Waiver requests remain contingent on the principal investigator having an alternate plan for assuring compliance with all requirements related to investigational drug management.

8. Radiation Safety Service

The U-M Environment, Health & Safety (EHS) [Radiation Safety Service \(RSS\)](#) oversees the use of radioactive materials and radiation-producing devices at the University, and promotes radiological safety through safety training, professional guidance, and technical support, in accordance with federal and state regulations and the University's Byproduct Material License.

9. Research Centers

Many other centers distribute resources or provide other support on a merit basis, or perform functions such as peer review and research oversight, which include but are not limited to, [OVPR](#), the [Michigan Alzheimer's Disease Center](#), the [Institute for Research on Women and Gender](#), and the [Caswell Diabetes Institute](#).

10. Human Pluripotent Stem Cell Research Oversight Committee (HPSCRO)

The [HPSCRO Committee](#) reviews research experiments with human pluripotent stem cells that:

- Include derivation of hESC lines and/or human iPSC lines.
- Use already-derived hESC and/or human iPSC lines.
- Are designed or expected to yield gametes (oocytes or sperm).
- Have the intent to (or potential for) integrate the stem cells into the central nervous system of animals.

The committee's work complements review functions of the U-M IRBs and the Institutional Animal Care & Use Committee (IACUC) by providing an additional level of coordination and review warranted by the complex issues raised by human pluripotent stem cell research.

11. Additional Units Supporting the HRPP

A variety of additional administrative units and functions contribute to the operation of the University's HRPP. Examples include:

- Biomedical Research Council
- [Research Administrators' Network](#)
- [Center for Statistical Consultation and Research](#)

- [Michigan Medicine Corporate Compliance](#)
- IRBMED Leadership

F. Independence of Research Review Units and Response to Undue Influence

Although the research review units, and particularly the IRBs, are accountable to the IO for appropriate conduct of research and for protecting research participants, they maintain their independence by formulating their policies and procedures and, in some cases, through independent funding and oversight mechanisms. Specific procedures for reporting and responding to allegations of noncompliance, including exercise of undue influence, are described in [Part 1](#) and [Part 12](#) of this OM. In addition, all faculty, staff, and trainees have access to advice and assistance outside of their units and traditional lines of supervision through the Provost's Office, the Office of the Vice President and General Counsel, and other central University offices.

G. Resources

The University maintains adequate resources for support of the operations of the HRPP, including but not limited to resources such as space and personnel, to meet Association for the Accreditation of Human Research Protection Programs (AAHRPP) accreditation standards. The Associate Vice President for Research-Clinical and Human Subjects works in coordination with the Assistant Vice President for Research-Human Research Protection Program, to identify resource needs for core HRPP units, including the IRBs, ORCR, and HRPP-wide efforts related to education and training and quality assurance and improvement, and makes recommendations to the Office for the Vice President for Research and the Medical School Office of Research for additional resource needs as part of the annual budget review processes. Resources for the HRPP components are provided through the annual budget review processes in the administrative units in which the components reside. The Associate Vice President for Research-Clinical and Human Subjects and the Assistant Vice President for Research-Human Research Protection Program collaborate with other institutional offices, committees, and units (e.g., Office of General Counsel, Conflict of Interest Committees, MICH (Michigan Institute for Clinical and Health Research)) to identify and make recommendations regarding resource needs in HRPP components to further support HRPP policies, procedures, community outreach, and quality assurance activities.

The need for study-specific resources is evaluated at the local level. Researchers and sponsoring units are responsible for ensuring that sufficient resources are allocated to all projects, whether sponsored or investigator-initiated. See [Part 3](#) of this OM for details on study-specific resources required for IRB approval.

The need for incremental or off-cycle resources may emerge as a result of special or unusual demands on the offices, either as reported by quality assurance/review activities, or by Executive Officer deliberations.

Requests for incremental or off-cycle resources may be made to the responsible unit at any time, to the IO, or through the IO to the Provost.

PART 3: HRPP Policy

Describes how the University of Michigan (U-M) Human Research Protection Program (HRPP) policies are developed, approved, and implemented, and articulates minimum requirements for IRB standard operating policies and procedures.

I. INTRODUCTION

Rulemaking within the U-M is divided three ways: (i) the [Bylaws of the Board of Regents](#); (ii) rules initiated by University authorities that become effective only upon approval by the Board of Regents (Regents Policies); and (iii) rules adopted by subordinate University authorities, under delegated legislative powers, that become effective as provided by such subordinate authorities.

HRPP policies fall within the third class of rulemaking. In [Standard Practice Guide \(SPG\) 303.05](#), the University has delegated to the VPR general executive responsibility for the research programs of the University and, in that role, the responsibility for implementing the HRPP, including the legislative powers to adopt and enforce HRPP policy and procedures.

II. HRPP OPERATIONS MANUAL

The HRPP Operations Manual (OM) is the primary location for compiling, organizing, integrating, and pointing to the rules, policies, practices, and guidance encompassing the University's HRPP. The Institutional Official (IO) has approved the OM and approves each substantial modification or amendment to it. The HRPP maintains records of such approvals.

At least once every five years, typically in conjunction with the Association for the Accreditation of Human Research Protection Programs (AAHRPP) re-accreditation cycle, the HRPP initiates a comprehensive review of the OM, IRB SOPs, and supporting HRPP/IRB guidance documents. Revisions may be made at any time, but are required when there are changes in law, ethical standards, institutional policy, quality assurance activities, or other considerations. Non-substantive revisions such as correction of typographical errors, corrections of website links, or incorporating new or revised laws or regulations may be made upon approval of the HRPP Director and communicated to the IO and DIO, as necessary, by the HRPP Director.

III. IRB STANDARD OPERATING POLICIES AND PROCEDURES

The Institutional Review Boards (IRBs) designated by the University to review and monitor human research under the University's [Federalwide Assurance \(FWA\)](#) must adopt Standard Operating Procedures (SOPs). The IRBs may issue additional guidance as necessary to ensure appropriate review and oversight of University research and to facilitate compliance by researchers and research staff with applicable laws and regulations and with University policy, including IRB requirements.

The SOPs must be consistent with this OM, other central institutional policies (e.g., Standard Practice Guides (SPGs)), and applicable laws and regulations. IRBs are free, however, to implement and enforce additional or more restrictive policies and procedures. SOPs may incorporate, by reference, elements of this OM, as appropriate. SOPs, however, are intended to be stand-alone descriptions of the actual

procedures used by the IRB.

1. SOP Development, Review, Update, and Maintenance

The SOPs must describe development, review, update, and maintenance processes, including the following activities:

- Responding to requests from the HRPP for new local policy development;
- Considering input from IRB chairs, members, and staff, as well as researchers and other stakeholders;
- Soliciting and considering input from standing and ad hoc research and advisory councils;
- Reviewing SOPs at regular intervals, generally in conjunction with accreditation activities or revision of this OM; and
- Revising in response to comments by the IRB Leadership Council and the IO or designee.

When writing SOPs, IRBs should review Sections A through E, below, and include all applicable provisions.

2. SOP Approval Process

All IRB SOPs, including substantive revisions, must be reviewed and approved before implementation as outlined in that IRB's SOPs and according to the procedures of the office providing resources and administrative oversight of that IRB, as well as the HRPP Director and DIO.

The HRPP Director may, at the request of the IRB and their discretion, review and approve for implementation individual components as they are developed. IRBs may issue additional guidance without prior approval, but guidance must be revised or rescinded if directed by the HRPP Director. Guidance may require additional approvals at the unit level.

A. IRB Authority and Guiding Principles

SOPs must describe:

- The authority under which the IRB is established;
- The relationship of the IRB to the IO and other institutional leadership;
- The scope of its jurisdiction over human research conducted at the U-M or by its faculty, staff, or trainees;
- The ethical principles under which it operates; and
- The IRB's purpose (i.e., to protect research participants).

IRBs, as a matter of policy, may regularly apply ethical principles in addition to those described in the [Belmont Report](#) (e.g., the Nuremberg Code), or comply with laws, regulations, or policies other than those described in this OM (e.g., guidelines published by the [International Council on Harmonisation](#)). However, IRB SOPs must describe additional guiding principles in sufficient detail to apprise researchers of the standards against which their studies will be reviewed and monitored, including sponsor-specific

requirements. This requirement does not apply to the concerns and considerations that an individual reviewer may bring to their analysis of an application nor preclude the IRB from considering any principles or rules beyond those formally articulated in its SOPs on an ad hoc basis.

B. IRB Organization and Personnel

SOPs must describe the following:

- How the composition of the IRBs is periodically evaluated and, when necessary, adjusted so that the membership and composition of the IRB meet legal, regulatory, and organizational requirements;
- The selection, appointment, length of service, duties, attendance requirements, training, and evaluation of IRB chairs and vice chairs, members and alternate members;
- The duties and functions of IRB staff and their relationship with IRB chairs and vice chairs, members, researchers, and other stakeholders; and
- Any ethical expectations of these individuals in addition to those described in this OM.

1. IRB Composition

Each IRB must have at least five members, with varying backgrounds to promote a complete and adequate review of research activities commonly subject to that IRB's oversight. SOPs must provide that:

- a. The IRB will be sufficiently qualified through the experience and expertise of its members, and their diversity (including consideration of race, gender, and cultural backgrounds and sensitivity to such issues as community attitudes), to provide for effective review of research.
- b. In addition to possessing the professional competence necessary to review specific research activities, the IRB will be able to determine the acceptability of proposed research in terms of institutional commitments and policies, applicable laws and regulations, and standards of professional conduct and practice. To this end, the SOPs will require the IRB to include members knowledgeable in these areas.
- c. For any IRB that regularly reviews research that involves vulnerable participants, such as children, prisoners, persons who have decisional impairment, or persons who have economic or educational disadvantages, consideration must be given to inclusion as members on the IRB of one or more individuals knowledgeable about and experienced in working with such participants.
- d. When reviewing U.S. Food and Drug Administration (FDA) regulated studies, the IRB must include at least one physician.
- e. The IRB must include at least one member whose primary concerns are in scientific areas and at least one member whose primary concerns are in nonscientific areas. The IRB also must have members with sufficient knowledge of the specific scientific discipline(s) relevant to the research that it reviews.

- 1) A scientist is a member whose training, background, and occupation would incline him or her to view scientific activities from the standpoint of someone within a behavioral or biomedical research discipline.
 - 2) A nonscientist is a member whose training, background, and occupation would incline him or her to view research activities from a standpoint outside of any biomedical or behavioral scientific discipline.
- f. The IRB must include at least one member who is not otherwise affiliated with the University (including by relationship with an immediate family member, spouse, domestic partner, or dependent) who represents the general perspective of participants, is sensitive to community attitudes in promoting respect of research participants regardless of race, gender, and cultural background, and safeguard the rights and welfare of human participants. The University supports the efforts of the IRBs to include additional unaffiliated members.
- 1) "Unaffiliated" individuals include (provided they have no other affiliation with the University):
 - Michigan Medicine patients or research participants of the University
 - Former faculty, staff, and students of the University (not receiving benefits from the University)
 - Individuals contributing to fund-raising drives
 - Unaffiliated IRB members who have been paid at reasonable market rates for their services to an IRB.
 - 2) "Affiliated" individuals include:
 - Full-time and part-time employees
 - Active emeritus faculty
 - Former or retired employees receiving benefits from the University
 - Paid and unpaid consultants
 - Current students
 - Members of any governing panel or board of the University
 - Healthcare providers with medical staff membership or other credentials to practice at University clinical sites
 - Healthcare providers with appointments at University of Michigan Health West (UMHW) and University of Michigan Health Sparrow (UM Health - Sparrow)
 - Volunteers working at the University on business unrelated to the IRB

IRB rosters reflect the above requirements and are maintained by the IRB offices. The IRB offices submit drafts of the revised membership rosters to the DIO for review and approval. Approved membership rosters are forwarded to OVPR. OVPR registers each IRB with the Office for Human

Research Protections (OHRP) and updates registrations as needed.

2. Use of IRB Consultants

The IRB must possess sufficient knowledge of the local research context to fulfill its review responsibilities under federal regulations and this OM. To supplement this knowledge, the IRB may, at its discretion, invite individuals with competence in special areas to assist in the review of issues that require expertise beyond or in addition to that available on the IRB.

SOPs must include provisions that:

- Describe when and how an IRB will use consultants to supplement the IRB's knowledge;
- Prohibit these consultants from voting with the IRB; and
- Require consultants to disclose any relevant conflicts of interest or commitment before agreeing to assist in a review.

3. Alternate IRB Members

SOPs may include provisions for designating alternate members to an IRB. If they do, each alternate IRB member should have experience, expertise, background, professional competence, and knowledge comparable to that of the primary IRB member whom the alternate would replace. SOPs must describe the function of alternate members and procedures regarding:

Determining whether the primary member or an alternate is the official voting member of the IRB for review of protocols or applications (or any individual protocol or application); and

Ensuring that only the vote of one is counted in any particular circumstance.

4. IRB Educational and Training Activities

SOPs or other documents must describe:

- Any orientation procedures for new IRB chairs and vice chairs, members and alternate members, and staff;
- Continuing education requirements and opportunities for IRB chairs and vice chairs, members and alternate members, and staff;
- Available reference materials (e.g., library resources, internet sites, etc.); and
- Training and education requirements for researchers who plan to submit IRB applications and reports.

5. IRB Compensation and Liability Coverage

The SOPs or other policies or guidance developed by the administrative unit responsible for the IRB's operations must describe arrangements, if any, for compensating IRB chairs and vice chairs members and alternate members, and consultants for their IRB service. Liability coverage is a matter of institutional policy and is described in [Insurance and Claims Administration policies](#). In brief, the University's self-insurance policies generally cover the actions of faculty, staff, trainees, and non-affiliated volunteers performing authorized activities on behalf of the University (such as membership

on an IRB). These policies do not cover acts of willful misconduct or illegal activities, nor do they cover losses for personal property or for personal injury of non-employees sustained while engaged in the authorized activities.

6. Evaluations of IRB Chairs, Members, Staff, and Regular Consultants

The performance of each IRB chair, vice chair, member, staff, and regular consultant must be evaluated regularly. SOPs must:

- Describe the process and content that is used to conduct evaluations of IRB chairs, vice chairs, members, staff, and regular consultants;
- Indicate the frequency of the evaluations;
- Identify who conducts the evaluations; and
- Describe how the results of the evaluations are used.

7. IRB Member and Consultant Conflicts of Interest

SOPs must include:

- A statement that no IRB member or consultant may participate in any review of any project in which the member has a conflicting interest (as defined in [Part 9](#) of this OM), except to provide information requested by the IRB;
- A statement that any conflicted IRB member or consultant may not be present for, count towards quorum, participate in the deliberations of, nor vote on the disposition of an application in which the member has a conflict. However, the member may be invited by the IRB to provide information relevant to the IRB's consideration of the application;
- A description of the process used by IRB members and consultants to report conflicts of interest and commitment with any IRB application for review; and
- A description of the process the IRB will use to manage reported conflicts.

[Part 9](#) of this OM provides further information on IRB member and consultant conflicts of interest.

C. IRB Review Policies and Procedures

SOPs must describe key IRB review policies and procedures in sufficient detail to inform IRB members and staff, researchers, and other stakeholders of the IRB's rules and expectations. Policies and procedures must include, at a minimum, the elements described below in Subsections 1 to 7. To the extent these elements are addressed through this OM or other institution-wide policy, they need only be referenced in the IRB SOPs.

1. IRB Jurisdiction and Authority

SOPs must describe:

- What types of studies are typically reviewed by the IRB;

- The authority of the IRB to approve, disapprove, or require modifications for approval of human research under its jurisdiction;
- The IRB’s authority to suspend or terminate approval of a study, or to place restrictions on the performance of the study, and the circumstances under which these actions may be taken; and
- If the IRB issues a “not-regulated” determination or notifies the researcher that research is exempt from review, the procedures that researchers must follow to request such determinations and the internal processes to perform them.

2. Institutional Approval/Disapproval of IRB Decisions

SOPs must acknowledge that:

- Research approved by an IRB is subject to disapproval by the IO and, as applicable, other institutional officials;
- No institutional official, including the IO and the University President, is empowered to overrule an IRB’s disapproval.

3. Submission of IRB Applications and Reports

The University has developed a web-based system for submission, routing, approval, and management of human research information. The system called [eResearch Regulatory Management](#) (eRRM), is designed to help the University meet its obligation to conduct research ethically and follow laws and regulations governing research conduct. Access to eRRM is granted based on roles and oversight responsibilities. eRRM is designed so that:

- Only one Principal Investigator (PI) is allowed for each application;
- The PI must assume full responsibility for a project and the compliance with applicable laws and regulations and institutional policy and must be knowledgeable about a project’s existence, scope, and progress;
- The PI is required to functionally submit initial, continuing review, amendment, and termination applications to ensure that the PI has reviewed the entire content of the submission and has approved all information submitted, including all supporting documentation (and in doing so to make certain attestations regarding the conduct of the project and their involvement in it and certify that the PI is responsible for that information);
- The PI may specifically delegate the responsibility to a Co-Investigator or faculty mentor to submit reports of an Adverse Event (AE) or Other Reportable Information or Occurrence (ORIO) due to the possible time-sensitive nature of these reports, although the PI is still ultimately responsible for these reports; and
- Exceptions to this policy are limited and must be approved by the IO or designee

SOPs must describe the PI's role and responsibilities for submission of applications and reports to the IRB and the process to be used.

4. General Review and Approval Procedures

The SOPs must describe the procedures the IRB follows when making the determinations specified in Subsections (a) to (f) below.

a. Determining Whether and Under What Authority the Research is Regulated

The SOPs must describe the role of IRB staff in determining whether the research is regulated by the IRB. In making this determination, the IRB considers the following for each application submitted to the IRB for initial, amendment, or continuing review:

- Is the activity described in the application “human research” as defined in the Common Rule?
- Is the activity “human research” as defined in FDA regulations?
- Is the University of Michigan engaged?
- Does the research qualify for exemption from IRB oversight?

These determinations are made consistent with the guidance provided by the U.S. Department of Health and Human Services (HHS) [Human Subject Regulations Decision Charts](#) and in consultation with IRB administrators or chairs, as appropriate. If the research:

- Involves activities or data subject to other rules or regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, the Health Information Technology for Economic and Clinical Health Act (HITECH) Security Rule, the Family Educational Rights and Privacy Act (FERPA) or rules of other federal agencies, the SOPs describe the process for reviewing and ensuring compliance with these other regulations or rules.
- Is not-regulated, the SOPs indicate that a PI may obtain documentation of a "not-regulated" determination for IRB applications submitted through eRRM either via review by an IRB staff member to confirm the not-regulated status or via a system-generated determination issued through the smart form logic of the IRB application.
- Is exempt, the SOPs direct an IRB staff member to ensure that the application indicates an appropriate request for an exemption determination, or to direct the PI to revise the application to do so, and, to ensure that, where appropriate, the IRB conducts a "limited IRB review." The SOPs allow for a system-generated exemption determination through the smart form logic of the IRB application for certain types of exempt research.

b. Reviewing IRB Applications

1) Information Required for IRB Review

IRBs must obtain sufficient information before reviewing applications for initial review, continuing review, review of amendments to previously approved research, and AE/ORIOs so that it can apply and satisfy the requirements for approval of research. SOPs must describe what information the IRB must obtain before reviewing an application.

2) Review Process/Primary Reviewers

SOPs must describe the IRB’s review and approval process, including any primary reviewer process used for initial review, continuing review (see [OHRP's Guidance on Continuing Review](#)), review of

protocol changes, AE/ORIOS, review of reports of unanticipated problems involving risks to participants or others, or of noncompliance, particularly serious and/or continuing noncompliance. SOPs must include all of the following:

- a. A list or description of specific documents and other information distributed or otherwise communicated to primary reviewers (if applicable), and to all other IRB members for each review;
- b. The timing of the distribution;
- c. Links to all supporting awards, contracts, and other sponsor information;
- d. The regulatory criteria considered by the IRB and primary reviewers (if applicable); and
- e. The range of possible actions taken by the IRB for protocols undergoing initial or continuing review and protocol changes undergoing review.

3) Approval with Conditions

If the IRB approves research with conditions (approved pending contingencies), SOPs must describe the following:

- a. A study may not be approved with conditions if substantive changes or requirements, requests for more information, or clarification of other issues are necessary for the IRB to determine that the criteria for IRB approval are met.
- b. Minor changes or requirements may be reviewed for approval by a qualified staff member or IRB member designated by the IRB Chair, or by the IRB Chair via the expedited approval process.

c. Determining Frequency of Review

SOPs must describe how IRBs determine the frequency of review of each study, including:

- 1) IRBs review all non-exempt University research at least once each year, except for:
 - a. Minimal risk research that does not require continuing review in accordance with applicable regulatory, University, or sponsor requirements.
 - b. Non-FDA-regulated research that has progressed to the point that it involves only one or both of the following:
 - i. Data analysis, including analysis of identifiable private information or identifiable biospecimens, or
 - ii. Accessing follow-up clinical data from procedures that participants undergo as part of clinical care.
- 2) To ensure proper monitoring of studies, the IRB may determine that some projects require review more often than annually. SOPs should include the criteria the IRB uses to make these determinations. For example, an IRB may set a shorter approval period for high-risk protocols or protocols with a high risk-to-potential benefit ratio.

- 3) For projects that require a continuing review, a statement that the expiration date is the last date the protocol is approved, and the method of calculating the expiration date. Effective dates of IRB approval and expiration are noted in the approval letters for initial review, continuing review, and amendments. The eRRM uses the expiration date to calculate the end of the approval and the exact time at which the approval period ends is noted on the approval letter by the following statement: "Approval for this study expires on 11:59 p.m. on mm/dd/yyyy."
- 4) For non-FDA regulated projects qualifying for expedited review, continuing review is not required unless the reviewer determines that it is necessary or is required by other laws or regulations. The effective date of approval is cited in the approval letter for initial review and includes a notice that continuing review is not required.

d. Monitoring and Verification

SOPs must describe how the IRB determines which projects need enhanced monitoring, such as verification from sources other than the researchers that no material changes have occurred since the previous IRB review. SOPs should include specific criteria used to make these determinations, for example:

- Random selection of projects;
- Complex projects involving unusual levels or types of risk to participants;
- Projects conducted by researchers who previously have failed to comply with applicable regulations, institutional, or IRB requirements;
- Projects where other concerns have been raised about possible material changes occurring without IRB approval.

e. Reporting Changes in Research to the IRB

SOPs must describe the process for submitting and approving changes to research projects, including all of the following:

- 1) The eRRM IRB application is the method by which researchers report and IRBs approve changes in non-exempt research.
- 2) The IRB requires prompt submission of proposed changes in research activity via an amendment before initiation of the changes.
- 3) Changes may not be initiated until approved by the IRB except when necessary to eliminate apparent immediate hazards to the participant. Changes initiated without IRB approval to eliminate apparent immediate hazards to the participant:
 - a. Are promptly reported to the IRB.
 - b. Are reviewed by the IRB to determine whether each change was consistent with ensuring participants' continued welfare.

- 4) In approving such changes, the IRB will apply applicable regulatory criteria and will require that any significant new findings that might relate to willingness to continue participation are provided to participants; and
- 5) The HRPP ensures compliance with this requirement through its post-approval monitoring program and the IRB's internal monitoring activities.

f. Lapses in IRB Approval

For projects requiring continuing review, SOPs must describe the process used to prevent lapses of IRB approval of a study due to late submission of a required continuing review application, including all of the following:

- 1) The IRB requires researchers to submit a continuing review application before expiration of IRB approval, and in ample time for IRB review.
- 2) To assist the researchers in meeting this requirement, eRRM provides notification of impending expiration and directions for submitting a continuing review application.

If a researcher fails to provide a continuing review application to the IRB, and the IRB has not completed the review and approval of the application by the expiration date of the current approval, the study will be considered lapsed and:

- 1) All research activities must stop;
- 2) Interventions and interactions with current participants must stop unless the IRB finds it is in the best interest of individual participants currently participating in the study to continue the research interventions or interactions;
- 3) Enrollment of new participants during a lapse is prohibited;
- 4) The IRB will remind researchers that resources must not be expended for unallowable activities; and
- 5) The IRBs notify other University units of lapses, as needed.

5. Expedited Review

SOPs must describe the expedited review process, including:

- Which categories of projects or applications may be eligible for expedited review;
- The process (if any) for requesting expedited review;
- The procedures for reviewing applications by expedited review;
- The rationale for requiring continuing review of research qualifying for expedited review;
- Review of amendments using the expedited procedure; and
- The method for keeping all IRB members apprised of applications that have been approved on an expedited basis.

a. Applicability Criteria and Categories

SOPs must describe the types of research that are eligible for expedited review as specified by [OHRP's Expedited Review Categories](#) and the [FDA](#). An IRB generally may use expedited procedures (through its chair or one or more experienced members designated by the chair) to review research meeting the following criteria:

- 1) Research procedures present no more than minimal risk to participants;
- 2) The identification of the participants and/or their responses will not reasonably place them at risk of criminal or civil liability or be damaging to their financial standing, employability, insurability, reputation, or be stigmatizing unless reasonable and appropriate protections will be implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal;
- 3) The research is not classified; and
- 4) The research falls into one or more of the categories of projects or applications appearing on a list of studies that may be reviewed by the IRB through an expedited review procedure published by the Secretary of the Department of Health and Human Services, and only in those categories. (See [45 CFR 46.110](#) and [21 CFR 56.110](#)).

The IRBs may also use the expedited review procedure for research for which limited IRB review is a condition of exemption under 46.104(d)(2)(iii), (d)(3)(i)(C), and (d)(7) and (8). Note: U-M has not implemented broad consent for storage, maintenance, and secondary research with identifiable private information or identifiable biospecimens, and therefore regulatory requirements regarding exempt research in 46.104(d)(7) and (8) are not applicable.

b. Minor Changes

The IRB also may use expedited procedures to review "minor" changes to research previously approved by the full committee. SOPs must provide that a proposed change in research is deemed "minor" if it does not significantly affect an assessment of the risks and benefits of the study and does not substantially change the aims or design of the study. A modification cannot be deemed "minor" if it involves the addition of procedures that involve more than minimal risk or that do not fall into [categories \(1\) - \(7\) of research](#) that may be reviewed through an expedited review procedure published by the Secretary of the HHS.

Examples of "minor" changes to a research study include, but are not limited to, the following:

- 1) Addition or deletion of study team members;
- 2) Addition of procedures that do not significantly increase the risk to participants, considering the original purpose and study design of the approved study (i.e., new procedures that fall under any of the expedited categories can usually qualify as minimal risk);
- 3) Addition of non-sensitive questions to a survey or interview, and procedures;
- 4) Addition of, or revision to, recruitment materials or strategies; and
- 5) Change to improve the clarity of statements or to correct typographical errors provided that such changes do not alter the content or intent of the statement.

The University may also undertake demonstration projects that allow for the addition of expedited review categories for research that is not federally sponsored.

c. Expedited Reviewers

SOPs must describe how expedited reviewers are chosen. Generally, IRB Chairs appoint experienced IRB members to serve as expediting reviewers. For purposes of this policy, a member is deemed experienced if they have completed all mandatory education for IRB members, has served on an IRB for a minimum of six months or has described and documented comparable experience, and has been approved by the IRB Chairs as qualified to perform expedited reviews. The IRBs may adopt more restrictive criteria in their SOPs.

d. Expedited Review Determinations

If the IRB employs expedited review procedures, the SOPs should address the method the IRB will use to ensure that expedited reviewers either approve or forward the application for full board review within a reasonable period of time. The expedited reviewer must review the same materials that the convened IRBs receive for protocols reviewed by the convened IRB. Applications may not be disapproved using expedited procedures; rather, full board action is required for disapproval.

e. Requirements for Continuing Review

Continuing review for projects qualifying for expedited review is not required for non-FDA-regulated research unless otherwise required by law or regulation. Expedited reviewers must document the rationale for requiring continuing review. If a reviewer determines that continuing review is required, IRB SOPs must describe the process whereby at least one IRB member reviews the complete protocol, including a status report (continuing review application) and any amendments previously approved by the IRB.

IRB SOPs must describe an alternate process to maintain oversight of ongoing research for projects approved using the expedited procedure and no longer requiring continuing review.

f. Limitations on Use of Expedited Review

SOPs must describe any limitations placed on the use of expedited review, including:

- 1) The IRB Chair or experienced IRB member designated by a Chair, may use their discretion to refer studies qualifying for expedited review to the full committee;
- 2) For federally supported or FDA-regulated research, the relevant department or agency head may restrict, suspend, terminate, or choose not to authorize an institution's or IRB's use of expedited review procedures; and
- 3) The IO retains the authority to require a full-board review of any project or category of projects.

6. Criteria for IRB Approval

IRBs ensure research submitted for initial review, continuing review, and review of modifications, whether reviewed by the convened board or by expedited review procedures, is approved only when

all of the requirements in [45 CFR 46.111 and Subparts B, C, and D, as applicable](#) and/or [21 CFR 56.111](#) and Subpart C, as applicable are met. SOPs must include all of the criteria described below.

a. Scientific Merit and Feasibility

In its review of research applications, the IRB considers whether research procedures are consistent with sound research design to yield the expected knowledge and examines the scientific merit in relationship to the risks and benefits of the research.

b. Minimizing Risk

A research plan approved by the IRB must ensure that risks to participants are minimized by using procedures consistent with a sound research design that do not unnecessarily expose participants to risk, and whenever appropriate, by using procedures already being performed on participants for clinical purposes. When ensuring that risk is minimized, the IRB should evaluate the resources available at each site where research will be conducted (see (j) Resources).

c. Risk-Benefit Analysis

Research may be approved only if the risks to participants are reasonable in relation to any anticipated benefits to participants and to the importance of the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB should consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies that participants would receive even if not participating in the research). The IRB should not consider possible long-range effects of applying knowledge gained in the research (e.g., the possible effects of the research on public policy) as among those research risks or benefits that fall within the purview of its responsibility.

d. Equitable Participant Selection

An IRB must determine that recruitment and enrollment plans will promote equitable participant selection. In making this assessment, the IRB should review any proposed direct advertising to prospective participants (i.e., communications intended to be seen or heard by potential participants to solicit their participation in a study). The IRB should also take into account the purposes of the research, the setting in which the research will be conducted, the influence of payments to participants, and participant selection criteria. The IRB should be particularly cognizant of the special problems of research involving vulnerable populations, such as children, prisoners, persons who have decisional impairment, and persons with economic or educational disadvantages.

e. Informed Consent and Parental Permission

1) General Requirements

Information given to participants as part of informed consent must meet applicable regulatory and institutional requirements, including those described in [Part 6](#) of this OM. Generally, all of the elements of informed consent and documentation of informed consent required by HHS and/or FDA regulations must be satisfied before the IRB will approve a research study unless the IRB waives or alters the requirements as provided in further detail below.

An IRB may require that additional information be given to participants when, in the IRB's judgment, the information would meaningfully add to the protection of participant rights and welfare.

If vulnerable populations are included in the study, additional standards related to informed consent must be applied. See [Part 7, Section II](#) of this OM for details.

2) Short Form Consent

The IRB may approve the use of a short form written consent document in certain circumstances. Refer to [Part 6](#) of this OM for additional information.

3) Informed Consent Waivers, Alterations, and Exceptions

In some cases, an IRB may approve a consent procedure that does not include, or that alters, some or all of the required elements of informed consent or may waive the requirement to obtain informed consent. The IRB must document its findings justifying the waiver or alteration of informed consent.

The following standards apply to all federally and non-federally supported human research that is not FDA-regulated. Different rules for FDA-regulated studies are found further below.

Note: U-M has not implemented broad consent for storage, maintenance, and secondary research with identifiable private information or identifiable biospecimens per 45 CFR 46.116(d), and therefore regulatory requirements related to the waiver or alteration of broad consent per 45 CFR 46.116(e) are not applicable.

Waiver or Alteration of Informed Consent

1. An IRB may generally waive or alter the requirements for informed consent only if it finds and documents that:
 - a. The research involves no more than minimal risk to the participants;
 - b. The research could not practicably be carried out without the requested waiver or alteration;
 - c. If the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format;
 - d. The waiver or alteration will not adversely affect the rights and welfare of the participants; and
 - e. Whenever appropriate, the participants or legally authorized representatives will be provided with additional pertinent information after participation.
2. Public Demonstration Project: An IRB may waive or alter the requirements for informed consent in research involving public benefit and service programs if the IRB finds and documents that:
 - a. The research or demonstration project is to be conducted by or subject to the approval of state or local government officials; and

- b. The project is designed to study, evaluate, or otherwise examine: (i) public benefit or service programs; (ii) procedures for obtaining benefits or services under those programs; (iii) possible changes in or alternatives to those programs or procedures; or (iv) possible changes in methods or levels of payment for benefits or services under those programs; and
 - c. The project could not practicably be carried out without the waiver or alteration.
 3. Screening, Recruiting, and Determining Eligibility: An IRB may approve a research proposal in which a researcher will obtain information or biospecimens for screening, recruiting, or determining the eligibility of prospective participants without the informed consent of the prospective participant or the participant's legally authorized representative if either of the following conditions are met:
 - a. The researcher will obtain information through oral or written communication with the prospective participant or legally authorized representative, or
 - b. The researcher will obtain identifiable private information or identifiable biospecimens by accessing records or stored identifiable biospecimens.

For emergency research, the IRB may approve a waiver of consent consistent with the guidelines found at: [IRBMED guidance: Emergency Research \(Planned and Approved\) with Exception from Informed Consent and OHRP guidance](#).

Waiver of Requirement for Parental Permission

For research involving children as participants, an IRB may waive the requirement to obtain parental permission if it finds and documents that:

1. The research involves no more than minimal risk to the participants;
2. The waiver or alteration does not adversely affect the rights and welfare of the participants;
3. If the research involves using identifiable private information or identifiable biospecimens, the research could not practicably be carried out without using such information or biospecimens in an identifiable format;
4. The research cannot practicably be carried out without the waiver or alteration;
5. When appropriate, the participants will be provided with additional pertinent information after participation.

Alternatively, the IRB may waive the requirement to obtain parental permission if it finds and documents that:

1. The research is designated for conditions or for a participant population for which parental or guardian permission is not a reasonable requirement to protect the participants; and
2. An appropriate mechanism for protecting the children who will participate as participants in the research is substituted.

Waiver of Documentation of Informed Consent

The IRB may waive the requirement for documentation of informed consent if it finds and documents any of the following:

1. That the only record linking the participant and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each participant (or legally authorized representative) will be asked whether the participant wants documentation linking the subject with the research, and the participant's wishes will govern;
2. The research presents no more than minimal risk of harm to participants and involves no procedures for which written consent is normally required outside of the research context; or
3. The participants or legally authorized representatives are members of a distinct cultural group or community in which signing forms is not the norm, the research presents no more than minimal risk of harm to participants, and there is an appropriate alternative mechanism for documenting that informed consent was obtained.

Even if the IRB approves a waiver of documentation of consent, the IRB will review a written description of the information provided to participants and may require the researcher to provide subjects with a written statement regarding the research.

4) Studies Subject to FDA Regulations

Waiver or Alteration of Informed Consent

1. Exception from Informed Consent Requirements for Minimal Risk Clinical Investigations: An IRB may waive or alter the requirements for informed consent per [21 CFR 50.22](#) if it finds and documents that:
 - a. The clinical investigation involves no more than minimal risk to the participants;
 - b. The clinical investigation could not practicably be carried out without the requested waiver or alteration;
 - c. If the clinical investigation involves using identifiable private information or identifiable biospecimens, the clinical investigation could not practicably be carried out without using such information or biospecimens in an identifiable format;
 - d. The waiver or alteration will not adversely affect the rights and welfare of the participants; and
 - e. Whenever appropriate, the participants or legally authorized representatives will be provided with additional pertinent information after participation.
2. Emergency Exception from Prospective IRB Approval: An IRB may waive or alter the requirements for informed consent in certain emergency situations if it finds and documents that certain requirements have been met.
 - a. When the IRB receives a request to use an investigational agent without informed consent, the IRB will assess whether or not the regulatory criteria outlined in [21 CFR](#)

[50.23](#) apply. See IRBMED guidance: [Emergency Use of a Test Article in Life-Threatening Situations](#).

- b. Where the IRB is informed after the use of an investigational agent without informed consent, the IRB will assess whether or not regulatory criteria in 21 CFR 50.23 were followed. See [Part 12](#) of this OM for potential corrective action measures in response to non-compliance.
3. [Exception from Informed Consent Requirements for \(Planned\) Emergency Research](#): An IRB may approve a study with an "Exception from Informed Consent Requirements for Emergency Research," ensuring that the research satisfies criteria outlined in 21 CFR 50.24, and OHRP guidance.

Waiver of Documentation of Informed Consent

The IRB may waive the requirement for documentation of informed consent if it finds and documents the following:

1. The research presents no more than minimal risk of harm to participants; and
2. The research involves no procedures for which written consent is normally required outside of the research context.

Even if the IRB approves a waiver of documentation of consent, the IRB will review a written description of the information provided to participants and may require the researcher to provide participants with a written statement regarding the research.

5) Studies Subject to Both HHS and FDA Regulations

The following tables may be referenced when a study is regulated by both FDA and HHS regulations. Tables 2 and 3 compare the types of waivers or exceptions that may be requested by a researcher under one agency's regulations and determine if it can be approved if the other agency also has jurisdiction.

Table 2: Comparison of FDA Criteria to HHS Criteria

HHS OHRP criteria are met	General Waiver or Alteration of Consent 45 CFR 46.116 (f)	Waiver, or Alteration of Parental Permission 45 CFR 46.116(f); 45 CFR 46.408(c)	Waiver of documentation of informed consent 45 CFR 46.117 (c)
Applicability if the study is regulated by the FDA	Allowed if the criteria at 21 CFR 50.22 is met.	A waiver or alteration is not allowed for the aspects of the project that meet the FDA definition of research.	Allowed if both apply: The study is minimal risk; and Involves no procedures for which written consent is normally required outside the research context. 21 CFR 56.109 (c)(1)

Table 3: Comparison of HHS Criteria to FDA Criteria

FDA criteria are met	FDA Emergency Use Exception 21 CFR 50.23 (a)	FDA Emergency Research Exception 21 CFR 50.24	FDA Terrorism/ Public Health Emergency Exception 21 CFR 50.23 (e)	FDA/DOD Presidential Waiver for Military 21 CFR 50.23 (d)
HHS OHRP applicability if the study is supported by	Agent can be administered but data collected	Allowed if informed consent is obtained	Allowed if 46.116(d) applies.	HHS has not provided specific guidance. The

federal funding.	cannot be used for research.	after the research is initiated.		IRB should consult with the IO or DIO in the event this waiver is requested.
------------------	------------------------------	----------------------------------	--	--

6) Studies Subject to the Health Insurance Portability and Accountability Act (HIPAA)

Under HIPAA regulations, researchers must obtain written authorization from a research participant for the use, or disclosure of protected health information for the study unless one of the following applies:

- a. Waiver or alteration of authorization approved by the IRB;
- b. Use of limited data set shared under the terms of a written data use agreement;
- c. Research solely on the protected health information of decedents (deceased individuals); or
- d. Preparatory to research activities, such as assessing the feasibility of conducting a study.

See additional IRBMED guidance: [Uses and Disclosures of Protected Health Information](#).

Waiver or Alteration of HIPAA Authorization

The IRB may waive or alter the requirement to obtain written authorization if the IRB finds and documents all of the following:

- 1. The use or disclosure of protected health information involves no more than minimal risk to the participants' privacy, as demonstrated by:
 - a. An adequate plan to protect any identifiers from improper use or disclosure;
 - b. An adequate plan to destroy the identifiers at the earliest opportunity consistent with the conduct of the research (unless there is a health or research justification for retaining the identifiers or retention is required by law); and
 - c. Adequate written assurances that the protected health information will not be reused or disclosed except as required by law, for research oversight, or other research approvable under a waiver.
- 2. The research could not practicably be conducted without the waiver; and
- 3. The research could not practicably be conducted without access to and use of the protected health information.

f. Data and Safety Monitoring

SOPs must provide that the IRB will ensure, when appropriate, that research plans make adequate provision for monitoring data collected to ensure participant safety and describe how the IRB makes this determination. Additional information on data and safety monitoring plans is available

in [Part 7 \(III\)](#) of this OM.

g. Privacy and Confidentiality Protection

“Privacy” refers to the willingness of research participants to allow access to themselves and their information. “Confidentiality” refers to the agreement between the researcher and participants on how the participants’ identifiable private information will be managed and used. SOPs must provide that the IRB will ensure that research plans make adequate protections for safeguarding participant privacy and confidentiality. See [U-M HRPP Guidance: Protecting Participant Privacy and Maintaining Confidentiality of Data](#) for additional information.

h. Vulnerable Subjects

SOPs must describe the different standards that apply to research involving vulnerable populations. These groups include but are not limited to: children, pregnant women, fetuses and neonates, prisoners, individuals with decisional impairment, persons with economic or educational disadvantages, or employees, students, or patients of researchers. The IRBs will comply with the standards described in [Part 7 \(II\)](#) of this OM for review and approval of research involving these populations. These standards limit the categories of research that may be performed and require, as appropriate, additional safeguards to protect participants’ rights and welfare when they do participate. Additional information is also available in [Part 11](#) of this OM.

i. Test Article Accountability Procedures

SOPs must provide that:

- 1) The IRB may not approve an application for research involving drugs, biologics, or devices unless it determines that the test articles will be used only in approved research protocols, under the direction of approved researchers, or in emergency circumstances, consistent with FDA requirements and the University policies on emergency use;
- 2) Protocols must describe local drug/biologic or device accountability procedures, if applicable, including procedures required by:
 - a. [Michigan Medicine Research Pharmacy](#) (formerly Investigational Drug Service (IDS)); and
 - b. Clinical Engineering;
- 3) Investigational drug management and accountability is performed according to Research Pharmacy Policies 400.00-400.10;
- 4) Investigational device accountability, under most circumstances, is performed by the PI and study teams, who are responsible for documenting the processes for handling and dispensing of investigational devices according to the plan approved by the IRB. Note that investigational devices may need to undergo additional quality control measures to ensure they are safe, and may need to be registered with the University.

j. Resources

SOPs must include provisions requiring IRBs to determine that research studies have the resources necessary to protect participants by evaluating all of the following:

- 1) There is adequate time for the researchers to conduct and complete the research;
- 2) There are an adequate number of qualified staff;
- 3) The facilities where the research will be conducted are adequate;
- 4) Researchers have access to a population that will allow the recruitment of the necessary number of participants; and
- 5) Medical or psychosocial resources that participants may need as a consequence of the research are available.

For certain categories of research that are not federally supported and not subject to FDA regulations, a researcher or IRB may submit a request to the IO or Designee for an exception to any of the above approval criteria, consistent with the provisions of 45 CFR §46.101(i) except that the IO or Designee assumes the role of the HHS Secretary in considering the request.

7. IRBs Reviewing and Monitoring FDA-Regulated Research

IRBs that review FDA-regulated studies must address additional items in their SOPs (details of which are provided in [Part 8](#) of this OM).

D. IRB Administrative Functions

SOPs must describe key IRB administrative functions and requirements in sufficient detail to inform IRB members and staff, researchers, and other stakeholders of the IRB's rules and expectations. These must include, at a minimum, the elements described below in Subsections 1 to 4. To the extent these elements are addressed through this OM or other institution-wide policy, they need only be referenced in the IRB SOPs.

1. IRB Meetings

SOPs must describe requirements for convened IRB meetings, including the following:

- a. A majority of the members of the IRB must be present.
- b. At least one non-scientist member must be present to meet a quorum.
- c. At least one unaffiliated member, who represents the general perspective of participants, should be present at the majority of meetings in a given year.
- d. For the research to be approved, it must receive approval by a majority vote of the quorum (as described above). If, during the meeting, a quorum is lost, votes may not be taken until it has been restored.
- e. When reviewing research involving prisoners, the prisoner representative is present.
- f. When reviewing research that involves participants vulnerable to coercion or undue influence, one or more individuals who are knowledgeable about or experienced working with such participants are present.

- g. When convened-board review is not required, the SOPs must include details of any process, such as expedited review procedures (as described above) or subcommittee procedures, which may be used to supplement the IRB's review responsibilities.
- h. IRB members may agree, during an appropriately convened meeting, to issue conditional approval for a project only if any requested clarifications or modifications are not relevant to the determinations required by the IRB under the Common Rule or its Subparts [\(45 CFR 46\)](#) or, as applicable, FDA regulations ([21 CFR 56](#)). If substantive clarifications or modifications regarding the protocol or informed consent documents are required as a condition of approval, approval must be deferred pending subsequent review of responsive material by the convened IRB.
- i. IRB meetings may occur as remote (electronic), in-person with members physically present, or hybrid with a combination of members joining electronically and some attending in person. Each meeting format must include a means for all participants to receive the meeting materials before the meeting and for the facilitation of active and equal participation of all members in the discussion of all protocols.

2. Notification of Decisions

SOPs must describe requirements for how the IRB will notify researchers and the University of its decisions, including the following:

- a. An IRB will notify researchers in writing of its decision to approve or disapprove a proposed research activity or of modifications to the proposal that are required to secure IRB approval.
- b. If the IRB decides to disapprove a research activity, it must include a statement of the reasons for its decision in its written notification and must allow the researcher to respond in person or writing.
- c. An IRB will notify the IO or designee and other institutional officials, when appropriate, of its decisions regarding proposed research activities by formal or informal means, such as through access to relevant electronic databases.

SOPs must also describe any process for reviewing and acting on researcher responses to IRB actions.

3. IRB Response to Reportable Information

SOPs must require prompt reporting to the IRBs, HRPP Director, IO, DIO, and any other institutional officials, as appropriate, of the following:

- a. Any unanticipated problems involving risks to participants or others;
- b. Any serious or continuing noncompliance with federal regulations, institutional policy, or IRB requirements; and
- c. Any suspension or termination of IRB approval consistent with the requirements of [Part 12](#) of this OM.

SOPs must describe the procedures that the IRB uses to receive, investigate, and address such reports, including the range of actions the IRB may take in response to such reports, consistent with

the requirements of [Part 12 of this OM](#). The process for making additional reports to sponsors and government authorities with jurisdiction outside of the institution is described in [Part 12 of this OM](#).

4. IRB Records and Reports

SOPs must describe how the IRB documents its activities and decisions and maintains records of that documentation, including:

- a. Copies of:
 - Research proposals reviewed;
 - Scientific evaluations, if any, accompanying the proposals;
 - Approved sample consent documents;
 - Recruitment materials;
 - Status reports (Scheduled Continuing Review Applications) submitted by researchers;
 - Investigator brochures, if any;
 - Data and safety monitoring reports, if any;
 - Unanticipated problems involving risks to participants or others; and
 - Reports of injuries to participants.
- b. Records of continuing review activities, including the rationale for conducting continuing review of research that would not require continuing review as described in [45 CFR 46.109\(f\)\(1\)](#);
- c. Records of modifications to previously approved research;
- d. Statements of significant new findings provided to participants;
- e. Documentation of non-compliance;
- f. Copies of official correspondence between the IRB and researchers;
- g. All previous and current rosters of IRB members;
- h. Resumes for all IRB members;
- i. The rationale for an expedited reviewer's determination that research appearing on the expedited review list is more than minimal risk and requires convened review;
- j. Description of the action taken by the reviewer;
- k. Documentation of exemption determinations, including the category by which research was determined to be exempt;
- l. Documentation of approvals using the expedited procedure; and
- m. Minutes of IRB meetings that document compliance with regulatory, institutional, and other applicable requirements.

SOPs must describe IRB record retention mandates and destruction standards, including the following:

- IRBs must maintain applicable records for at least three years after the completion of the study;
- If a protocol is terminated without participant enrollment, IRB records are maintained for at least three years after termination;
- If an IRB performs functions on behalf of a "covered entity" (such as Michigan Medicine) related to HIPAA and research, those records must be retained for at least seven years, either by the IRB or by the covered entity; and
- Administrative units responsible for IRB operations may impose longer retention and specific destruction standards.

All IRB records must be maintained securely and made accessible, at reasonable times and in a reasonable manner, for inspection and copying by authorized representatives of the University, relevant sponsors, and government authorities with jurisdiction (such as OHRP, FDA, and National Institutes of Health (NIH)), and accrediting bodies.

E. Quality Assurance and Quality Improvement

At least once every five years, in conjunction with the AAHRPP accreditation cycle, the HRPP initiates a comprehensive review of the HRPP OM. IRB SOPs must make provisions for such a review of SOPs on the same cycle or more frequently at the IRB's discretion. Revisions to the SOPs may be made at any time, as required by changes in law, ethical standards, institutional policy, quality assurance activities, or other considerations. Substantive revisions require approval as outlined in the SOPs. Additional requirements for quality assurance and quality improvement are described in [Part 12](#) of this OM.

IV. OTHER REVIEW UNIT STANDARD OPERATING POLICIES AND PROCEDURES

Other review units listed in [Part 2](#) of this OM must develop, implement, and enforce their own standard operating procedures relevant to their role in the HRPP.

PART 4: Activities Subject to the HRPP

Describes when a particular activity is subject to the University's Human Research Protection Program (HRPP), provides examples of not regulated activities, and outlines the policy on exempt research.

I. DETERMINING WHAT IS AND WHAT IS NOT HUMAN SUBJECTS RESEARCH

Research is defined under the Common Rule as "a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge." (See [45 CFR 46.102\(l\)](#))

For purposes of human subjects research at the University of Michigan, a "systematic investigation" is an activity conducted in pursuit of answering a specific research question or to permit conclusions to be drawn. The research is described in a formal protocol that sets forth an objective and a set of procedures to reach that objective, and results in the formulation of generalizable knowledge based on conclusions drawn. In turn, "generalizable knowledge" is knowledge based on the findings of a particular research study (or studies) that may be applied more broadly with the expectation of predictable outcomes.

The distinction between research and clinical practice, non-research evaluation, journalism, and other activities involving interactions with living individuals or use of their private information may be vague. The [Belmont Report](#) illustrates the difference between research and practice in the clinical realm.

In the clinical realm, the term "practice" generally refers to interventions that are designed solely to enhance the well-being of an individual patient or client and that have a reasonable expectation of success. The purpose of medical or behavioral practice is to provide diagnosis, preventive treatment, or therapy to particular individuals. By contrast, the term "research" designates an activity designed to test a hypothesis, permit conclusions to be drawn, and thereby to develop or contribute to generalizable knowledge (expressed, for example, in theories, principles, and statements of relationships). When a clinician departs in a significant way from standard or accepted practice, the innovation does not, in and of itself, constitute research. The fact that a procedure is "experimental, innovative, or novel," in the sense of new, untested, or different, does not automatically place it in the category of research. Radically new procedures of this description should, however, be made the object of formal research at an early stage in order to determine whether they are safe and effective. Research and practice may be carried on together when research is designed to evaluate the safety and efficacy of a therapy. The general rule is that if there is any element of generalizable research in an activity, the activity should undergo review for the protection of human subjects.

A "clinical investigation" under FDA regulations ([see 21 CFR 56.102\(c\)](#)) generally refers to any experiment that:

- Involves a test article (defined as a drug, biological product, medical device, human food additive, color additive, electronic product, or any other article subject to regulation under the [Food, Drug and Cosmetic Act](#) (FD&C Act) or the [Public Health Service Act](#));
- Involves one or more human subjects; and

- Meets the requirements for prior submission to the FDA or whose results are intended to be submitted to FDA as part of an application for a research or marketing permit.

Section III below describes who has the authority to make a determination about whether or not a particular activity constitutes human subjects research subject to the U-M HRPP, provides illustrations, and describes the process for notifying a researcher of the determination.

II. DETERMINING WHETHER RESEARCH INVOLVES HUMAN SUBJECTS

The fact that an activity is research does not mean that it is "human subjects" research under the Common Rule or a clinical investigation under corresponding FDA regulations.

The Common Rule ([45 CFR 46.102\(e\)](#)) defines a human subject as a living individual about whom an investigator (whether professional or student) conducting research:

- Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or
- Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens.

Refer to [45 CFR 46.102](#) for the definitions of intervention, interaction, private information, identifiable private information and biospecimens.

FDA regulations ([21 CFR 56.102\(e\)](#)) define a "human subject" as an individual who is or becomes a participant in research, either:

- As a recipient of a test article (drug, biologic, or device); or
- As a control.

A subject may be either a healthy individual or a patient. A human subject also includes individuals on whose specimen a device is used. When medical device research involves in vitro diagnostics and unidentified tissue specimens, the FDA defines the unidentified tissue specimens as human subjects.

Research on specimens derived from living individuals may be considered human subjects research under both the Common Rule and FDA regulations and, therefore, for purposes of the University's HRPP. Guidance on whether or not a project involving human specimens may be considered regulated research is available on the following federal websites:

- [Office for Human Research Protections Decision Charts](#)
- [NIH Office for Extramural Research Human Subjects Research Homepage](#)
- [FDA Guidance Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable](#)
- [FDA 21 CFR 812.3\(p\)](#)

Private information must be individually identifiable (i.e., the identity of the participant is or may readily be ascertained by the researcher or associated with the information being collected) in order for obtaining or using the information to constitute research involving human subjects per the Common Rule. The following

illustrations may assist researchers in determining whether their activities constitute human subjects research:

- A researcher requests a University department to release individually identifiable private information to the researcher for use in a research project. *Because the information is individually identifiable, the research is considered "human research" and the investigator must obtain IRB (Institutional Review Board) approval or verification of exemption before initiating the protocol.*
- A researcher obtains a completely de-identified dataset from an institution or agency outside of the University. The researcher will not make any attempt to re-identify the information contained in the dataset. *The researcher has not received identifiable private information and, therefore, the project is not subject to University IRB approval or HRPP oversight. However, the originating institution may impose additional requirements.*

Determining when information may be considered "de-identified" can be difficult. Privacy regulations issued under the [Health Insurance Portability and Accountability Act of 1996 \(HIPAA\)](#) provide the standard for de-identification of protected health information by either:

- The "Safe Harbor" method which requires nineteen identifiers be eliminated from a data set to render it "de-identified"; or
- The "Expert Determination" method which requires a statistician to verify that the recipient of the dataset will not, based on the dataset and any other information to which the recipient may have access, be able to re-identify an individual.

For more information, see the following:

- [45 CFR 164.514\(b\)](#)
- [OCR Guidance on Methods for De-Identification of PHI](#)

The NIH has developed additional guidance in its [grant application instructions](#) to help determine when research involves human subjects.

III. DETERMINING WHETHER THE UNIVERSITY IS RESPONSIBLE FOR IRB OVERSIGHT OF HUMAN SUBJECTS RESEARCH

U-M is responsible for assuring IRB oversight of human subjects research when its *employees or agents* are engaged in the conduct of human subjects research. An institution is considered to be *engaged* in a particular non-exempt human subjects research project when its employees or agents for the purposes of the research project obtain:

- Data about the subjects of the research, including identifiable biospecimens, through intervention or interaction with them;
- Identifiable private information about the subjects of the research; or
- The informed consent of the human subjects for the research.

An institution's employees or agents are individuals who:

- Act on behalf of the institution;
- Exercise institutional authority or responsibility; or
- Perform institutionally designed activities.

Employees and agents can include staff, students, contractors, and volunteers, among others, regardless of whether the individual is receiving compensation.

The activities and obligations of U-M employees, students, and agents are considered to be “University responsibilities.” However, a faculty member who performs outside activities for unrelated institutions and not as part of their U-M appointment is not involved in “University responsibilities” in that context. For example, university responsibilities do not include activities performed by Agency Fund organizations (e.g. Alumni Association, MERIT Network, University Musical Society, William Davidson Institute, and others). Therefore, Agency Fund employee activities, including those performed by university employees leased to the external entity, are not considered University responsibilities. Conversely, a faculty member who provides professional services at an outside institution under a contract between the University and the outside institution, and who is paid for their work by the University, is performing “University responsibilities.”

If the institution is the direct recipient of a Health and Human Services (HHS) grant for non-exempt human subjects research, it is also considered to be engaged even where all of the human subjects research activities are carried out by another institution.

See [OHRP, Guidance on the Engagement of Institutions in Human Subjects Research, 2008](#) for additional guidance.

When the University collaborates on a research project involving another institution or an outside individual, the U-M IRB may accept oversight for the project and serve as the Single IRB (sIRB). In addition, U-M may decide to cede oversight to a commercial IRB or another institution's IRB. See [Part 5](#) of this OM for additional information.

IV. DETERMINING WHEN RESEARCH BEGINS AND ENDS

Research begins when a researcher first “obtains data through intervention or interaction,” or otherwise obtains “private information,” as described above. For example, biomedical research begins when a researcher first collects individually identifiable private information about potential participants, contacts those individuals, or performs eligibility testing solely for research purposes. Because the initial data access and contact constitute research, an IRB must review and approve the proposed data access and communication in advance.

Research is considered to continue and IRB approval must remain active through data collection, while personally-identifiable data are being analyzed, or as long as there is intent to conduct long-term follow-up on participants of the currently approved research. When IRB approval lapses, expires, or is terminated, no interventions or interactions may occur and no identifiable data may be collected or analyzed, until the project is re-approved by the IRB. See [Part 3 of this OM regarding lapse in IRB approval](#).

Once all personal identifiers and links to identifiers are destroyed, the research is no longer regulated under federal regulations or the University's HRPP.

Secondary analysis of data collected as part of a previous study that retains identifiers must be submitted to the IRB for approval or exemption. The language of the original consent is a factor in the IRB's determination of whether secondary data analysis may be conducted.

V. AUTHORITY TO MAKE REGULATED/NOT REGULATED DETERMINATIONS (PER THE COMMON RULE AND FDA) AND NOTIFICATION OF DECISIONS

A. Authority to Make Regulated/Not Regulated Determinations

The Institutional Official (IO) has delegated to the IRBs and their staff the authority to make regulated/not-regulated determinations in a manner consistent with their approved standard operating procedures. The IO also has the authority to make a regulated/not-regulated determination for any specific project or category of projects.

The University does not require researchers to seek a formal "Not Regulated" determination from the IRB when the activity falls outside of the Common Rule and FDA definitions of human subjects research or where the University is not engaged in the research. Some types of projects that are not regulated under the Common Rule may require review only for the purpose of assessing compliance with HIPAA or other regulations or institutional policies. Researchers may consult informally with IRB staff or members to facilitate a self-determination of "Not Regulated" activities. To obtain formal documentation of a "Not Regulated" determination, an "Activities not regulated as human subjects research" IRB application must be submitted in eResearch Regulatory Management. This application type allows the PI to self-generate a "Not Regulated" determination letter that may be used for funding or publication purposes or to request an IRB review to confirm the status of the project.

For "Not Regulated" projects that will be conducted outside of the University, in addition to meeting University requirements, researchers are strongly encouraged to consult proactively with the external institution to ensure that their work aligns with all relevant requirements at the collaborating institution.

B. Common Activities

The HRPP Leadership has developed the following list of common activities for which categorical regulated/not-regulated determinations have been made; some of these categories are "deemed not to be research" under Federal Common Rule [45 CFR 46.102\(l\)](#). See [Part 5 of this OM](#) for additional examples of research-related activities considered to constitute "engagement" or "non-engagement" in research. Selected activities that often are particularly difficult to categorize are discussed in further detail below. Even though submission of an IRB application is not required for certain activities, it may be beneficial to obtain a prospective "Not Regulated" determination in the event it is requested at the time of any publication.

Table 4: Regulated vs. Not Regulated Human subjects research and Activities Requiring or Not Requiring IRB Review and Approval Prior to Initiation

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
Clinical Investigations	Experiments using a test article (e.g. investigational drug, device, or biological) on one or more human subjects, or on the specimen of a human subject, that are regulated by the FDA or support applications for research or marketing permits for products regulated by the FDA. Products regulated include foods, including dietary supplements that bear a nutrient content claim or a health claim, infant formulas, food and color additives, drugs for human use, medical devices for human use, biological products for human use, and electronic products that aid in diagnosis or treatment of injury or illness.	YES
Medical Practice	Standard practice, innovative care, or off-label use of FDA-approved drugs, biologics, devices and other articles or substances that are used in the normal course of medical practice, provided the activity does not involve systematic collection of safety or efficacy data, and is limited to prevention, diagnosis, mitigation, treatment, or cure of disease in affected individuals.	NO
Standard Diagnostic or Therapeutic Procedures	The collection of data about a series of established and accepted diagnostic or therapeutic procedures, or instructional methods for dissemination or contribution to generalizable knowledge.	YES
Standard Diagnostic or Therapeutic Procedures	An alteration in patient care or assignment for research purposes.	YES
Standard Diagnostic or Therapeutic Procedures	A diagnostic procedure added to a standard treatment for the purpose of research.	YES

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
Standard Diagnostic or Therapeutic Procedures	An established and accepted diagnostic, therapeutic procedure or instructional method, performed only for the benefit of a patient or student but not for the purposes of research. (See Case Studies).	NO
Public Health Surveillance Activities	Public health surveillance activities, including the collection and testing of information or biospecimens, conducted, supported, requested, ordered, required, or authorized by a public health authority. Such activities are limited to those necessary to allow a public health authority to identify, monitor, assess, or investigate potential public health signals, onsets of disease outbreaks, or conditions of public health importance (including trends, signals, risk factors, patterns in disease, or increases in injuries from using consumer products). Such activities include those associated with providing timely situational awareness and priority setting during the course of an event or crisis that threatens public health (including natural or man-made disasters). See 45 CFR 46.102(l)(2) for additional information.	NO

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
Case Studies - Clinical	<p>Report about one or two clinical experiences or observations identified in the course of clinical care, provided that FDA regulations requiring IRB approval do not apply, such as use of:</p> <ul style="list-style-type: none"> • Articles (e.g. drugs, devices, biologics) that have not been approved for use in humans; • Articles requiring exemption from FDA oversight; or • Articles under an Investigational New Drug Application (IND)/Investigational Device Exemption (IDE). 	NO
Case Studies - Other	Report about experiences or observations associated with one or two individuals.	NO
Innovative Procedures, Treatment, or Instructional Methods	Systematic investigation of innovations in diagnostic, therapeutic procedure or instructional method in multiple participants in order to compare to standard procedure. The investigation is designed to test a hypothesis, permit conclusions to be drawn, and thereby develop or contribute to generalizable knowledge.	YES
Innovative Procedures, Treatment, or Instructional Methods	The use of innovative interventions that are designed solely to enhance the well-being of an individual patient or client and have a reasonable expectation of success. The intent of the intervention is to provide diagnosis, preventive treatment, or therapy to the particular individual. (See Case Studies and Medical Practice).	NO
Pilot Testing	Preliminary activities typically designed to help the researcher refine data collection procedures. Pilot testing is considered to be a research activity as defined in 45 CFR 46.102(l) ; "research means a systematic	YES

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
	investigation, including research development, testing, and evaluation."	
Repositories (e.g., data, specimens, etc.)	A storage site or mechanism by which identifiable human tissue, blood, genetic material or data are stored or archived for research by multiple researchers or multiple research projects.	YES
Pre-Review of Clinical Data Sets	Activities (e.g. review of medical data, queries, etc.) intended only to assess the feasibility of future research. Note that Michigan Medicine or other "covered entity" might need to obtain researcher representations for a review preparatory to research for HIPAA compliance purposes.	YES (required by HIPAA regulations)
Research involving Coded Biological Specimens/Coded Private Information	<p>Analysis of coded human specimens or coded private human data where:</p> <ul style="list-style-type: none"> ● The specimens/data were not collected specifically for the proposed study through an interaction or intervention with living individuals; ● The researchers cannot readily ascertain the identities of the individuals from whom the specimens/data were obtained either directly or indirectly through the coding system because, for example: <ul style="list-style-type: none"> ○ The researchers and the holder of the key enter into an agreement prohibiting the release of the key to the researchers under any circumstances, until the individuals are deceased (HHS regulations do not require IRB review and approval for this agreement); ○ There are IRB-approved written policies and operating procedures for a repository 	YES

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
	<p>or data management center that prohibit the release of the key to the researchers under any circumstances, until the individuals are deceased; or,</p> <ul style="list-style-type: none"> ○ There are other legal requirements prohibiting the release of the key to the researchers, until the individuals are deceased; and ● The investigator is not a researcher or collaborator on the specimen or data provider's research. <p>For use of specimens, the research must not be testing a drug or biologic in support of an IND application.</p> <p>Use of specimens or data may require HIPAA compliance review.</p>	
<p>U-M functioning as the Coordinating Center for a Multi-Center Research Project</p>	<p>U-M is not an enrolling site and the U-M PI has agreed to serve as the coordinating center for a multi-center project, which may include activities such as data collection, data analysis, reporting of adverse events to regulatory authorities, and/or oversight of the research at participating sites.</p>	<p>YES</p>
<p>U-M functioning as the Coordinating Center for a Multi-Center Research Project</p>	<p>U-M is an enrolling site and the U-M PI has agreed to serve as the coordinating center for the multi-center project, which may include activities such as data collection, data analysis, reporting of adverse events to regulatory authorities, and/or oversight of the research at participating sites.</p>	<p>YES</p>
<p>Emergency Use of an Investigational Drug or Device</p>	<p>Institutional policies do not permit research activities to be started, even in an emergency, without prior IRB acknowledgment.</p>	<p>IRB NOTIFICATION AS SOON AS POSSIBLE OR</p>

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
	<ol style="list-style-type: none"> 1. This does not limit the physician's ability to deliver emergency care. The physician may deliver such care, but the data derived from such care may not be used in any prospectively conceived research. 2. Emergency care involving investigational drugs, devices or biologics must meet the FDA requirements and data from such use may not be used in any manner of research. 	WITHIN 5 DAYS
Classroom Assignments/ Research Methods Classes	Activities designed for educational purposes that teach research methods or demonstrate course concepts. The activities are not intended to create new knowledge.	NO
Research Using Publicly Available Data Sets	Use of publicly available data sets that do not include information that can be used to identify individuals. "Publicly available" is defined as information shared without conditions on use. This may include data sets that require payment of a fee to gain access to the data.	NO
Research on Organizations	Information gathering about organizations, including information about operations, budgets, etc. from organizational spokespersons or data sources. Does not include identifiable private information about individual members, employees, or staff of the organization.	NO
Scholarly and Journalistic Activities	Activities (e.g. oral history, journalism, biography, literary criticism, legal research, and historical scholarship), including the collection and use of information, that focus directly on the specific individuals about whom their information is collected. (45 CFR 46.102(l)(1))	NO (exercise of professional ethics is expected)

ACTIVITIES	DESCRIPTION	SUBMISSION REQUIRED TO IRB
Quality Assurance and Quality Improvement Activities - Clinical or Procedures	Systematic, data-guided activities designed to implement promising ways to improve clinical care, patient safety and health care operations. The activity is designed to bring about immediate positive changes in the delivery of healthcare, programs, or business practices in the local setting.	NO
Quality Assurance and Quality Improvement Activities - Non-Clinical	Data collected with the limited intent of evaluating and improving existing services and programs or for developing new services or programs. Examples include teaching evaluations or customer service surveys.	NO
Research Involving Only Decedents	Research involving only data or tissue obtained from individuals who are deceased prior to the conduct of the research. There must not be any interaction or intervention with living individuals, or collection of private data or specimens associated with living individuals. Note that Michigan Medicine or other "covered entity" might need to obtain researcher representations for research involving decedents' data for HIPAA compliance purposes.	YES (required by HIPAA regulations)
Research Involving De-identified Biological Specimens or Information	Research involving a de-identified set (data/biospecimens) which cannot be "re-identified" by any known entity.	NO

Federal regulations also consider certain activities for criminal justice or criminal investigative purposes and agency operational activities to not be research. See [45 CFR 46.102\(l\)](#) for additional information.

C. Student Practicums and Internships

Many of the professional schools within the University actively seek opportunities for their students to become involved in “real world” activities or work assignments that will introduce them to and provide practical experiences in their chosen profession. This involvement may take the form of an internship requirement. In other situations, the opportunities may come in the form of a “practicum” in which

students are assigned to work “in the field” (e.g., in a government agency or in industry) to see firsthand how problems are addressed by professionals in their chosen field. The student intern is under the day-to-day direction of the sponsoring organization, may be given specific work assignments, and may work side-by-side with regular employees of the organization. A faculty member, in turn, provides the “bridge” between the work experience and the learning experience – giving guidance to the student and striving to place the fieldwork into the broader context of the student's educational program.

In general, the development and acceptance of formal University agreements for student practicums or internships are acceptable when, in the opinion of the head of the department in which the practicum would be conducted, the activity may be of educational value or lead to an extension of knowledge, or increase effectiveness in teaching, or increase effectiveness in research. Some student practicums/internships include research activities that are designed to contribute to generalizable knowledge and, thus, are research and reviewable by the IRB and some are not. The following table illustrates the distinctions between activities that do and do not require IRB review.

Table 5: When is U-M IRB approval required for student practicums or internships?

CIRCUMSTANCE	U-M IRB REVIEW REQUIRED?
<p>A practicum/internship that falls within the work scope of a local, state, or federal agency (e.g. Public Health Agency) or employment by private industry involving data collection for non-research purposes. No <i>a priori</i> research design or intent.</p>	NO
<p>Use of or access to human subjects data previously collected for non-research purposes (perhaps through a circumstance like the one above) in a systematic investigation designed to contribute to generalizable knowledge, one indicator of which is publication.</p>	YES
<p>Participation with or providing services to a U-M PI conducting IRB-approved research. No work outside the scope of the IRB approval.</p> <p>U-M Student is providing research assistance at the level not normally requiring an IRB project amendment. For example, providing administrative support for manuscript preparation or working with a fully de-identified data set.</p>	NO
<p>Participation with or providing services to a U-M PI conducting IRB-approved research. No work outside the scope of the IRB approval.</p> <p>U-M Student is providing research assistance at the level of key personnel. For example, accessing identifiable data/biospecimens or interacting with participants for the purposes of the research.</p>	YES (amendment required to add the student to study team)

CIRCUMSTANCE	U-M IRB REVIEW REQUIRED?
<p>U-M Student is participating with or providing services to a non-UM research project. Research is approved by a non-UM IRB.</p> <p>Requires a confirmation letter from the non-UM PI if the student is not engaged in the conduct of human subjects research. The letter should be maintained in the student file by the student's U-M faculty mentor.</p>	NO
<p>U-M Student is participating with or providing services to a non-UM research project. Research is approved by a non-UM IRB.</p> <p>U-M IRB Authorization Agreement ceding oversight to non-UM IRB or IRB review at U-M is necessary if the student is engaged in the conduct of human subjects research.</p>	YES
<p>Independent research project not falling within the scope of a previously approved project.</p>	YES (faculty member assigned as faculty advisor is ultimately responsible.)

If a student or faculty member is unsure whether a particular activity requires U-M IRB approval or an authorization agreement ceding oversight to a non-UM IRB, they should contact the U-M IRB that traditionally monitors research conducted within their academic unit. See [Part 5](#) of this OM to determine the correct IRB.

D. Notification of Decisions

Within eResearch when a determination is made with regards to whether or not a proposed activity is human subjects research or does not meet the definition of human subjects research, the person requesting the determination is informed by electronic confirmation.

VI. POLICY ON EXEMPT RESEARCH

A. Introduction

Under certain circumstances, human subjects research activities subject to the HRPP may be granted exempt status per [45 CFR 46.104](#). This means a study is considered to be research with human subjects, but if it meets the criteria for one or more of the exemption categories, the research is not subject to *all* of the regulatory requirements of 45 CFR 46. For some exemption categories, the regulations require a "limited

IRB review" and/or Privacy Board review of the initial application as part of the exempt determination. Researchers are not required to return to the IRB for approval of amendments to exempt studies, except where changes to the study exceed the scope of the original exemption category. Exempt status does not, however, lessen the ethical obligations to subjects as articulated in the Belmont Report and in disciplinary codes of professional conduct.

IRB SOPs require an eResearch IRB application be submitted for exempt projects. The application includes specific questions to evaluate the protection of human subjects and to determine eligibility under each exemption category per 45 CFR 46.104. The IRB application is configured to permit researchers to obtain a system-generated exemption letter for certain exemption categories based upon responses to qualifying questions. Researchers may also choose to submit these applications to the IRB for review. All other applications for exemption are reviewed and determinations issued by the IRB or qualified IRB staff. Exemption applications requiring limited IRB review are evaluated via the expedited review process for assessment of provisions for subject privacy and confidentiality of data found at [45 CFR 46.111 \(a\)\(7\)](#) before an exempt determination is made.

The applicable exemption category or categories are recorded in the eRRM system and included in the determination letter issued to the researcher. The application and determination letter remind researchers of the ethical obligation to ensure that participants are fully informed about the nature of a research project so that they can make an informed decision to participate.

B. Categories of Eligibility for Exempt Determination

It is the policy of the University that to be determined to be exempt, research must pose **no more than minimal risk** and the IRB does not determine that continuing review would enhance protection of research participants.

1. Federal Exemption Categories

For a list and detailed requirements of the federal exemption categories see [45 CFR 46.104](#).

Note: U-M has not implemented Broad Consent and therefore exemption categories 7 and 8 are not applicable to U-M research.

Each of the federal exemption categories may be applied to research subject to [45 CFR 46, Subpart B](#), Additional Protections for Pregnant Women, Human Fetuses, and Neonates Involved in Research, if the conditions of the exemption are met per [45 CFR 46.104\(b\)\(1\)](#).

Exempt status is not granted for research subject to [45 CFR 46, Subpart C](#), Additional Protections Pertaining to Biomedical and Behavioral Research Involving Prisoners as Subjects, except where the research is intended for a broader subject population and only incidentally involves prisoners per [45 CFR 46.104\(b\)\(2\)](#).

Exemptions 1, 4, 5 and 6 may be applied to research subject to [45 CFR 46, Subpart D](#), Additional Protections for Children Involved in Research. [45 CFR 46.104\(b\)\(3\)](#) indicates special limitations in the application of exempt status to research with children for exemption 2(i) and 2(ii). Exemptions 2(iii) and 3 cannot be applied to research with children.

FDA-regulated research may not be granted exempt status, except for Exemption 6. Subject to the

exceptions above, and consistent with IRB-specific SOPs, research may be granted exempt status if all proposed research activities involve procedures listed in one or more of the specific exempt categories. (See [45 CFR 46.104d](#).)

For Exemptions 2 and 3, in order for the IRB to conduct limited review, the researcher is required to submit information as part of the eResearch application, including:

- A protocol document or a protocol summary that describes the participant population, study procedures, and research locations;
- Documents relevant to the research (e.g. recruitment materials, a proposed consent document, survey instruments); and
- Information regarding the sensitivity of data to be collected.

2. U-M Exemption Categories

The following exemption is defined by U-M policy:

- U-M Exemption 5: Research and demonstration projects sponsored by the State of Michigan which are designed to study, evaluate, or otherwise examine: public benefit or service programs; procedures for obtaining benefits or services under those programs; possible changes in or alternatives to those programs or procedures; or possible changes in methods or levels of payment for benefits or services under those programs.

C. Authority to Grant Exempt Status

The IO has granted to the University IRBs the authority to invoke federal exemptions 1- 4 and 6 listed at [45 CFR 46.104](#). How and to whom the IRBs distribute the authority to issue exemptions is described in the IRB SOPs. IRB SOPs will ensure that individuals issuing exemptions receive initial and continuing training in the details of the exempt determination process.

The IO allows the IRBs, consistent with their SOPs, to permit researchers to obtain a system-generated exemption determination letter based upon responses to qualifying questions. System-generated exempt determinations may be subject to audit by the IRBs or the HRPP to validate the outcome. Research eligible for system-generated exemption determination must meet the criteria for exemption categories 1-3 and is subject to the following limitations:

- The research does not involve any data subject to HIPAA or Family Educational Rights and Privacy Act, (FERPA) regulations;
- For Exemption 3, the research cannot involve deception or concealment;
- The research does not require "limited IRB review" under 45 CFR 46.104.

The IRB does not grant Exemption 5. The IO has delegated the authority to grant Exemption 5 (Federal and U-M Exemption 5) to the HRPP Director. Any project that may be eligible for Exemption 5 will be forwarded to the HRPP Director for review.

D. Notification and Documentation of Exempt Status

The individual requesting the exempt determination is informed by electronic confirmation from eResearch. The notice of exempt determination includes the exemption category assigned to the project and a statement that an amendment must be submitted to the IRB for any change in the research that **might affect the exempt status or exceeds the scope of the determined category/ies, or if ancillary review is indicated**. The amendment must be submitted before the change is initiated.

Part 5: IRB Jurisdiction, Cooperative Research, and Reliance Agreements

Describes the scope of jurisdiction of the various University IRBs and policies on cooperative research and IRB reliance agreements.

I. INTRODUCTION

U-M has registered eight IRBs under its [Federalwide Assurance](#) with the U.S. Department of Health and Human Services. Six IRBs (collectively referred to as IRBMED) review Michigan Medicine (including U-M Medical School) research. Two IRBs (collectively referred to as IRB-Health Sciences and Behavioral Sciences, or IRB-HSBS), are operated by the Office of the Vice President for Research (OVPR) and review health, behavioral, educational, and social science research occurring at UM-Ann Arbor, Dearborn, or Flint campuses (exceptions described below). This section of the OM describes the scope of jurisdiction of these various University IRBs and outlines University policies on cooperative research and reliance agreements when sharing oversight of research with another institution.

II. WHICH UNIVERSITY OF MICHIGAN IRB

The guidance below describes in more detail primary IRB jurisdiction, indicating when research must be reviewed by either IRBMED or IRB-HSBS, common exceptions to primary jurisdiction, and the procedures to follow in determining jurisdiction in unusual cases. For any transfer, the receiving IRB will be provided with all information associated with the review by the original IRB via eResearch.

A. IRBMED

1. Primary Jurisdiction

- All research for which the Principal Investigator is faculty, staff, a student, or a trainee with a primary appointment in Michigan Medicine, including the Medical School
- All research using the patients, medical records, or facilities of Michigan Medicine
 - All FDA-regulated research or medical intervention research conducted by faculty and staff from other U-M units including Dentistry and the campuses of U-M Ann Arbor, Flint, and Dearborn
- All clinical investigations conducted by the School of Dentistry
- Research using the Functional MRI (fMRI) Laboratory, except for researchers under IRB-HSBS jurisdiction that conduct projects using the IRBMED-approved fMRI Master Protocol
- Research conducted with the U-M Statewide Network of Care sites, including when the Principal Investigator is faculty, staff, a student or a trainee with a primary appointment in U-M Ann Arbor, Dearborn, or Flint schools, colleges, and units

2. Exceptions

By agreement of the IRBs, IRB-HSBS may review:

- Some categories of exempt research submitted by Medical School researchers, and
- Research for which the Principal Investigator is faculty, staff, a student, or a trainee with a primary appointment outside of Michigan Medicine, but the research involves recruitment activities that intend to enroll Michigan Medicine patients, but do not involve the conduct of the research within a Michigan Medicine facility or access to Michigan Medicine medical records.

B. IRB-Health Sciences and Behavioral Sciences

1. Primary Jurisdiction

- All research for which the Principal Investigator is faculty, staff, a student, or a trainee with a primary appointment in UM-Ann Arbor, Dearborn, or Flint schools, colleges, units, or programs and not subject to IRBMED jurisdiction. These include but are not limited to:
 - U-M Institutional Research
 - UM-Ann Arbor campus units:
 - College of Architecture and Urban Planning
 - College of Engineering
 - College of Literature, Science, and the Arts
 - College of Pharmacy
 - Institute for Social Research (ISR)
 - Ford School of Public Policy
 - Law School
 - Mary A. Rackham Institute
 - Rackham Graduate School
 - Ross School of Business
 - School of Dentistry
 - School of Education
 - School of Environment and Sustainability
 - School of Information
 - School of Music, Theatre, and Dance
 - School of Kinesiology
 - School of Nursing
 - School of Public Health
 - School of Social Work
 - Stamps School of Art and Design

- University Health Services
- UM-Dearborn campus units:
 - College of Arts, Sciences, & Letters
 - College of Business
 - College of Education, Health, & Human Services
 - College of Engineering & Computer Science
- UM-Flint campus units:
 - College of Arts and Sciences
 - College of Health Sciences
 - School of Education and Human Services
 - School of Management
 - School of Nursing

C. General Exceptions

1. In any case where the IRB with primary jurisdiction determines that it does not have the appropriate expertise or is not appropriately constituted to review a research proposal, the project may be transferred to the IRB with appropriate expertise for review and approval.
2. When a Conflict of Interest (COI) precludes achieving a quorum for review, the project may be transferred to an alternate IRB with appropriate expertise for review and approval. The selection of an alternative IRB will be made by the chair of the referring IRB in consultation with the receiving IRB if the chair does not have a disqualifying conflict. If the chair has a disqualifying conflict of interest, the IO or designee will make the selection.
3. In those instances, in which another IRB or a faculty member, staff member, student, or other trainee requests review by an alternate U-M IRB, the IRB Directors will review the reasons for such a request; and decide which IRB shall conduct the review. The IO or HRPP Director may overrule a Director's refusal to refer an application to another U-M IRB.
4. In rare instances, in which the rules outlined in this section do not clearly define which IRB to use and the IRB Directors cannot agree on jurisdiction, the matter may be referred to the IO or HRPP Director for a recommendation.

The IRB is also authorized, at its discretion, to invite individuals with special expertise to assist in the review of issues that require expertise beyond or in addition to that available on the IRB. These individuals will disclose any conflicts of interest to the IRB and they may not vote with the IRB.

III. COLLABORATIVE AND MULTI-SITE RESEARCH

Researchers at U-M frequently interact with entities or individuals outside the University. The types of relationships are too numerous to list, but they may include:

- Establishing research collaborations by subcontracting from or to the University;

- Serving as the coordinating site for a multi-center clinical trial being conducted elsewhere or serving as a performance site in a multi-center clinical trial;
- Conducting research at clinics, schools, etc., where the outside site provides only access to participants or where the outside site has or will have identifiable data;
- Conducting research in another country, but not in partnership with an established entity in that country, and establishing relationships with individuals, such as volunteer research assistants, who will provide services.

The University’s (and its researchers’) regulatory obligations and alternatives for addressing cooperative research situations differ depending on the relationship with the entity or individual outside the University in the context of the research project. In analyzing the many types of relationships that exist between the University and its researchers, on one hand, and outside entities or individuals, on the other, a primary distinction can be made between those institutions that are “engaged” in human research and those that are “not engaged”. This distinction is important because each engaged institution is responsible for safeguarding the rights and welfare of research participants and for complying with applicable laws and regulations (including the Common Rule, as appropriate) and with its own HRPP policies and procedures.

The HRPP has implemented the policies described below and in [Part 3](#) of this OM to ensure that the University can fulfill its affirmative obligation to ensure appropriate oversight of research in which the University is “engaged” and also, under certain circumstances, of other “engaged” entities associated with University research.

A. Engagement in Human Research

The circumstances under which an institution is considered engaged in research are described in [Part 4 of this OM](#) and the [OHRP guidance on engagement of institutions](#).

B. Researcher and IRB Responsibilities Concerning Engaged Performance Sites

When multiple sites are engaged in non-exempt research, the U-M IRB must approve the arrangements for review. The process for determining the appropriate review arrangements including the use of a single IRB of Record (sIRB) and the circumstances under which the University will agree to serve as the sIRB for other engaged sites or to cede review of University research to other IRBs are described below in section IV and on the IRB websites. When the overall PI of research conducted at multiple locations is affiliated with the University or the University is otherwise involved as the primary or coordinating center, the PI must assure the University IRB that each performance location involved in the research has a Reliance Agreement or that the research has been properly approved at that location before the research is initiated there and must notify the University IRB if any lapse or other change in approval status occurs. The IRB may take any steps it deems appropriate to verify the information provided by the PI.

C. Researcher and IRB Responsibilities Concerning Performance Sites not Engaged in Research

When a performance site is not engaged in research, it is the responsibility of the PI to ensure that the site’s facilities and resources are appropriate for the nature of the activities that will be conducted there. It is also the responsibility of the PI to notify the IRB promptly if a change in research activities changes the

performance site's engagement in research.

IRBs may ask researchers to submit statements from entities not engaged in research but providing research services or site access as evidence of permission by those entities for their involvement. The researcher may begin research activities at each site as it is approved by the IRB. Sites may be added to a research study with the submission of an amendment and the appropriate documents to the IRB for review and approval before beginning research activities at the new performance sites.

D. University Responsibilities for Multi-Site Research in Which the University is Engaged

1. General

NIH policy, the Common Rule, and certain sponsors require that multi-site and collaborative research use a sIRB model. IRBs whose jurisdiction typically extends to research in which the University is one of multiple engaged sites must have a method to:

- Determine when other IRBs are involved and if sIRB is required;
- Define their respective responsibilities in connection with the research;
- Communicate as appropriate with the other involved IRBs; and
- Notify researchers of any special expectations for the conduct of multi-site research.

This may be accomplished through any combination of SOPs, application forms, formal and informal guidance, inter-institutional agreements, and other communications. For example, the University IRB should determine prior to the initiation of research how it will solicit and review reports of unanticipated problems involving risks to research participants or others, regardless of location, when those risks may have an impact on any matter within that IRB's jurisdiction.

2. Reliance Agreements

When one IRB acts as the Reviewing IRB on behalf of other engaged institutions, referred to as Relying IRBs, a written reliance agreement (also called an IRB Authorization Agreement) among the involved institutions is required. The agreement will include the applicable responsibilities listed below and any applicable requirements set forth by accreditation standards. Whether using a sIRB or not, the U-M IRB must approve the arrangement either for individual studies or categorically (e.g., Master Agreements with commercial IRBs). The University does not enter into reliance agreements with external entities for projects that have been determined to be exempt. Note: See [FDA Policy on "Non-Local IRB Review"](#) for additional guidance on cooperative research and reliance on non-local IRBs for approval of FDA-regulated research.

The IO has delegated authority for approving IRB reliance agreements to the HRPP Director.

IRBs have a central role in determining whether proposed arrangements preserve and promote protections for human participants in research for which they have responsibility, and, thus, are acceptable. Executed reliance agreements are maintained in the electronic IRB system and by each IRB.

3. University of Michigan as Single IRB of Record (sIRB)

An IRB is considered the sIRB when it assumes IRB responsibilities for another institution. In appropriate circumstances, described on the IRB websites, the University will consider becoming the sIRB for an outside entity engaged in the research or ceding authority for review and oversight of University research to an outside IRB.

a. Statement of Principles

Under certain circumstances, the University will agree to become the sIRB for research conducted at another entity or allow another institution's IRB to serve as sIRB for University research. The University will not normally provide sIRB services for research in which the University is not engaged or in which its researchers are not otherwise involved. Nor will the University provide sIRB services for research over which the University does not feel it can appropriately address the local context or otherwise exercise adequate oversight. Researchers must obtain approval of the U-M HRPP via a reliance agreement prior to seeking review by an external IRB. When possible, the University prefers to cede oversight to an AAHRPP accredited IRB.

Additional information is provided on the [HRPP website](#).

b. Procedures for a University IRB to Become sIRB for Another Institution

Upon receiving a request for sIRB services, the U-M IRB reviewing the request must decide whether it wishes to accept the obligation. In such a review the U-M IRB should consider any relevant information including, for example:

- The time and resources required to accept the review, given other demands;
- The expertise required for initial and continuing review;
- The ability to comply with requirements for "local" knowledge of the research context at the outside organization and any research sites;
- The resources, ability, and willingness of the outside organization, the PI, and the research sites to handle complaints, review adverse events, and monitor compliance with applicable laws and regulations and IRB requirements; and
- The ability and willingness to comply with any additional requirements the outside organization may impose on the U-M review.

If the U-M IRB agrees to accept the responsibility of being the sIRB, the HRPP Director will indicate agreement via a reliance agreement and prepare a recommendation based on the IRB's willingness to provide services and any other relevant institutional-level factors, including the ability to manage any potential conflict of interest. An arrangement to accept responsibility as the sIRB must be documented in a written reliance agreement under which the respective responsibilities of the two organizations will be described.

c. Responsibilities of the Reviewing IRB in Accordance with Reliance Agreement Terms

- Review of initial submission, continuing review and review of amendments and reportable events for all sites in accordance with the human subject protection requirements of each Relying Institution's FWA, the federal regulations and ethical principles referenced therein, any other applicable federal human subjects research regulations or policies;

- Ensure that local context information provided by relying sites (such as state or local laws, conflict of interest determinations, and site-specific information requested for certain sections of the informed consent) satisfies IRB approval criteria;
- Make Privacy Board determinations per HIPAA, when applicable;
- Review COI and ICOI management plans provided by the relying institution and, if needed, require modifications;
- Communicate all IRB findings and determinations in writing to researchers, institutions, sponsors, and federal agencies, as appropriate. This includes decisions on protocols, changes, suspensions, terminations or research participant continuation during lapses in approval, unanticipated problems involving risks to research participants or others, noncompliance, audits, or complaints; and
- Make its policies and procedures available to relying institutions, when applicable and upon request.

d. Responsibilities of the Relying IRB

- Identify and provide local considerations to the reviewing IRB, related to state or local laws, and institutional policies and/or standards;
- Identify and analyze COIs and ICOIs, and propose management plans, if needed;
- Provide local ancillary and institutional approvals, including any applicable COI management plans, to the reviewing IRB;
- Ensure research personnel are appropriately trained to conduct human research;
- Ensure research personnel are notified of their responsibilities when conducting research pursuant to a reliance agreement;
- Comply with the determinations and requirements of the reviewing IRB;
- Have access to a Quality Assurance and Quality Improvement (QA/QI) program to ensure proper monitoring of research and perform audits upon request from the reviewing IRB;
- Have a mechanism by which complaints about the research can be made by local research participants and others; and
- Ensure the study team notifies the reviewing IRB of:
 - Unanticipated problems;
 - Serious and/or continuing noncompliance;
 - Restriction/suspension of study team activities;
 - PI and personnel changes;
 - Changes that require informed consent or HIPAA revisions;
 - Audits and inspections, including findings and corrective actions;
 - Communication with regulatory agencies;

- Institutional legal requests and claims; and
- Research misconduct.

4. Procedures for Ceding Authority to a Non-U-M IRB

Requests to cede U-M IRB authority to the IRB associated with another entity, to a commercial IRB, or a central IRB generally arise in U-M IRB offices in the context of IRB review of projects under their jurisdictions. Requests typically involve oversight of a single project.

Among the considerations involved in the review of a request to cede authority are the following:

- The requirement to cede to an external IRB that is designated as the sIRB for a federally-sponsored research project;
- The reduction of regulatory and administrative burden by ceding review to an external IRB;
- The appropriateness of the external IRB to review local context; qualifications of the IRB to which the review will be ceded (with due consideration given to such objective factors as accreditation status); and level of confidence in its review and determinations; and
- The proposed arrangements for monitoring the outside review and oversight.

When reliance on a non-accredited IRB is proposed, the evaluation may involve additional considerations, based on the risks of research, the research activities that the University will be involved in, and the assessed experience and regulatory knowledge of the external IRB. Such considerations include, but are not limited to, review of IRB rosters for identification of areas of expertise, other evidence of self-evaluation by the external IRB, and the University's prior experience with the external IRB.

U-M does not typically cede non-IRB review functions (e.g. biosafety review, radiation safety review, recombinant DNA research review, human stem cell research review, and conflict of interest review), but if these reviews are performed by an external organization the following applies: The review is communicated to the U-M IRB via the correspondence mechanisms in the eResearch system; the external organization will be informed of any additional regulatory requirements during communication to establish the review functions; through the eResearch system, the researcher will be kept informed of the process.

Final approval of ceding requests is the responsibility of the HRPP Director who will authorize the IRB to establish a formal agreement between the University and the entity in which the external IRB resides (if one does not already exist), under which the respective responsibilities of the two organizations will be described. The IRB may follow procedures according to established master agreements or prior agreement with the U-M IRB for specified project types or study networks.

5. University of Michigan as a Lead or Operations Coordinating Center

In general, the Lead Site (also referred to as the Lead Coordinating Center (LCC), Clinical Coordinating Center (CCC), or Data Coordinating Center (DCC)) has the responsibility for providing administrative oversight, management of data, and the provision of organizational support in the conduct of a multi-site research project. Serving as the LCC, CCC, or DCC does not always mean the institution is also serving as the sIRB. If a U-M faculty is designated as the Lead Site PI for the conduct of a multi-site

research project, the IRB will require additional information to ensure there is appropriate regulatory oversight and management, and may suggest the submission of a separate multi-site application in [eResearch](#). Information reviewed by the IRB will include, but is not limited to, the following:

a. Regulatory Documentation

The Lead Site PI should submit a plan to the IRB for managing the regulatory documentation (e.g., informed consent, protocol amendments, site IRB approvals, etc.) from each of the participating sites. The Lead Site PI must also require each participating site to maintain and manage its own regulatory documentation according to their institutional policies and procedures. The Lead Site may also be responsible for creating a manual or other relevant documentation (e.g., a Manual of Operations binder) which contains all the information required by each individual site to complete the study. This manual will be shared with each site.

b. Participating Site Communication Plan

The Lead Site PI should have a plan for documented communications between the participating sites and the LCC, CCC, or DCC. Communications may include information on changes to the regulatory documentation (i.e., research protocol, informed consent, etc.), interim analysis on the progress of the research project, or safety reporting.

c. Reporting of Serious Adverse Events and Unanticipated Problems

The Lead Site PI is responsible for the development, collection, and maintenance of a plan to review, in a timely fashion, all serious adverse events (SAEs) and unanticipated problems. The Lead Site is responsible for meeting the reporting timelines to the IRB as described in the research protocol, as well as monitoring the participating sites reporting obligations to their own IRB and the U-M Lead Site.

d. Data Collection and Analysis

The Lead Site PI is responsible for either the development of case report forms (CRFs), or other data collection instruments, or delegating the task to another site, such as the DCC. The Lead Site PI is also responsible for managing retention of documents according to institutional or sponsor policies and procedures. If the Lead Site PI also has the responsibility of data coordination, then he/she should submit a separate application in eResearch for the functionality of the DCC and provide the IRB with a plan for the review of the study data and the submission of any required interim analysis results sent to participating sites.

e. Participating Site Training

The Lead Site PI should confirm that all participating sites have received appropriate human subjects research training for the conduct of the project and understand the regulatory reporting requirements. In general, the Lead Site PI should ensure that the participating sites are familiar with the research project design and procedures, reporting of SAEs and unanticipated problem(s), administration and documentation of study drug or device dispensation, compliance monitoring, and record retention.

f. Additional Responsibilities

The Lead Site PI should also determine the plan for delegation of authority within the study team and the participating site(s), for ongoing project management as necessary. The Lead Site PI is responsible for ensuring appropriate IRB approval is obtained by sites prior to initiation of the project at that site.

6. SMART IRB

U-M is a signatory to the [SMART IRB Master Reliance Agreement](#). The agreement is designed to streamline and harmonize the IRB review process for multi-site studies and eliminate the time and effort of negotiating IRB reliance agreements for each new study. When possible, U-M will use the SMART IRB process for establishing reliance agreements with other member institutions when serving as the sIRB or being a relying IRB.

7. Responsibilities of the HRPP and Local IRB in Multi-Site Research

Even when the University or another institution serves as IRB-of-Record for multi-site research, each organization remains responsible for maintaining a system to protect research participants. The ceding institution retains responsibility for the compliant conduct of research occurring at its site, including safeguarding the rights and welfare of research participants and educating members of its research community to establish and maintain a culture of compliance with applicable laws and regulations and with institutional policies relevant to the protection of research participants. The ceding institution also remains responsible for implementing appropriate oversight mechanisms to ensure compliance with the determinations of the reviewing IRB. Thus, for example, a U-M performance site may be subject to not-for-cause compliance reviews and for-cause inspections through the University's HRPP even if oversight of the project has been ceded to an outside IRB.

IV. UNAFFILIATED INVESTIGATORS

Researchers engaged in federally funded research conducted by or at U-M who are not affiliated with the University and not agents of an outside entity that can provide IRB review must sign an "Individual Investigator Agreement" to assure that they understand their obligations as researchers (the IRB may grant an exception to the signature requirement in cases involving literacy or technology constraints).

For non-federally funded research, unaffiliated researchers generally are required to sign an "Individual Investigator Agreement" but may be granted an exception by the IRB in limited cases.

See the [flow diagrams for IRB authorization agreements and individual investigator agreements](#).

V. COMMUNITY BASED PARTICIPATORY RESEARCH (CBPR)

In certain studies, local community members may be involved in the conduct of U-M human subjects research, such as assisting in the development of the research protocol and study materials, implementation of the research, and dissemination of the research results. Community members engaged in the research and participating on a U-M study team sign an agreement that outlines their roles and responsibilities, identifies training and reporting requirements, and specifically indicates that any modifications to the research must be communicated to the U-M PI and approved by the reviewing IRB before implementation ([See OM Part 5, Section IV for information about unaffiliated investigators](#)).

When reviewing these studies, IRBs should consider whether the community members are provided with sufficient training to perform the research functions and whether there is a clear communication plan between the community members and the PI to convey information about the conduct of the study, as well as any adverse events or unanticipated problems that may have been encountered.

When community members are both study team members and research participants, IRBs should examine the study protocol and informed consent materials to ensure that there is a clear delineation between each role, attendant expectations and risks, and whether community members have been provided with sufficient information to understand the voluntary nature of each role. IRBs should ensure that community members in this dual role have been provided the contact information for the IRB to ask questions about their rights as a study team member and/or a research participant to protect them from coercion and undue influence and ensure research integrity.

VI. U-M HEALTH STATEWIDE CLINICAL RESEARCH PARTNERSHIPS

U-M Health and Michigan Medicine have developed several collaborations and affiliations with health systems, hospitals, and providers throughout the state of Michigan. These collaborations and affiliations open an opportunity for researchers at the U-M to extend clinical research throughout the [U-M Health Network of Care Sites](#) for patients to participate in clinical research. To support this effort, the Medical School Office of Research and the Michigan Institute for Clinical & Health Research (MICHHR) developed resources through the [U-M Statewide Clinical Research Partnership \(SCRIP\)](#) unit to support U-M researchers in extending clinical research opportunities to patients at the U-M Health Network of Care Sites.

The HRPP has implemented procedural requirements for working with U-M researchers and the SCRIP team to ensure that the University can fulfill its affirmative obligation to assure appropriate IRB oversight of research in circumstances when [U-M Health Network of Care Sites](#) are “engaged” in research associated with the University. All research conducted with the U-M Health Network of Care Sites must work with SCRIP team prior to initiation. The SCRIP team will work closely with the U-M researchers to assess the study protocol and all the other supporting materials and guide U-M researchers through the necessary steps to address the unique administrative and regulatory requirements that are needed when working across affiliated and collaborating sites.

PART 6: Roles and Responsibilities of Researchers and Research Staff

Describes the roles and responsibilities of researchers and research staff engaged in University research.

I. ELIGIBILITY TO PERFORM RESEARCH AT THE UNIVERSITY OF MICHIGAN

Eligibility requirements for conducting research involving research participants vary depending on the role of the researcher. Engaged study team members must be appropriately qualified by training and/or experience to perform their research responsibilities, and must be listed on the IRB application. See [Part 5](#) of this OM for additional examples of research-related activities considered to constitute “engagement” in research.

A. Principal Investigator

The Principal Investigator (PI) bears ultimate responsibility for all activities associated with the conduct of a research project, including compliance with federal, state, and local laws, institutional policies, and ethical principles. The PI remains ultimately responsible even when some aspects of the research are delegated to other members of the study team or third parties. For additional guidance pertaining to FDA regulated research see: [Guidance for Industry: Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects](#).

Students/trainees (i.e., undergraduate students, graduate students, postdoctoral fellows, and other individuals in programs designed to provide non-independent research experiences) are permitted to serve in the role of PI but must have a Faculty Advisor (FA) who shares in the student’s/trainee's responsibility for the conduct of the research. Undergraduate students may be permitted to serve in the role of PI on minimal risk studies only.

B. Co-Investigator

Co-Investigators (Co-Is) are a subset of the study team who have special responsibilities on research projects. Co-Is are obligated to ensure that the project is designed and conducted in compliance with applicable laws and regulations and institutional policy governing the conduct of research involving research participants. A Co-I must be qualified by training and experience to conduct his or her responsibilities on the research project.

Each Co-I must explicitly acknowledge to the IRB their participation as a Co-Investigator on the study and will be asked to acknowledge their addition to any existing IRB-approved study. Co-Is will be notified of, but will not be required to acknowledge, submissions from the PI to the IRB, such as amendments, adverse event reports, scheduled continuation reviews, terminations, and any related communications regarding such submissions.

C. Subinvestigator

"Subinvestigator" is a term specific to FDA-regulated studies. It identifies study team members who

perform critical clinical trial-related procedures and/or make important trial-related decisions. Generally, these are also study Co-Is, but other study team members with critical trial-related roles may serve as Subinvestigators. The term “Subinvestigator” is not used in the U-M IRB application.

D. Faculty Advisor

All research conducted by students/trainees as PI, including postdoctoral fellows, must include a Faculty Advisor (FA) as a member of the study team. In addition to the expectation that the FA provide active mentorship to the trainee during the conduct of the research, the FA shares responsibility with the student/trainee researcher for the ethical and regulatory compliance, conduct of the research and is institutionally accountable for the study. FAs must access eResearch Regulatory Management and accept their role before an application can be submitted.

E. Other Study Team Members

Other study team members include individuals who contribute to the scientific development or execution of a study in a substantive, measurable way, and include:

- **Study Coordinator:** The Study Coordinator is a research professional who works under the direction of the PI to support, facilitate, and coordinate the daily study activities and plays a critical role in the conduct of the study. Study coordinators must access eResearch Regulatory Management and accept their role before an application can be submitted, unless the study is Not Regulated or Exempt.
- **Administrative Staff:** Individuals who are not involved in the design, conduct, or reporting of research (e.g., unit administrators). Administrative Staff do not interact with research participants or with identifiable data. These individuals are not required to accept their role. **Research Staff:** Individuals who are involved in the design, conduct, or reporting of research. These individuals must accept their role before IRB submission of the application.
- **Biostatistician:** Statisticians are study staff that analyze data collected during the study. These individuals must access eResearch Regulatory Management and accept their role before an application can be submitted, unless the study is Not Regulated or Exempt.
- **Consultant:** A consultant is a specialist in a specific area of the study, usually from outside the normal study staff. These individuals must access eResearch Regulatory Management and accept their role before an application can be submitted, unless the study is Not Regulated or Exempt.
- **Other:** ‘Other’ can include engaged External Collaborators (study team members who are not affiliated with U-M but are conducting U-M human subjects research and whose institution is not otherwise a performance site in the research, or the IRB of record), as well as, affiliated individuals such as, active emeritus faculty, adjunct faculty, visiting scholars, visiting graduate students, International Visiting Scholars, and Volunteers vetted through Volunteer services during their sponsorship/appointment. These individuals must access eResearch Regulatory Management and accept their role before an application can be submitted, unless the study is Not Regulated or Exempt.

F. Students/Trainees

U-M students/trainees may serve as PIs, however, supervision by a faculty member is required for any

research performed by students/trainees in any role, to ensure the proper conduct of research and protection of participant rights and welfare. Undergraduate students may be permitted to serve in the role of PI on minimal risk studies only.

Table 6 provides information about permissible roles for U-M faculty, students/trainees, and staff on IRB applications. Exceptions to these requirements are at the **discretion of the IO or designee**.

Table 6: Who May Serve as PI, Co-I, or Faculty Advisor on IRB Applications

Current Status	PI	Co-I	Faculty Advisor	Additional Requirement(s) (non-exempt human research)
Instructional Faculty Research Faculty Clinical Faculty Active Emeritus Faculty Librarian Curator Archivist	Yes	Yes	Yes	None
Adjunct Faculty Visiting Faculty Lecturer Instructor	Yes	Yes	No	<ul style="list-style-type: none"> • Application includes Faculty Advisor, OR • Documented participation on a sponsored project (PAF), OR • Other documented permission of the unit
Staff	Yes	Yes	No	<ul style="list-style-type: none"> • Documented participation on a sponsored project (PAF), OR • Other documented permission of the unit or as required as part of their U-M job responsibilities

Current Status	PI	Co-I	Faculty Advisor	Additional Requirement(s) (non-exempt human research)
Students/Trainees: <ul style="list-style-type: none"> • Undergraduate Students (minimal risk studies only) • Graduate Students • Professional Degree Students • Residents/Interns/House Officers • Clinical Fellows • Postdoctoral Fellows 	Yes	Yes	No	Application must include Faculty Advisor (exempt and non-exempt human subjects research)
Other qualified individuals, including external collaborators and providers from the UM Health Statewide Network of Care sites, conducting non-exempt research	No	Yes	No	Permission of the IRB

II. ROLES AND RESPONSIBILITIES OF RESEARCHERS AND RESEARCH STAFF FOR THE PROTECTION OF RESEARCH PARTICIPANTS

A. Key Responsibilities for Principal Investigators

The PI has primary responsibility for protecting the rights and welfare of research participants in research. Details about the HRPP general requirements for protecting research participants are provided in [Part 7](#) of this OM. The PI's primary responsibilities also include the following:

1. Delegation of Responsibilities

PIs must personally perform or delegate to qualified Co-Is or research staff all of the necessary tasks to carry out their studies. Even when specific tasks are delegated, the PI remains ultimately responsible for the proper conduct of the study and fulfillment of all associated obligations.

2. Oversight of the Research Team

The PI, or Faculty Advisor when the PI is a student/trainee, must provide members of the research

team with sufficient oversight, training, and information to facilitate appropriate safety procedures and protocol adherence. In addition, the IRB must be informed if a PI, or Faculty Advisor, is no longer able to fulfill his or her duties for any reason, but not limited to, medical, sabbatical, or other leave, including traveling for a prolonged period. (Note: any absence longer than three months must be reported to the IRB).

3. Knowledge of Human Research Protection Standards

The PI, Co-Is, and study team members (together referred to as “researchers” or the “study team”) are expected to be knowledgeable about and comply with the requirements of each of the following:

- The [Common Rule](#) and other federal research laws and regulations;
- Applicable state law;
- The [University’s Federalwide Assurance](#);
- Institutional policies and procedures for the protection of research participants and reporting and managing conflicts of interest;
- Requirements of the U-M and non-U-M IRBs reviewing the research;
- The terms and conditions of any research agreements (with government or private sponsors); and
- The basic ethical principles that guide human research.

Some of the laws and regulations that most directly and routinely impact the conduct of human participant research studies are described in [Part 11](#) of this OM. Institutional policies and procedures include this OM, as well as policies and procedures maintained by the academic units to which researchers and research staff are appointed, IRB policies and procedures, and the policies and procedures of other research review units with relevant oversight responsibilities, such as the [Research Pharmacy](#) and [Radiation Safety Services](#).

4. Evaluation of Adequacy of Resources

PIs must ensure that adequate resources (facilities, equipment, supplies, and personnel) are available to:

- Conduct the research (e.g., through internal or external funding for staff, facilities, and equipment);
- Protect participants; and
- Ensure the integrity of the research.

Researchers responsible for multi-site research should evaluate the resources available at each site where the research will be conducted.

5. Training Requirements

Researchers must complete educational training as required by the University, relevant IRB, Sponsor, and other review units before initiating research, and should not undertake responsibility for human

research studies unless they understand these requirements and are willing to be held accountable for complying with the relevant standards and protecting the rights and welfare of research participants. For additional information on training for human research refer to [Part 13](#) of this OM.

B. Key Responsibilities for Researchers

Following are descriptions of some of a researcher's central obligations when conducting studies involving research participants. They are intended only as a general guide and do not contain a comprehensive description of all researcher responsibilities.

1. Minimizing Risks to Participants and Protecting Participant Rights and Welfare

Federal regulations, institutional policy, and guiding ethical standards require that human research be designed to minimize risks to participants. Minimizing risks and protecting research participants take precedence over the goals and other requirements of any research endeavor.

Study Design

One of the ethical justifications for research involving research participants is the social value of advancing scientific understanding and promoting human welfare. However, the value of research depends upon the integrity of the study results. If a research study is so methodologically flawed that little or no reliable information will result, it is unethical to put participants at risk or even to inconvenience them through participation in such a study.

To minimize risks to participants and protect participants' rights and welfare:

- Researchers are expected to design protocols that comply, at a minimum, with applicable regulatory and institutional policy requirements, as well as the principles of the [Belmont Report](#) (i.e., respect for persons, beneficence, justice);
- The research must be reasonably expected to answer its proposed question; and
- The knowledge reasonably expected to result from the research must be sufficiently important to justify the undertaking.

All research procedures must be consistent with sound research design. For example:

- Recruitment and enrollment plans should promote equitable participant selection (i.e., participants should equitably bear the burdens and enjoy the benefits of participation in research);
- Whenever appropriate, researchers should use procedures already being performed on participants for diagnostic and treatment purposes;
- When appropriate, research plans should make adequate provision for (a) monitoring participants to promptly detect any adverse events and (b) reviewing data collected to ensure participant safety;
- Research plans must contain adequate provisions to protect the privacy of participants and maintain the confidentiality of data collected;

- If some or all of the participants in a study are likely to be vulnerable to coercion or undue influence (e.g., children, prisoners, adults with decisional impairment, or economically or educationally disadvantaged people), the research plan should provide additional safeguards, as appropriate, to protect their rights and welfare. For additional information on protections for vulnerable participants refer to [Part 7](#) of this OM.

2. Obtaining and Documenting Informed Consent

a. Informed Consent Required Before Research Participation

Informed consent must be obtained from and documented for each prospective research participant (or their legally authorized representative) for all non-exempt human research before they begin to participate in the research (including any related eligibility testing not conducted solely for clinical purposes) unless the appropriate IRB has approved a waiver or alteration of consent, or waiver of documentation, as described in [Part 3](#) of this OM. [45 CFR 46.116\(a\)](#) provides the general requirements of informed consent.

b. Informed Consent Is an On-Going Process

Informed consent is not a single event or document, but an ongoing process that takes place between the PI (or other key personnel, as appropriate) and the research participant. Informed consent requires full disclosure of the nature of the research and the participant's involvement, adequate understanding on the part of the participant (or their legally authorized representative), and the participant's voluntary decision to participate. "The prospective subject or the legally authorized representative must be provided with the information that a reasonable person would want to have in order to make an informed decision about whether to participate, and an opportunity to discuss that information." ([45 CFR 46.116\(4\)](#))

c. Responsibility for Obtaining Informed Consent

The PI is responsible for ensuring that each potential participant or their legally authorized representative understands the nature of the research and participation in the project and gives their informed consent to participate. Although the PI may delegate responsibility for part or all of the consent process to Co-Is or research staff, the PI remains responsible for ensuring each participant has properly consented; and must describe the consent process to the IRB, including who on the study team is responsible for obtaining consent and any waiting period between informing the prospective participant and obtaining consent, as applicable. If the PI contracts with a firm to obtain consent, the firm must have its own IRB approval, or formally rely on the U-M IRB.

d. Elements of Informed Consent

The [OHRP Informed Consent Checklist](#) outlines the information that must be conveyed to participants as part of the informed consent document and process ([45 CFR 46.116](#)).

General Requirement - Key Information Section

Informed consent "must begin with a concise and focused presentation of the key information that is most likely to assist a prospective subject or legally authorized representative in understanding the reasons why one might or might not want to participate in the research. This

part of the informed consent must be organized and presented in a way that facilitates comprehension.” ([45 CFR46.116\(a\)\(5\)\(i\)](#))

Required Basic Elements

The informed consent document must contain at least the basic elements listed below:

1. A statement that the study involves research

This includes explaining the purposes of the research and any procedures that the participant will undergo and specifying which procedures are experimental (e.g., a new drug, extra tests, non-standard methods of management such as randomizing the participant to a treatment or placebo arm). The statement must describe how much time the participant can expect to devote to the study (e.g., how long will study visits or research-related procedures take, what is the total expected length of participation after enrollment).

2. A description of any reasonably foreseeable risks

This includes any reasonably foreseeable risks, discomforts, inconveniences, and harms associated with the research activities. These risks should neither be understated nor glossed over. If additional risks are identified during the course of the research project, the IRB must be informed. In such cases, the IRB may require revisions to the consent process and document(s), and may require participants previously consented to be re-contacted and informed about the new risks. The IRB must approve any protocol or consent revisions and any proposed communication to participants about these revisions.

3. A description of any benefits to the subject

Subjects must be provided with information about any benefits that may reasonably be expected from the research, either to them individually or to society at large. If there is no reasonable expectation of direct benefit, the subject must be informed. Payments for participation may never be listed as benefits of the research.

4. A disclosure of appropriate alternative treatment

To ensure participants can make an informed choice about participation in therapeutic research, appropriate alternatives to the study’s therapeutic benefits must be described, where applicable. Researchers should be reasonably specific in describing the nature and type of available alternatives.

5. A statement describing the protections to privacy and confidentiality

Participants must be told the extent, if any, to which individual privacy and confidentiality of research records that may identify them will be maintained, and who will have access to those records. For example, sponsors, funding agencies, regulatory agencies, IRBs and other institutional officials may review research records. Depending on the nature and scope of the study, other regulations may apply, in addition to the Common Rule, such as HIPAA for studies that involve the collection, use, or disclosure of protected health information.

6. For research involving more than minimal risk, a statement addressing research related injury

For research involving more than minimal risk, the consent process must provide an explanation as to whether any compensation or medical treatment will be provided to an injured participant (injury in this context refers both to physical injuries and to less tangible injuries, such as injury to reputation or legal rights). If so, the compensation and treatment should be described, or the participant should be told where to find additional information. In no event may the consent process or the documentation of consent include exculpatory language (e.g., requiring participants to give up legal rights to which they otherwise would be entitled, such as the right to sue in case of an adverse response to a study intervention). Additional information on medical care for research-related injury for sponsored projects is described in [Part 10](#) of this OM.

7. An explanation of whom to contact for questions, concerns, or to obtain information

Participants must be informed about whom to contact for answers to pertinent questions or concerns about the research and their rights as research participants, as well as whom to contact in the event of a research-related injury, if injuries are foreseeable. Specifically, they should be told how to contact the researchers and whom they can contact if they cannot reach or do not want to speak with the researchers. They also should be told how to lodge a complaint and offer input. Participants may file an anonymous complaint using the [University's Compliance Hotline](#).

8. A statement that participation is voluntary

Participants must be specifically informed that participation in a project is on a voluntary basis; that they may discontinue participation at any time; and that no penalty will be imposed, and no rights to which they would otherwise be entitled be waived as a result of refusal to participate in the research or later withdrawing from the research.

9. One of the following statements about the collection of identifiable private information or identifiable biospecimens, as applicable:

- a) A statement that identifiers might be removed from the identifiable private information or identifiable biospecimens and that, after removal, the information or biospecimens could be used for future research studies or distributed to another researcher for future research studies without additional informed consent from the participant or the legally authorized representative, if this might be a possibility; or
- b) A statement that the participant's information or biospecimens collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies.

e. Additional Elements of Informed Consent

One or more of the following elements of information, when appropriate, shall also be provided to each participant or the legally authorized representative:

1. A statement that the particular treatment or procedure may involve risks to the participant (or to the embryo or fetus, if the subject is or may become pregnant) that are currently unforeseeable;

2. Anticipated circumstances under which the participant's participation may be terminated by the researcher without regard to the participant's or the legally authorized representative's consent;
3. Any additional costs to the participant that may result from participation in the research;
4. The consequences of a participant's decision to withdraw from the research and procedures for orderly termination of participation by the participant;
5. A statement that significant new findings developed during the course of the research that may relate to the participant's willingness to continue participation will be provided to the participant;
6. The approximate number of participants involved in the study;
7. A statement that the participant's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the participant will or will not share in this commercial profit;
8. A statement regarding whether clinically relevant research results, including individual research results, will be disclosed to participants, and if so, under what conditions; and
9. For research involving biospecimens, whether the research will (if known) or might include whole genome sequencing (i.e., sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen).

Additional requirements that apply to FDA regulated research are listed in section (f) below and in section II.C of this part.

Note: U-M has not implemented “broad consent” for storage, maintenance, and secondary research with identifiable private information or identifiable biospecimens (collected either for research studies other than the proposed research or non-research purposes) and therefore regulatory requirements per 45 CFR 46.116(d) are not applicable.

f. Other Consent Requirements

- The consent form should not release or appear to release the researcher, sponsor, institution, or its agents from liability for negligence.
- The consent form should include the amount and schedule of all payments to the participant.
- For FDA-regulated research, the consent form should include a statement that notes the possibility that the FDA may inspect the records, and that the results of the research will be posted on ClinicalTrials.gov, if applicable.
- The consent form must be approved in advance by the IRB.
- The consent form will be signed and dated by the participant or their legally authorized representative.
- In some cases, the IRB may approve a waiver or alteration of consent, or waiver of documentation, as permitted by federal regulations and as described in [Part 3](#) of this OM. A waiver of documentation means that the potential participant is provided all of the

information required for informed consent, but is not asked to sign a consent form.

- Oral or written information must be conveyed in language that is understandable to the participant or their legally authorized representative.
- Researchers must ensure that consent is sought only under circumstances that minimize the possibility of coercion or undue influence. For example, participants must be given a sufficient opportunity to read the consent information and determine whether or not to participate in the study. It is therefore desirable to allow time between the initial discussion of the opportunity to participate in the research and the final decision, as recorded in the consent document.
- Each participant (or their legally authorized representative) must be provided with a copy of the consent document at the time of consent, unless the IRB specifically has waived this requirement. If the study is using or disclosing PHI, the participant must be provided a copy of the signed document, per HIPAA regulations, otherwise, this need not be a signed copy.

g. Short Form Consent Process

In limited circumstances, (e.g., participants with low literacy or limited English proficiency), the IRB may approve the use of a “short form” consent process. In the “short form” consent process, the required elements of informed consent normally presented in writing are presented orally to the participant or participant’s legally authorized representative in the presence of a witness ([45 CFR 46.117\(b\)\(2\)](#) and [21 CFR 50.27\(b\)\(2\)](#)).

Requirements for using “short form” consent:

- The IRB must approve a written summary of what is to be said to the participant or representative and ensure that it includes the elements of informed consent required by HHS and/or FDA regulations;
- An independent witness must be present at the oral presentation;
- The participant or their legally authorized representative signs only the short form itself;
- The witness must sign both the short form and a copy of the written summary;
- The person obtaining consent must sign a copy of the written summary;
- Copies of both the short form and the written summary must be provided to the participant or their legally authorized representative;
- For participants who are not proficient in English, the witness must be conversant in both English and the language of the participant.

h. Retention of Signed Consent Document

Signed consent documents must be retained for:

- At least three years after completion of the research (seven years if protected health information will be used or disclosed in connection with the study in accordance with HIPAA requirements); or

- Longer if required by institutional policy or applicable sponsor agreements or regulations.

A copy of the complete signed consent should be placed in the medical record of participants, particularly when the research intervention may affect other treatment or care. However, doing so may not be appropriate in all cases, if identification of the individual as a study participant might put the participant at risk of criminal prosecution or harm to reputation.

Signed HIPAA authorization forms must be retained for seven years. See [Part 11](#) for information about retention of signed HIPAA Authorization forms.

Signed documents can be retained as part of research records in hard copy or as certified electronic copies. If the research is FDA regulated, electronic storage must be FDA compliant.

3. Compliance with IRB and Other Requirements

An IRB must review and approve all research activities that meet the definition of human research before they are initiated unless an IRB has determined that the activities are exempt from IRB oversight (see [Part 4](#) of this OM for additional details). Prior IRB approval is also required for pre-research activities such as access to databases containing private information and screening data for possible recruitment and enrollment. IRB approval for such activities is necessary, but not sufficient; the PI must also comply with other policies, at the University or otherwise, governing access to such databases. For example, access to a U-M database would typically require permission of the University data steward as well as the creation of a Memorandum of Understanding setting forth the terms and conditions applicable to the use of that database for approved research purposes.

When applicable, the IRB is also responsible for review and approval of continuing review (see [Part 3](#) of this OM for information on continuing review requirements), progress reports, change of protocol, adverse event reporting, ORIO reporting, monitoring, and record keeping. Researchers must at all times cooperate with the IRB in fulfilling its responsibilities.

PI Obligations

1. IRB Submissions

The PI is responsible for the content of all submissions (e.g., initial review, continuing review, adverse event reporting, ORIO reporting) to the IRB and other review units and for ensuring that those documents are submitted promptly, as required by the IRB or other review unit. The PI must include on the IRB application all study team members who contribute to the scientific development or execution of a study in a substantive, measurable way. Multi-site studies relying upon a U-M IRB as the Single IRB must have procedures to ensure timely communication of information in association with these reporting requirements.

2. Responding to IRB Requests for Information

To assist the IRB in fulfilling its responsibilities, researchers must provide all information requested by the IRB in a timely fashion.

3. Adhering to Approved Protocol

Researchers must conduct research as specified in the IRB-approved protocol and must comply with all IRB determinations, including directives to terminate participation in designated research

activities.

4. Changes to Research

Any proposed changes in the research must be submitted to the IRB via an amendment application and approved **in advance** by the IRB unless necessary to eliminate apparent immediate hazards to participants. Similar requirements apply for other review units (e.g., Research Pharmacy, Radiation Safety Services, etc.) responsible for oversight of research activities. Researchers must promptly report to the IRB any additional risks that are identified during the research project.

5. Continuing Review (when required by the IRB)

PIs are responsible for monitoring their approval periods and submitting a continuing review application promptly so as to permit the IRB to review and issue an approval before the expiration of the study's previous approval.

6. Lapse of IRB Approval

If IRB approval for a study lapses for any reason, even if the researcher submitted an application for review in a timely manner and promptly responded to any requests for clarifications or changes, the research must stop until the IRB issues its formal approval or determines that it is in the best interest of individual participants to continue participating in the research interventions or interactions.

7. Reporting to the IRB

Researchers must promptly report to the IRB any of the following:

- Unanticipated problems involving risks to participants or others, such as an adverse event or exposure of a member of the research team to a harmful substance;
- Potential noncompliance with applicable laws or regulations or IRB requirements, whether by researchers, research staff, or others, even if the noncompliance was unintentional or was discovered in the course of quality assurance or quality improvement activities; and
- Disapprovals, suspensions, or terminations of the project by any University or non-University review units or agencies (e.g., the Research Pharmacy or Institutional Biosafety Committee, or the IRB at another performance site, or a regulatory agency such as the Food and Drug Administration).

[Part 12 of this OM](#) provides additional details on reportable events.

8. Audits and Inspections

Researchers and research staff are expected to cooperate with:

- Internal evaluations, inspections, and audits performed by authorized internal oversight authorities, including the IRBs, the [Office of Research Compliance Review \(ORCR\)](#), and the [Office of University Audits](#); and
- External reviews (e.g., by government agencies such as the FDA or NIH Office of Research Integrity). Any external investigation, inspection, or other external review and its outcome

must be reported to the IRB responsible for the research in question upon receiving notice. Researchers should consult with their administrators, the IRBs, and as appropriate, the Office of the Vice President for Research, and/or General Counsel for assistance and representation.

4. Conflict of Interest

Outside interests relating to human research must be disclosed in both the University's outside interest disclosure system known as M-Inform and in eResearch forms (e.g., HUMs, PAFs). Such interests are not inherently wrong, even when they create a conflict of interest, as long as they are disclosed and appropriately managed or resolved. A conflict of interest may arise when a faculty or staff member has a relationship with an outside organization that puts the faculty or staff member in a position to influence the university's decisions in ways that could lead directly or indirectly to financial gain for the faculty or staff member or his or her family, or give improper advantage to others to the detriment of the University.

The University and individual academic units have established mechanisms to identify and manage potential conflicts, including annual disclosure requirements, research and sponsored project application questions, and informal communications. In addition, when a U-M IRB agrees to be the Single IRB for multi-site research, each site must provide information to the reviewing IRB about any potential COI situations disclosed by non-U-M individuals involved in the research, including any existing management plans. For detailed information about the University's conflict of interest and commitment policies, see [the Conflict of Interest Policies webpage](#).

A researcher who believes they or other members of the research team may have a related interest or conflict that has not otherwise been disclosed should consult with the appropriate conflict of interest committee for guidance to determine whether the conflict is reportable and, if so, how it might be managed (see [Part 9](#) of this OM for additional guidance).

5. ClinicalTrials.gov Registration and Results Reporting

Certain clinical trials involving research participants must be registered and have results posted on ClinicalTrials.gov. For a full description of ClinicalTrials.gov requirements, refer to [Part 11](#) of this OM.

6. Clinical Trial Informed Consent Posting

One IRB-approved consent form used to enroll participants, for each federally-funded clinical trial must be posted on a publicly available federal website, as specified by the US Federal government ([45 CFR 46.116\(h\)](#)). See [OHRP's guidance on uploading clinical informed consent](#).

- The PI or designee is responsible for posting the consent form;
- The consent form must be posted on the website after the clinical trial is closed to recruitment, but no later than 60 days after the last study visit by any participant, as required by the protocol; and
- Any requests from the federal agency for an exception to the requirement to post the consent document, or to redact certain information prior to posting must be submitted to the Federal department or agency supporting the clinical trial prior to posting.

C. Studies Regulated by the Food and Drug Administration

When conducting research involving FDA-regulated products, researchers must comply with all applicable FDA regulations and fulfill all investigator responsibilities or all sponsor-investigator responsibilities, as applicable. Refer to [Part 8](#) of this OM for a description of the circumstances under which human research becomes subject to FDA regulations. In addition to requirements outlined in this part and in [Part 8](#), the following data access and retention requirements apply:

- When a participant withdraws from a study, the data collected on the participant to the point of withdrawal remains part of the study database and may not be removed. The consent document cannot give the participant the option of having the data removed;
- A researcher may ask a participant who is withdrawing whether the participant wishes to provide continued follow-up and further data collection subsequent to their withdrawal from the interventional portion of the study. Under this circumstance, the discussion with the participant distinguishes between study-related interventions and continued follow-up of associated clinical outcome information, such as laboratory results obtained through chart review, and addresses the maintenance of privacy and confidentiality of the participant's information;
- Using an IRB-approved consent document, the researcher must obtain the participant's consent for this limited participation in the study (assuming such a situation was not described in the original consent document); and
- If a participant withdraws from the interventional portion of a study and does not consent to continued follow-up of associated clinical outcome information, the researcher must not access for purposes related to the study the participant's medical record or other confidential records requiring the participant's consent. However, a researcher may review study data related to the participant collected prior to the participant's withdrawal from the study, and may consult public records, such as those establishing survival status.

D. Other

PIs have additional responsibilities when studies are required to follow guidelines of the International Conference on Harmonisation Good Clinical Practice (ICH GCP). Guidance on ICH GCP is included in [Part 11 of this OM](#).

PIs may have additional responsibilities for federally sponsored research based on the department providing support (e.g., Department of Defense, Department of Education, etc.). See the [HRPP Guidance documents on the HRPP Policies & Procedures webpage](#).

PART 7: Participant Protection

Describes some of the ways research participants are protected under the HRPP, including:

- Special protections for vulnerable participants;
- Requirements for Data and Safety Monitoring Plans and Boards;
- Review of advertising and recruitment materials;
- Payment to research participants; and
- Compensation for injuries.

I. HRPP PROTECTION EXTENDS TO ALL PARTICIPANTS

The HRPP protects the rights and welfare of all individuals who participate in University research as research participants, regardless of whether they are intended “primary” participants of the research or their participation is ancillary to the main study intervention. For example, a survey might ask primary participants for private information about their friends or family members. If that information is identifiable, those friends and family members are considered research participants in addition to the primary participant. See [Part 4 section II](#) of this OM for a definition of human subjects.

II. VULNERABLE PARTICIPANTS

Additional protections are required when vulnerable participants participate in research. Federal regulations identify pregnant women, fetuses, neonates, children, and prisoners as vulnerable participants ([45 CFR 46](#), Subparts [B](#), [C](#), [D](#)). IRBs and researchers must consider if some or all participants in a protocol are likely to be vulnerable, beyond these regulatory definitions, and ensure that additional safeguards are in place to protect the rights and welfare of these participants. The U-M HRPP recognizes that vulnerable populations include, but are not limited to:

- Children (individuals who have not attained the legal age to consent for procedures involved in the research under the applicable law of the jurisdiction in which the research will be conducted);
- Pregnant women, fetuses, and neonates;
- Prisoners (individuals involuntarily confined or detained in a penal institution, including individuals detained in other facilities by virtue of statutes or commitment procedures that provide alternatives to criminal prosecution or incarceration in a penal institution, and individuals detained pending arraignment, trial, or sentencing);
- Individuals who are decisionally impaired; and
- Individuals who otherwise may be subject to coercion or undue influence (e.g., economically or educationally disadvantaged persons; employees or students of researchers conducting the study; patients of physician-researchers).

When members of any of these groups participate in research, University IRBs require researchers to specify what additional protections, if any, will be provided to these participants to protect their rights and welfare (e.g., minimize risks unique to these groups and the possibility of coercion or undue influence). In reviewing these research projects, the IRBs ascertain that the inclusion of a vulnerable population is adequately justified and that safeguards are implemented to minimize risks unique to that population.

Laws governing research involving vulnerable populations, including laws on who may consent on behalf of children, adults with decisional impairment, or incapacitated adults, vary from state to state. Guidance on Michigan law, additional requirements of federal funding agencies, and international research are described in [Part 11](#) of this OM.

The University IRBs apply the following standards when reviewing research involving vulnerable populations:

- For federally supported research, the IRBs comply with all of the requirements of [45 CFR 46](#) to the extent the sponsoring agency has adopted the standards reflected in Subparts B-D.
- For FDA-regulated research involving children, the IRBs comply with the requirements of [21 CFR 50, Subpart D](#), and [21 CFR 56](#).
- For research not subject to the above regulations, U-M has developed standards that are intended to provide protections equivalent to those described in federal regulations. In some cases, the Institutional Official (IO) or the Deputy Institutional Official (DIO) substitutes to provide judgment normally assigned to the HHS Secretary in certain situations described below.

A. Research Involving Pregnant Women, Fetuses, and Neonates

1. Federally Funded Research

See [45 CFR 46, Subpart B](#) for additional protections for pregnant women, fetuses, and neonates involved in federally-funded research.

2. Non-Federally Funded Research

When applying equivalent protections to non-federally funded research involving pregnant women, fetuses, and neonates, the following exceptions may apply:

Research that does not hold out the prospect of direct benefit to the woman or fetus may still be approved as long as the IRB finds and documents that (1) the risk presented is no more than minimal and (2) the research is intended to generate generalizable or scientific knowledge. This is different from the requirements of [45 CFR 46.204](#) and [45 CFR 46.205](#), which require the research to contribute to the development of important biomedical knowledge.

Research described as not otherwise approvable, which presents an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of pregnant women, fetuses, or neonates may be approved by the IO or DIO after consultation with a panel of experts in pertinent disciplines. In granting the approval, the IO or the DIO must determine that the research will be

conducted in accordance with sound ethical principles and that informed consent will be obtained in accordance with the informed consent standards described in [45 CFR 46, Subpart A](#).

B. Research Involving Prisoners

1. Federally Funded Research

See [45 CFR 46, Subpart C](#) for additional protections for prisoners involved in federally funded research. In addition, the University IRBs follow [federal guidance](#) and [U-M guidance](#) when a research participant becomes a prisoner during the course of a study.

2. Non-Federally Funded Research

When applying equivalent protections to non-federally funded research involving prisoners, the following exceptions may apply:

The IO or DIO assumes the role of the HHS Secretary for studies requiring certification or approval as described in [45 CFR 46.306\(a\)\(2\)](#). The IRB will certify to the IO or DIO that the research meets the criteria for approval of research with prisoners.

3. IRB Composition and Review Requirements for Research Involving Prisoners

a. For research reviewed by the convened IRBs involving prisoners:

- The prisoner representative must be a voting member of the IRB, or an alternative member who becomes a voting member when needed;
- The prisoner representative must review the research involving prisoners and receive all materials pertaining to the research as primary reviewers;
- The prisoner representative must be present at a convened meeting (in-person, by phone, or video conference) when the research involving prisoners is reviewed. If the prisoner representative is not present, research involving prisoners cannot be reviewed or approved;
- The prisoner representative must present their review either orally or in writing at the convened meeting of the IRB when the research involving prisoners is reviewed;
- Substantial modifications to previously approved research reviewed by the convened IRBs must use the same procedures for initial review, including review responsibilities of the prisoner representative;
- Continuing review conducted by the convened IRB must use the same procedures used for the initial convened review, including the review responsibilities of the prisoner representative. If the continuing review qualifies for expedited review, it will follow the requirements for expedited review of research involving prisoners that follow below.

Minor modifications to previously approved research may be reviewed using the expedited procedure described below, using either of the two procedures described based on the type of modification.

b. Expedited review of research involving prisoners:

- Research involving interaction or intervention with prisoners (including obtaining consent) may be reviewed using the expedited procedure if a determination is made that the research poses no more than minimal risk to the prisoners included and that the research meets the criteria for expedited review. The research must be reviewed by a prisoner representative, either as the expediting reviewer or as a consultant, who must confirm that the research poses no more than minimal risk to the prisoner participants. Review of subsequent modifications and continuing review submissions via expedited procedures must also involve the prisoner representative as a consultant or expediting reviewer.
- Research involving prisoners that does not involve interaction or intervention (e.g., existing data, record review) may be reviewed using the expedited procedure if a determination is made that the research poses no more than minimal risk to the prisoners being studied or included and the research meets the criteria for expedited review. The prisoner representative may review the research as an expediting reviewer or consultant, but such review is not required. Review of subsequent modifications and continuing review submissions via expedited procedures may involve review by the prisoner representative as a consultant or expediting reviewer but is not required.

C. Research Involving Children

1. Federally Funded Research

See [45 CFR 46, Subpart D](#) for additional protections for children involved as subjects in federally-funded research and [21 CFR 50, Subpart D](#) for additional safeguards for children involved in FDA-regulated clinical investigations.

Research involving children as participants conducted by U-M researchers also needs to comply with the [Children on Campus policy](#).

2. Non-Federally Funded Research

When applying equivalent protections to non-federally funded research involving children, the following exceptions may apply:

- For research that the IRB does not believe meets the requirements of [§46.404](#), [§46.405](#), or [§46.406](#), in order to approve, the IRB must find and document that the research presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and
- Approval is secured from the IO or DIO after consultation with a panel of experts in pertinent disciplines. In granting the approval, the IO or the DIO must determine that the research will be conducted in accordance with sound ethical principles and that adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians consistent with the standards described in [45 CFR 46.408](#).

3. Assent

Per [45 CFR 46.408](#), research involving children requires that adequate provisions are made for soliciting the assent of the children. In limited circumstances, the IRB may determine that assent is not a requirement with respect to some children involved in research for one of the following reasons:

- The capability of the children is so limited (based on an assessment of their age, maturity, or psychological state) that they cannot reasonably be consulted;
- The intervention or procedure involved in the research holds out a prospect of direct benefit that is important to the health or well-being of the child and is available only in the context of the research; or
- The assent can be waived using the criteria described in [45 CFR 46.116](#) for waiver of consent.

4. Participants who Reach the Legal Age of Consent while Enrolled in a Study:

Children who reach the legal age of consent to the procedures involved in ongoing research must provide consent to continue to participate, as described in 45 CFR 46.116, if continued interventions or interactions are planned, including the collection or analysis of identifiable private specimens or information. The IRB may grant a waiver of consent under [45 CFR 46.116\(f\)](#) if it finds that required conditions are met, but must document the decision and rationale for doing so.

D. Research Involving Adults with Cognitive Impairment or Otherwise Impaired Decision-making Capacity

Cognitive impairment or impaired decision-making capacity covers a broad spectrum of conditions and timeframes. One individual may be severely cognitively impaired from birth, whereas another otherwise healthy person, due to acute conditions, may be temporarily decisionally impaired. Alternatively, a person with a mental health condition may have fluctuating decision-making capacity.

Federal regulations do not include specific protections for adults with impaired decision-making capacity, as they do for research with pregnant women, prisoners, and children. Researchers are asked to identify within the IRB application if the research will include adults with decisional impairment. The IRBs may limit the types of research in which adults lacking consent capacity may be enrolled based on the purpose, risk, and potential benefit of the research and whether the research question could be answered by enrolling adults who are able to consent.

In each case, the protocol or application must describe any additional safeguards planned to ensure appropriate consent. The IRB must evaluate the appropriateness of the research and the adequacy of the PI's proposed plan for initial and, if applicable, ongoing assessment of participants' capacity to consent. For participants able to provide consent on their own behalf, the following guidance does not apply. For participants unable to consent, however, the IRB must determine whether assent must be secured and, if so, whether the PI's proposed plan for assent is adequate. The requirement for assent may be waived by the IRB only if:

- The capability of some or all of the participants is so limited that they cannot reasonably be consulted;

- The intervention or procedure holds out the prospect of direct benefit to the health or well-being of the participants and is available only in the context of the research; or
- The research otherwise meets the conditions for waiver of consent consistent with the standards described at [45 CFR 46.116](#) or [46.117](#).

An IRB may approve the participation of adults with decisional impairment resulting in a lack of consent capacity only under the following circumstances:

1. Research Involving No More Than Minimal Risk

Research involving no more than minimal risk may be approved if the IRB finds and documents that adequate provisions have been made for soliciting assent from the participant, if appropriate, and permission of the participant's legally authorized representative (LAR) (e.g., next-of-kin or legal guardian). The IRB may approve an exception to the assent requirements if the standards described in [45 CFR 46.408\(a\)](#) are met. The IRB may approve an exception to the requirement for permission of the participant's LAR if a waiver of consent or documentation of consent would be acceptable under [45 CFR 46.116](#) or [46.117](#).

2. Research Involving Greater Than Minimal Risk but Presenting the Prospect of Direct Benefit to the Individual Participants

Research involving greater than minimal risk may be approved if the IRB finds and documents that:

- The intervention or procedure under investigation holds out the prospect of direct benefit to individual participants, or any of the study procedures, including monitoring of the participant's condition, are likely to contribute to the participant's well-being;
- The risk is justified by the anticipated benefit to participants; and
- The relation of the anticipated benefit to the risk is at least as favorable to participants as that presented by available alternative approaches, and adequate provisions have been made for soliciting assent from the participant and permission from the participant's LAR, or assent is waived consistent with the standards described in [45 CFR 46.408\(a\)](#).

3. Research Presenting as Greater Than Minimal Risk Without the Prospect of Direct Benefit to the Individual Participants

Research involving greater than minimal risk may be approved if the IRB finds and documents that:

- The research presents a minor increase over minimal risk without the prospect of direct benefit to the individual participants, but the research presents a reasonable opportunity to further understand, prevent, or alleviate a serious problem affecting the health or welfare of adults with decisional impairment; and
- Approval is secured from the IRB in consultation with experts in pertinent disciplines who determine that the research will be conducted consistent with sound ethical principles and that adequate provisions have been made to solicit the assent of the participant and permission of their LAR, consistent with the standards described at [45 CFR 46.408\(a\)](#).

III. DATA AND SAFETY MONITORING PLANS AND BOARDS

Data and safety monitoring is a process designed to protect the safety of individual participants in research studies and to ensure the validity of research results and the scientific integrity of a study. The portions of a protocol that describe the steps the research team will take to identify, address, and report any physical, social, or psychological events that may result from participation in a study constitute a Data and Safety Monitoring Plan (DSMP). A DSMP typically describes the timing, tools, and/or methods to be employed for monitoring and evaluating study data during the course of the project, procedures for treatment or resolution (including a description of circumstances that will result in halting or terminating research), and procedures for and timing of reports to oversight bodies, such as the IRB, an independent monitor, an internal committee, a Data and Safety Monitoring Board (DSMB), the NIH, or the FDA.

University IRBs are required to ensure that, when appropriate, research plans make adequate provisions for monitoring data collected to ensure participant safety. DSMPs are submitted as part of the [eResearch application](#) and are reviewed as part of the initial review, or as part of an amendment, and must be approved before implementation. The IRB may consider:

- What safety information will be collected, including serious adverse events;
- How the safety information will be collected;
- The frequency of data collection, including when safety data collection starts, and the frequency of review of cumulative data;
- Inclusion of a DSMB, and the plan for reporting findings to the IRB and sponsor;
- For studies that do not have or are not required to have a DSMB and are blinded, multi-site, enroll vulnerable participants, or use high-risk interventions, the IRB carefully reviews the DSMP to determine if a DSMB is needed;
- If applicable, studies not using a DSMB may use statistical tests to analyze safety data to determine if harm is occurring;
- Provisions for the oversight of safety data (e.g., by a DSMB); and/or
- Conditions that trigger an immediate suspension of research, if applicable.

In some cases, such as NIH-sponsored multi-site clinical trials involving risks to participants, DSMBs are required. In other cases, such as high-risk research or where institutional or individual conflicts of interest dictate the need for external review mechanisms, a DSMB may be established. A DSMB is a formally chartered, independent committee whose stated goal is to protect the welfare and safety of the participants participating in a specified research study and to promote scientific integrity. For example, DSMBs may be chartered when:

- The study is intended to provide definitive information about the effectiveness and/or safety of a medical intervention;
- Prior work suggests that the intervention under investigation may induce a potentially unacceptable toxicity;

- The study will evaluate mortality, morbidity, or other significant endpoints such that the inferiority of one treatment arm has safety, as well as effectiveness implications; and/or
- The study raises ethical issues and it would be important for the study to stop early if the primary scientific question had been definitively answered, even if secondary questions or complete safety information were not yet fully addressed.

Periodically, a DSMB:

- Approves proposed safety measures for a protocol;
- Provides written documentation of protocol review and agreement with study design;
- Reviews study progress as provided in its charter;
- Reviews cumulative data at established intervals to assess safety and efficacy;
- Consults with PIs concerning safety or integrity issues arising during the course of the study; and
- Provides written reports to the PI, IRB, and other oversight authorities summarizing its oversight activities (e.g., results of chart reviews, summaries of consultations with the PI, concerns regarding participant safety, etc.), and any recommendations (e.g., continuing the study, continuing the study with modifications, suspending the study for interim analysis, or terminating the study).

A DSMB charter should include the following elements:

- A detailed description of the membership, including qualifications and experience;
- Roles and responsibilities of the DSMB;
- Authority of the DSMB;
- Timing and purpose of DSMB meetings;
- Procedures for maintaining confidentiality;
- Format, content, and frequency of DSMB reports;
- Guidelines outlining the procedure for the PI's interaction with the board and whether the PI may be invited to attend any open sessions;
- Statistical procedures, including monitoring guidelines, used to monitor the identified primary, secondary, and safety outcome variables; and
- Plans for changing the frequency of interim analyses as well as procedures for recommending protocol changes.

DSMB membership generally should include:

- Multidisciplinary representation of at least three individuals, including physicians and scientists from relevant specialties, and a biostatistician;
- Members that have no involvement in the design and/or conduct of the trial;
- Members that have no significant conflicts of interest with the study, whether they are financial,

intellectual, professional, or regulatory in nature; and

- An appropriate number of members (beyond three, as necessary) to address the size and complexity of the study.

Not all studies require a DSMB; the PI and responsible IRB should assess the need for one based on the risk level, complexity, and size of the study.

Additional information on data and safety monitoring is provided in the [NIH Policy for Data and Safety Monitoring](#) and the [FDA Guidance for the Establishment and Operation of Clinical Trial Data Monitoring Committees](#).

IV. ADVERTISING AND RECRUITMENT MATERIALS

IRBs review all advertising materials intended to recruit prospective participants. Recruitment materials are submitted as part of the [eResearch application](#) and are reviewed as part of the initial review or as part of an amendment and must be approved before implementation. As part of its review, the IRB considers:

- The information contained in the advertisement;
- The mode of its communication;
- The final content of printed advertisements and web content; and
- The final content of audio or video-recorded advertisements.

In its review of advertising materials, an IRB should ensure that the materials:

- Do not state or imply a certainty of a favorable outcome or other benefits beyond what is outlined in the consent and the protocol;
- Do not include exculpatory language;
- Do not emphasize the payment or the amount to be paid, by such means as larger or bold type; and
- Do not promise "free treatment" when the intent is only to say participants will not be charged for taking part in the investigation.

Advertisements should be limited to the information needed by prospective participants to determine their eligibility and interest, such as:

- The name and address of the PI or research facility;
- The purpose of the research or the condition under study;
- A summary of the criteria that will be used to determine eligibility for the study;
- A brief list of benefits to participants, if any;
- The time or other commitment required of the participants; and
- The location of the research and the person or office to contact for further information.

When following FDA regulations, IRBs should review advertisements to ensure that they:

- Do not make claims, either explicitly or implicitly, about the drug, biologic, or device under investigation that are inconsistent with FDA labeling;
- Do not use terms such as "new treatment," "new medication," or "new drug" without explaining that the test article is investigational; and
- Do not allow compensation for participation in a trial offered by a sponsor to include a coupon good for a discount on the purchase price of the product once it has been approved for marketing.

Additional information on the review of recruiting methods for FDA-regulated research can be found in [Recruiting Study Subjects: Guidance for Institutional Review Boards and Clinical Investigators](#).

V. PAYMENT TO RESEARCH PARTICIPANTS

The University recognizes the importance of encouraging individuals to participate in research as research participants and recognizes the value of the time and effort contributed and risks undertaken in contributing to University research efforts. In accordance with [Standard Practice Guide 501.07](#), Research Subject Incentives, the University permits payments or other considerations to compensate participants for these contributions, as long as the following criteria are met:

- Payment arrangements are specifically approved in advance by the IRB;
- Payments or other considerations provided to participants in return for their participation are not so significant as to be unduly influential (e.g., inducing participants to accept unreasonable risks);
- Payments are prorated when appropriate, and should not be contingent upon the participant completing the study, to avoid inducing participants to continue in a study when they otherwise would withdraw;
- Arrangements are made by the PI to ensure proper accounting of payments made to participants and required reporting to tax authorities, as required by University policy, with due consideration of privacy concerns.

Note: See [Human Subject Incentives Program](#) for additional information about payments to participants.

VI. COMPENSATION FOR INJURIES

University policy and IRB procedures, per [45 CFR 46.116\(b\)\(6\)](#), require that for research involving more than minimal risk, the informed consent process explains whether any compensation or treatment will be provided to an injured participant. Injury in this context refers both to physical injuries and to less tangible injuries, such as injury to reputation or legal rights. If so, the compensation and treatment are described, or the participant is told where to find additional information. Exculpatory language (e.g., language that provides that a participant "assumes the risk" for participation in a study) is prohibited in informed consent documents.

[Part 10 of this OM](#) describes compensation for injuries in relation to sponsored research. Also, [OHRP provides additional guidance](#) regarding the use of exculpatory and non-exculpatory language in the informed consent process.

PART 8: Studies Regulated by the FDA and Use of Investigational Articles

I. INTRODUCTION AND DEFINITIONS

The Food and Drug Administration (FDA) enforces the Food, Drug, and Cosmetic (FD&C) Act and other laws and regulations governing the use of drugs, biologics, and devices, both in research studies and for treatment.

The FD&C Act generally prohibits the manufacture, delivery, use, receipt, or sale of any drug, biologic, or device that is adulterated or misbranded. New drugs, biologics, and devices that are not yet FDA-approved, as well as those used for a purpose or in a manner not approved by the FDA, may be considered either adulterated or misbranded, or both.

The FDA has adopted regulations to implement the FD&C Act and to specify the requirements that apply to the use of investigational test articles. FDA regulations for drugs are outlined in [21 CFR 312](#) and regulations for medical devices are outlined in [21 CFR 812](#). FDA regulations for informed consent, outlined in [21 CFR 50](#), and for Institutional Review Boards, outlined in [21 CFR 56](#), also apply.

The following sections describe when or under what circumstances an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) is needed (Sections II-VI) and describe the roles and responsibilities of the FDA, IRBs, sponsors, and investigators with respect to protocols involving investigational test articles (Sections VII and VIII). Reporting of adverse events and unanticipated problems related to research on FDA-regulated products is covered in the IRB Standard Operating Procedures and IRBMED Guidance. See [Part 6](#) of this OM for the Principal Investigator's (PIs) reporting responsibilities to the IRBs, University officials, federal regulators, and private sponsors. See [Part 12](#) of this OM for the written procedures regarding the reporting process for reportable events to the IRB, appropriate institutional officials, the head (or designee) of any federal department or agency conducting or supporting the research, and any applicable regulatory bodies.

Table 7: Definitions of FDA-regulated research.

TERM	DEFINITION
Biological Product	A diverse category of products that are generally large complex molecules that are produced through biotechnology in a living system. For example: blood, blood products, vaccines, allergenics, tissue, and tissue products.

TERM	DEFINITION
Clinical Investigation	Any experiment that involves a test article and one or more human subjects.
Device	An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component part, or accessory that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease; or intended to affect the structure or any function of the body; AND which does not achieve its primary intended purposes through chemical action within or on the body and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.
In Vitro Diagnostic Device (IVD)	An IVD is a medical device. While most other devices function on or in a human body IVDs include products used to collect specimens, or to prepare or examine specimens (e.g., blood, serum, urine, spinal fluid, tissue samples) after they are removed from the human body.
Drug	A substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. A substance (other than food) intended to affect the structure of any function of the body.
Investigator	An individual who actually conducts a clinical investigation (i.e., under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team. "Subinvestigator" includes any other individual member of that team.
Mobile Medical Applications (Apps)	Mobile apps are software programs that run on smartphones and other mobile communication devices. They can also be accessories that attach to a smartphone or other mobile communication devices, or a combination of accessories and software. Mobile medical apps are medical devices that are mobile apps, meet the definition of a medical device, and are an accessory to a regulated medical device or transform a

TERM	DEFINITION
	mobile platform into a regulated medical device.
Test Article	Any drug, biological product, medical device, electronic product, or other product regulated by the FDA.
Sponsor	A sponsor is an organization or individual who initiates and takes responsibility for a clinical investigation involving a drug, biologic or device.
Sponsor-Investigator	A sponsor-investigator is an individual who both initiates and conducts an investigation of an FDA-regulated drug, biologic or device and under whose immediate direction the drug, biologic or device is administered or dispensed. The term does not include any person other than an individual.

II. RESEARCH INVOLVING INDS OR IDES

INDs and IDEs are the mechanism by which the FDA grants investigators special permission to conduct research using (1) a new (not yet FDA-approved) drug, biologic, or device, or (2) an FDA-approved drug, biologic, or device for a purpose or in a manner not already approved or cleared for use by the FDA.

Investigators are responsible for determining whether research in which they are engaged requires an IND or IDE and, if so, for securing the necessary FDA permissions and IRB approvals. An investigator who holds an IND or IDE is considered a Sponsor-Investigator and must meet sponsor requirements described in Section VII of this part, in addition to investigator requirements. An investigator who is unsure whether an IND or IDE is required for a proposed research project should consult with the [Michigan Institute for Clinical and Health Research Investigator IND/IDE Assistance Program \(MIAP\)](#), and the [Medical School Institutional Review Board \(IRBMED\)](#). MIAP decision worksheets can be used to assist U-M investigators in determining whether an IND or IDE may be required before initiating a new study. Supporting documentation with confirmation of the IND or IDE is required as part of the IRB application for IRB review and approval.

Investigators who fail to obtain an IND or IDE when required by FDA regulations may be subject to university disciplinary actions, FDA disqualification, and to civil and even criminal sanctions.

A. IND Requirements for Research Involving an Investigational Drug or Biologic

An IND is the FDA regulatory mechanism that allows a sponsor to ship an unapproved drug or biologic to study sites and initiate clinical investigations involving the drug or biologic. IND regulations are outlined in

[21 CFR 312.](#)

An IND application is required for the use of:

- Unapproved drugs or biologics in clinical investigations; or
- Clinical investigations using approved drugs or biologics for new intended uses or to support significant change in the labeling; or
- Clinical investigations using approved drugs or biologics that involve a route of administration or dosage level or use in a patient population that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug product.

Human research involving unapproved drugs and biologics or FDA-approved drugs and biologics for new intended uses or in a way that significantly increases the risks associated with the use, may proceed only under an IND that is approved by the FDA before the research begins. The FDA assigns an IND number and allows the investigation to begin after it determines that research participants will not be exposed to unreasonable risk. When an IND is required, this information should be included in the IRB application.

1. Exemptions from IND Requirements

Certain investigations may be exempt from the requirement for an IND, if specified criteria are met. FDA exemption criteria are described in [21 CFR 312.2\(b\)\(1\)](#). Clinical investigations that are exempt from IND regulations still require IRB review and approval. Documentation of IND exemption criteria is required to be submitted in the IRB application.

Additionally, a limited number of specific types of clinical investigations (e.g., involving in vitro diagnostic biologicals such as blood grouping serum, reagent red blood cells, and anti-human globulin) conducted under certain conditions are also exempt from the IND requirements per [21 CFR 312.2\(b\)\(2\)-\(6\)](#). Separate rules for bioavailability studies are described at [21 CFR 320.31](#).

2. FDA guidance regarding IND requirements and exemptions

- [Investigational New Drug \(IND\) Application](#)
- [Investigational New Drug Applications \(INDs\) - Determining Whether Human Research Studies Can Be Conducted Without an IND - Guidance for Clinical Investigators, Sponsors, and IRBs](#)

B. IDE Requirements for Research Involving Investigational Devices

An IDE is the FDA regulatory mechanism which permits an investigational device to be shipped lawfully for use in a clinical investigation to collect safety and effectiveness data, including the evaluation of modifications or new intended uses of legally marketed devices. IDE requirements are outlined in [21 CFR 812](#). The FDA assigns an IDE number to a significant risk device and allows the investigation to begin after it determines that research participants will not be exposed to unreasonable risk.

IDE regulations apply to research investigations that test the safety and/or the effectiveness of the following investigational devices:

- Unapproved devices;
- Approved devices for new indications.

1. Level of FDA Oversight

The level of FDA oversight of research varies according to the level of risk (significant or non-significant) to research participants posed by the device. IDE regulations, [21 CFR 812](#), describe three types of device studies:

- Significant Risk (SR) Device Studies
- Non-significant Risk (NSR) Device Studies
- IDE Exempt Studies

Investigators conducting studies involving medical devices must provide the IRB with complete and accurate information about the regulatory status and risk level of each device.

a. Significant Risk (SR)/Non-significant Risk (NSR) Definition

A SR device is an investigational device that presents a potential for serious risk to the health, safety, or welfare of a subject, and meets one or more of the following criteria:

- Is intended as an implant;
- Is for a use in supporting or sustaining human life;
- Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health; or
- Otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

SR device studies are subject to all of the requirements of [21 CFR Part 812](#). An IDE application must be approved by the FDA and the study must have IRB approval before the study can begin.

b. NSR Device Studies

An NSR device is an investigational device that does not meet the definition of a significant risk device.

An NSR device study does not require submission of an IDE application to the FDA. Instead, the sponsor must conduct the study as required by abbreviated IDE requirements as outlined in [21 CFR 812.2\(b\)](#). The abbreviated IDE requirements include, among other items, requirements for IRB approval and informed consent per 21 CFR 50, record keeping, labeling, study monitoring, and prohibition against promotion. Unless the sponsor is notified otherwise by the FDA, an NSR device study is considered to have an approved IDE if the sponsor fulfills these abbreviated requirements, and the study may begin following final IRB approval.

c. SR/NSR Determination for Investigational Devices

The SR/NSR determination is made initially by the FDA-recognized sponsor (or sponsor-investigator) and must be confirmed by an IRB. The IRB may modify the risk determination if the IRB disagrees with the risk determination made by the sponsor. IRBs may not make the SR or NSR determination if the FDA has already made the risk determination. The following FDA guidance document helps sponsors, investigators and IRBs distinguish SR from NSR device studies:

[Significant Risk and Non-Significant Risk Medical Device Studies - Guidance For IRBs, Clinical](#)

[Investigators, and Sponsors.](#)

d. Investigational In Vitro Diagnostics (IVDs)

IVDs are tests done on samples from the human body and are used to diagnose or monitor disease or other health conditions and can be used to identify patients who may benefit from specific treatments or therapies. Additional rules for in vitro diagnostic devices are described at [21 CFR 809](#). When medical device research involves in vitro diagnostics and unidentified tissue specimens, the FDA defines the unidentified tissue specimens as human subjects.

Many studies involving investigational IVDs are considered IDE exempt per [21 CFR 812.2](#). However, investigational IVDs used in clinical investigations of therapeutic products may pose significant risk to subjects if the information generated by the use of the investigational IVD affects important aspects of the treatment for the enrolled subjects and, by doing so, directly influences the types of therapeutic products or therapeutic management strategies the subject may be exposed to during the study. See the following for additional information regarding IVDs in clinical investigations of therapeutic products:

- [Investigational In Vitro Diagnostics \(IVDs\) utilized in Clinical Investigations of Therapeutic Products](#)
- [Investigational IVDs Used in Clinical Investigations of Therapeutic Products - Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards](#)

e. Mobile Medical Apps

Mobile apps are software programs that run on smartphones and other mobile communication devices. They can also be accessories that attach to a smartphone or other mobile communication devices, or a combination of accessories and software. Mobile apps are considered medical devices when they incorporate device software functionality that meets the definition of a device in section 201(h) of the Food, Drug & Cosmetic Act, and are an accessory to a regulated medical device or transform a mobile platform into a regulated medical device. ([Device Software Functions Including Mobile Medical Applications](#))

Some mobile medical apps are subject to FDA regulations. The FDA will apply the same risk-based approach the agency uses to assure safety and effectiveness for other medical devices. Additional information about these apps can be found in the FDA guidance document: [Policy for Device Software Functions and Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff](#). In addition, many mobile applications have Terms of Service, or User Agreements, that researchers need to be aware of and consider when utilizing mobile applications in research.

2. The Role of the Sponsor in Device Risk Determination

If the sponsor believes the device is NSR, the sponsor provides the reviewing IRB with an explanation of its determination and any other information that may assist the IRB in evaluating the risk level of the device. This includes, at a minimum, the following information:

- A description of the device;

- Reports of prior investigations with the device (clinical, animal, and laboratory testing);
- The proposed investigational plan;
- A description of patient selection criteria;
- A description of monitoring procedures;
- FDA assessment of the risk level (SR or NSR) of the device, if one has been made, is final;
- Any other information that the IRB deems necessary to make its decision.

3. The Role of the IRB in Device Risk Determination

The IRB may agree or disagree with the sponsor's initial assessment. If the IRB agrees with a NSR assessment and approves the study, the study may begin without submission of an IDE application to the FDA. If the IRB disagrees, the sponsor must notify the FDA within five days that a SR determination has been made. The study can be conducted as an SR investigation following FDA approval of an IDE application and IRB approval of the study.

The SR/NSR determination must be based on the proposed use of the device in an investigation and not on the device alone. In making its determination, the IRB must consider the nature of the harm that may result from use of the device. If the harm could be life-threatening, result in permanent impairment, or necessitate medical or surgical intervention to preclude permanent impairment, the device must be treated as SR. If the participant must undergo a procedure as part of the study (e.g., surgery), the IRB must consider the potential harm that could be caused by the procedure in addition to the potential harm that could be caused by the device. In making an SR/NSR determination, the IRB may request that the Sponsor-Investigator consult directly with the FDA. Once a final SR/NSR decision is made by the IRB (or the FDA), the IRB must consider whether the study should be approved, using the same criteria it would use in reviewing any other research involving FDA-regulated products.

4. The Role of the FDA in Device Risk Determination

The FDA has the ultimate authority to determine whether a device study is SR or NSR. If the FDA disagrees with an IRB's NSR decision and determines that the study poses a significant risk, the sponsor may not begin their study until FDA approves an IDE. Conversely, if a sponsor submits an IDE to the FDA because the study is presumed to be SR, but the FDA classifies the study as NSR, the FDA will return the IDE application to the sponsor and the study may be presented to the IRB as an NSR device investigation.

A sponsor shall not begin an investigation for which the FDA's approval of an application is required until an IRB and the FDA have both approved the study, per [21 CFR 812.20\(a\)\(2\)](#) and [812.42](#).

5. Device Studies Exempt from IDE Requirements

Certain investigations may be exempt from the requirement for an IDE, if specified criteria are met. FDA exemption criteria are described in [21 CFR 812.2\(c\)](#). Investigations that are exempt from IDE regulations still require IRB review and approval.

Additional guidance regarding IDE requirements and exemptions is available at: [Device Advice](#):

[Investigational Device Exemption \(IDE\)](#).

C. Off-Label Use of an FDA-Approved Drug, Biologic or Device

“Off-Label use” means the use of legally marketed and/or FDA-approved drugs, biologics and devices for a purpose or in a manner not already approved by the FDA. Off-label use of a marketed product by a physician, when the intent is the “practice of medicine” (i.e., diagnosis, cure, mitigation, treatment, or prevention of disease in humans), does **not** require the submission of an IND or IDE or review by an IRB. If the off-label use of an FDA-approved product is intended to collect data about the product’s safety or efficacy, or for other non-diagnostic or non-therapeutic purposes, or if the use significantly increases risk to participants, an IND or IDE is generally required if human research participants are involved. Physicians should consult with [IRBMED](#) and with the [MICHHR IND/IDE Investigator Assistance Program \(MIAP\)](#) to determine when data collection for off-label use may require an IND or IDE.

III. EXPANDED ACCESS TO INVESTIGATIONAL DRUGS, BIOLOGICS AND DEVICES

The FDA has developed special mechanisms to expand access to promising investigational drugs, biologics, and devices (investigational medical products) for clinical treatment of patients with serious or life-threatening conditions and no comparable or satisfactory alternative therapeutic options. The use of a separate pathway allows patient access without compromising the protection of human subjects or the thoroughness and scientific integrity of product development and marketing approval. Collectively, these mechanisms are known as expanded access (or sometimes, compassionate use).

Regulatory support for expanded access to investigational products is provided through U-M Research Pharmacy. Treating clinicians may obtain advice from U-M Research Pharmacy at the following email: UM-Expanded-Access-Request@med.umich.edu.

Emergency Use of investigational drugs, biologics and devices (a category of expanded access) is discussed more fully in [Section IV](#) of this part.

A. Expanded Access as Research versus Clinical Treatment

Although an investigational article used under the FDA expanded access mechanism is intended for the purpose of clinical treatment, the FDA may consider the treatment to constitute a “clinical investigation” and require that data from the treatment be reportable in a marketing application. Conversely, under the Health and Human Services (HHS) human research protection rules, patients who receive investigational articles through the expanded access mechanism are **not** considered research subjects, and outcomes of expanded access treatments may not be included in reports of research funded by federal agencies that follow HHS rules.

If the FDA considers the treatment under the expanded access mechanism to constitute a “clinical investigation” an FDA accepted/approved IND submission or an amendment to an already existing IND is required prior to initiation of the use. For devices, FDA review and approval is also required. If an IDE for the device exists, a supplement to the existing IDE is required. If no IDE exists, an application for Compassionate Use is required. The only exception to this requirement is for individual patient emergency use, described more fully in Section IV, below.

Once submitted, an expanded access IND goes into effect 30 days after the FDA receives the IND submission, unless the FDA notifies the sponsor otherwise during the review period. For devices, the FDA will notify the sponsor regarding their decision within 30 days.

B. The Role of the IRB

In addition to an FDA-approved IND or IDE, expanded access requests must be approved by an IRB prior to administration of the treatment, and an IRB-approved informed consent form must be used to provide pertinent information to the patient and document their consent. The only exception to this requirement is for **individual patient emergency use**, described in Section IV, below.

C. Clinician Responsibilities

Any clinician providing treatment under expanded access has additional responsibilities and obligations to the IRB and the FDA, if functioning as the FDA-recognized sponsor, and may have additional responsibilities to the company providing the investigational article. These include:

- Submission of adverse event reports to the IRB and to the FDA, if functioning as the sponsor. Adverse events are submitted to the sponsor if the treating clinician is not the sponsor. Contractual agreements with the manufacturer of the investigational test article may also require adverse events to be reported;
- Any required follow-up, including annual and termination reports to the FDA, if serving as the sponsor; and
- Withdrawal of the IND or IDE with the FDA at the conclusion of the treatment period, if serving as the sponsor.

Annual reports and termination reports to the FDA must also be submitted to the IRB, as well as the submission of IRB applications for continuing review and termination of the IRB application after the submission of the termination report to the FDA.

D. Expanded Access to Investigational Drugs and Biologics for Treatment Use

Investigational drugs and biologics are sometimes used for treatment of serious or life-threatening conditions either for a single subject or for a group of subjects. The procedures that have evolved for an investigational new drug or biologic (IND) used for these purposes reflect the recognition by the FDA that, when no satisfactory alternative treatment exists, patients are generally willing to accept greater risks from drugs and biologics that may treat life threatening and debilitating illnesses.

The expanded access IND regulations are categorized into three levels depending on the expected numbers of patients to be treated:

- Expanded access for individual patients in emergency (see section IV below for information specific to emergency use) and non-emergency situations ([21 CFR 312.310](#));
- Expanded access for an intermediate-size patient population ([21 CFR 312.315](#)); and
- Expanded access for a large patient population under a treatment IND ([21 CFR 312.320](#)).

The regulations describe the criteria that must be met to authorize expanded access, list the requirements

for expanded access submissions, and describe the safeguards that will protect patients and preserve the ability to develop meaningful data about the use of the drug or biologic.

The following guidance on expanded access to investigational drugs and biologics is available on the FDA website:

- [Expanded Access to Investigational Drugs for Treatment Use - Questions & Answers – Guidance for Industry](#)
- [Institutional Review Board \(IRB\) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products Guidance for IRBs and Clinical Investigators](#)
- [Individual Patient Expanded Access Applications: Form FDA 3926 - Guidance for Industry](#)
- [IND Applications for Clinical Treatment \(Expanded Access\): Overview](#)
- Other mechanisms used by the FDA for [expanded access are described on the FDA website](#).

E. Right to Try

The Right to Try Act, was signed into law May 30, 2018. This law is another way for patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial, to access certain unapproved treatments. These treatments are limited to drugs and biologics that have advanced past Phase 1 clinical testing, have an active IND, and are not on clinical hold.

Additional information on Right to Try is available on the following websites:

- [Michigan Medicine Right to Try Guideline](#) (UMMS Level 2 password required)
- [Right to Try - Food and Drug Administration](#)

F. Expanded Access to Investigational Devices

There may be circumstances under which a health care provider may wish to use an unapproved device to save the life of a patient or to help a patient suffering from a serious disease or condition for which no other alternative therapy exists. Patients/physicians faced with these circumstances may have access to investigational devices under one of three main mechanisms by which the FDA may make an unapproved device available:

- Compassionate Use (or Single Patient/Small Group Access);
- Treatment Use;
- Emergency Use.

These mechanisms can be used during a certain timeframe in the IDE process if the criteria are met. FDA approval is required prior to treatment except in the case of emergency use. The mechanisms are summarized below.

1. Compassionate Use

The FDA “compassionate use” provision is intended to provide non-emergency access to an

investigational device by an individual or small number of patients with a serious or life-threatening disease or condition who the treating clinician believes will benefit from use of the device. Additional FDA requirements for compassionate use of devices are available on the [Expanded Access for Medical Devices - Compassionate Use \(or Individual Patient/Small Group Access\) webpage](#).

2. Treatment Use

A Treatment IDE provides a mechanism for a device that is not yet FDA approved to be used to treat a serious or immediately life-threatening disease or condition in patients for whom no comparable or satisfactory alternative device or other therapy is available. The treatment use provision of the IDE facilitates the availability of promising new devices to patients with a serious disease or condition as early in the device development process as possible. In the case of a serious disease or condition, a device may be made available for treatment use after all clinical trials have been completed. In the case of an immediately life-threatening disease or condition, a device may be made available for treatment use prior to the completion of all clinical trials. Additional information from the FDA is available on the [Expanded Access for Medical Devices - Treatment Use webpage](#).

3. Emergency Use

See Section IV of this part. Additional information about the FDA requirements for emergency use of a medical device is available on the [Expanded Access for Medical Devices: Emergency Use webpage](#).

Support for expanded access to investigational devices is available by contacting UM-Expanded-Access-Request@med.umich.edu.

IV. EXPANDED ACCESS: EMERGENCY USE OF INVESTIGATIONAL ARTICLES

Emergency use is defined as the use of an investigational drug, biologic, or device (i.e., test article) on a human subject in a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain IRB approval ([21 CFR 56.102\(d\)](#)). The emergency use provisions in the FDA regulations, [21 CFR 56.104\(c\)](#), provide an exemption from prior review and approval by the IRB as long as the emergency use is reported to the IRB within five working days. If time permits, the IRBMED Chair-on-Call should be contacted prior to the use of the investigational article. Additional requirements are described in the following IRBMED guidance: [Emergency Use of a Test Article in Life-Threatening Circumstances](#).

Life-threatening, for the purposes of section [21 CFR 56.102\(d\)](#), includes both life-threatening and severely debilitating, as defined below:

- **Life-threatening** means diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes where the end point of clinical trial analysis is survival.
- **Severely debilitating** means diseases or conditions that cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke.

A. IRB Review

Prospective IRB review is required unless the conditions for the emergency use exemption from prior review and approval by the IRB are met (21 CFR 56.104(c) and 56.102(d) linked above). When emergency use is reported to the IRB after treatment, the report must be reviewed by the full board. If the timing of the emergency use prevents IRB review and approval prior to treatment, the physician must obtain concurrence from the IRB chairperson (or designated IRB member) before the treatment use begins. The treating clinician must notify the IRB within five working days after the use of the investigational product. For additional information, see FDA guidance on [Emergency Use of an Investigational Drug or Biologic - Guidance for Institutional Review Boards and Clinical Investigators](#) and [Expanded Access for Medical Devices – Emergency Use](#).

B. Single Use

After each emergency use, the physician should consider whether appropriate actions can be taken to ensure prospective IRB review for future patients in need of the investigational product.

C. Informed Consent

Even for an emergency use, a treating clinician is required to obtain informed consent from the subject or the subject's legally authorized representative. If the circumstances of the emergency prevent informed consent from being obtained, both the investigator and a physician who is not otherwise participating in the clinical investigation certify in writing all of the following [21 CFR 50.23\(a\)](#):

- The subject is confronted by a life-threatening situation necessitating the use of the test article;
- Informed consent cannot be obtained because of an inability to communicate with, or obtain legally effective consent from, the subject;
- Time is not sufficient to obtain consent from the subject's legal representative; and
- No alternative method of approved or generally recognized therapy is available that provides an equal or greater likelihood of saving the subject's life.

If, in the investigator's opinion, immediate use of the test article is required to preserve the subject's life, and if time is not sufficient to obtain an independent physician's determination that the four conditions above apply, the clinical investigator should make the determination and, within five working days after the use of the article, have the determination reviewed and evaluated in writing by a physician who is not participating in the clinical investigation. The treating clinician must notify the IRB within five working days after the use of the test article ([21 CFR 50.23\(c\)](#)).

D. Additional Guidance For Emergency Use of Investigational Articles

Treating clinicians who seek to use an investigational article under the FDA emergency use provision are advised to consult [IRBMED and page the Chair on Call](#). Treating clinicians should also contact the U-M Research Pharmacy at the following email: UM-Expanded-Access-Request@med.umich.edu.

E. Emergency Use of Investigational Drugs and Biologics

Emergency use of an investigational drug or biologic generally requires an IND. If the intended patient does not meet the criteria of an existing study protocol, or if an approved study protocol does not exist, the

usual procedure is to contact the manufacturer and determine if the drug or biologic can be made available for the emergency use.

The need for an investigational drug may arise in an emergency situation that does not allow time for submission and FDA review of an IND in the usual manner. Even in an emergency, before shipment or clinical treatment can begin, FDA authorization is required. This authorization may be provided by an FDA official over the telephone or email. In these cases, the licensed physician or sponsor must file the complete IND application within 15 days of the date the FDA authorized the emergency use ([21 CFR 312.310](#)).

Support for emergency use of investigational drugs and biologics is available by contacting UM-Expanded-Access-Request@med.umich.edu.

1. Clinician Responsibilities

In the event that a treating clinician seeks to use an investigational drug or biologic to treat a life-threatening or severely debilitating condition under emergent circumstances, the following steps are generally required:

- Contact the manufacturer of the investigational drug or biologic to determine if they will make the drug or biologic available for emergency use and whether or not they will hold the IND.
- If an IND for the use already exists, notify the FDA-recognized sponsor (i.e., IND holder) of the emergency use.
- If an IND does not exist, or is not available for the emergency use under the existing IND, FDA may authorize shipment of the test article in advance of the IND submission.
- Obtain informed consent from the patient or legally authorized representative, if possible. See [IRBMED: FDA expanded access informed consent template](#).
- Contact the IRB Chair-on-call to discuss the case and obtain concurrence with the plan for emergency use.

After the emergency, the treating clinician must:

- Report the emergency use to the IRB (eResearch Single-patient Expanded Access Drug or Biologic application) within five working days and otherwise comply with IRB requirements.
- If consent could not be obtained from the patient or legally authorized representative prior to the use because of an inability to communicate with or obtain legally effective consent from, the subject and time is not sufficient to obtain consent from the subject's legal representative, obtain an independent assessment by a physician, who is not otherwise participating in the clinical investigation, within five working days of the use.
- Evaluate the likelihood of a similar need occurring again and, if future use is likely, initiate efforts to obtain IRB approval and an approved IND for subsequent use. NOTE: FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue.

- If the treating clinician is the FDA sponsor and holds the IND, provide the FDA, within 15 working days of emergency use, a written summary of the conditions constituting the emergency, subject protection measures and results; otherwise, provide the summary to the IND holder.
- If the treating clinician is the FDA sponsor and holds the IND, at the conclusion of the treatment, submit a final report (summary report) to the FDA and withdraw the IND.

2. FDA Guidance on Emergency Use of an Investigational Drug or Biologic

- [Emergency Use of an Investigational Drug or Biologic - Guidance for Institutional Review Boards and Clinical Investigators](#)
- [Expanded Access to Investigational Drugs for Treatment Use – Questions and Answers, Guidance for Industry](#)
- [Institutional Review Board \(IRB\) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products](#)

F. Emergency Use of Investigational Device

In general, an unapproved medical device may only be used on research participants when the device is under clinical investigation and when used by investigators participating in a clinical trial. However, the FDA recognizes that there may be circumstances under which a health care provider may wish to use an unapproved device to save the life of a patient, or to prevent an irreversible morbidity when no other alternative therapy exists.

Emergency use of an unapproved device may occur when: (i) an IDE for the device does not exist, (ii) when a treating clinician wants to use the device in a way not approved under the IDE, (iii) when the patient would not qualify for the study under the IDE, or (iv) when a treating clinician is not an investigator under the IDE. In each situation, emergency use of an unapproved device may occur without prior approval from the FDA. Support for emergency use of investigational devices is available by contacting UM-Expanded-Access-Request@med.umich.edu.

1. Clinician Responsibilities

If a treating clinician intends to treat a patient with an unapproved medical device in an emergency situation, the FDA expects the treating clinician to:

- Determine that:
 - The patient has a life-threatening condition that needs immediate treatment (including serious diseases or conditions such as sight-threatening and limb-threatening conditions as well as other situations involving risk of irreversible morbidity);
 - No generally acceptable alternative treatment for the condition exists; and
 - Because of the immediate need to use the device, there is no time to use existing procedures to get FDA approval for the use.
- Assess the potential for benefit and possible risk from the use of the unapproved device;

- c. Have substantial reason to believe that benefits will exist and outweigh the possible risks.

In the event that a device is used in circumstances meeting the criteria listed above, the treating clinician should follow as many patient protection procedures as possible. Such patient protection procedures include obtaining:

- Informed consent from the patient or a legally authorized representative;
- Clearance from the institution as specified by their policies;
- Concurrence of the IRB chairperson;
- An independent assessment from an uninvolved physician prior to, or after, use, as appropriate to the situation, if informed consent cannot be obtained; and
- Authorization from the IDE sponsor, if an approved IDE exists for the device.

After the emergency use occurs, the treating physician is responsible for ensuring that certain follow-up procedures occur:

- As soon as possible and no later than five working days of the use, report the emergency use to the IRB in an eResearch Single-patient Expanded Access Device Use application.
- Obtain an independent assessment by an uninvolved physician within five days of the use, if consent could not be obtained from the patient or legally authorized representative prior to the use.
- Evaluate the likelihood of a similar need occurring again and, if future use is likely, initiate efforts to obtain IRB approval and an approved IDE for subsequent use. *NOTE: FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue.*
- If an IDE exists for the device, within five working days of the use, the treating clinician should provide the IDE sponsor with sufficient patient follow-up information to allow the sponsor to comply with the reporting requirements of the IDE regulation. The sponsor must report the use to the FDA via a supplement within five working days from the time the sponsor learns of the use. The supplement should contain a summary of the conditions constituting the emergency, the patient protection measures that were followed (as discussed above), and patient outcome information.
- If no IDE exists, within five working days of the use, the physician should submit a follow-up report on the use of the device to the FDA and the device manufacturer, including a summary of the conditions constituting the emergency, patient protection measures that were followed, and patient outcome information.

2. FDA Guidance on Emergency Use of Investigational Devices

- [Expanded Access for Medical Devices – Emergency Use](#)
- [IDE Application: IDE Modifications](#)

V. PLANNED EMERGENCY RESEARCH USING INVESTIGATIONAL ARTICLES

Planned emergency research is a type of research that allows participants to be enrolled without prior informed consent. It differs from emergency use of a test article described above and has additional, specific requirements for investigators and the IRB ([21 CFR 50.24](#)). Researchers who wish to conduct planned emergency research should consult with IRB staff prior to submission of the protocol to the IRB. See IRBMED Guidance, [Emergency Research \(Planned and Approved\) with Exception from Informed Consent](#) and for more information about planned emergency research using an investigational article see [FDA guidance on Exception from Informed Consent for Emergency Research](#).

VI. HUMANITARIAN USE DEVICES (HUD) AND HUMANITARIAN DEVICE EXEMPTIONS (HDE)

A FDA-designated Humanitarian Use Device (HUD) is intended to benefit small populations (<8,000 individuals in the United States per year) with a rare condition for which effectiveness cannot be readily determined prior to marketing. Before the treating clinician may use a HUD, the FDA-recognized sponsor must obtain a Humanitarian Device Exemption (HDE). The treating clinician must also obtain prospective IRB approval (via full board approval), unless the use of the HUD meets criteria for emergency use. Informed consent documents must not refer to the humanitarian use of the device as “research”, unless the HUD is being used in a clinical investigation.

Additional information about HUDs and HDEs is found on the FDA’s [Humanitarian Device Exemption \(HDE\) Program - Guidance for Industry and Food and Drug Administration Staff webpage](#).

VII. FDA SPONSORS AND SPONSOR-INVESTIGATORS

As included in the table in [section I](#), FDA regulations at [21 CFR 312](#) and [21 CFR 812](#), define “sponsor” and “sponsor-investigator,” as follows:

- A sponsor is an organization or individual that initiates and takes responsibility for a clinical trial or other FDA-regulated project involving a drug, biologic or device.
- A sponsor-investigator is an individual who both initiates and conducts an investigation of an FDA-regulated drug, biologic or device and under whose immediate direction the drug, biologic or device is administered or dispensed. The term does not include any person other than an individual.

Part of an FDA sponsor’s or sponsor-investigator’s responsibility is to obtain any required IND or IDE from the FDA. For that reason, a sponsor is sometimes referred to as the IND or IDE holder.

A. University/University Employee as Sponsor/Holder

The University, itself, generally does not sponsor (or hold) INDs or IDEs and a University faculty or staff member (employee) may not apply for an IND or IDE **on behalf** of the University without written approval of the Vice President for Research (VPR) or their designee.

University employees may, however, act as sponsors or sponsor-investigators and hold their own INDs or IDEs if they: (1) have adequate training, experience, and support to properly conduct and monitor the

relevant project activities, and (2) are able and willing to comply with relevant regulatory and institutional requirements.

B. Sponsor-Investigator Responsibilities

Investigators who initiate and submit IND or IDE applications to the FDA assume the responsibilities of both the investigator and the sponsor. The responsibilities of a sponsor are described at [21 CFR 312.50-312.59](#) and [812.40-812.47](#). Under FDA regulations, an academic sponsor or sponsor-investigator has the same obligations as a multinational pharmaceutical manufacturer that sponsors or holds an IND or IDE.

When a U-M employee applies to be the sponsor or sponsor-investigator of an IND or IDE, they make a personal commitment to the FDA to comply with a complex set of requirements (21 CFR 312, 812, and others) regarding the investigational article itself and the overall management of the project(s), as described below in Section VIII. In addition, any U-M employee serving or seeking to serve as the sponsor or sponsor-investigator of an IND or IDE in conjunction with their University appointment must also:

- Utilize [MIAP services](#) for document preparation assistance, application review, and maintenance of an active IND or IDE;
- Complete an eResearch application and obtain IRB approval prior to initiating research;
- Complete a MIAP training session on FDA Sponsor-Investigator requirements;
- Ensure proper monitoring of the study and upload the monitoring reports in the eResearch IRB application;
- Archive all documents, related to the IND or IDE, including all FDA submissions and correspondence, in the eResearch IRB application.

FDA guidance for sponsor-investigators is available at:

- [Information for Sponsor-Investigators Submitting Investigational New Drug Applications \(INDs\)](#)
- [IDE Responsibilities](#)

C. Clinical Trials Registration

The holder of the IND or IDE (the IND or IDE sponsor or sponsor-investigator) for a clinical investigation is responsible for registering the trial on ClinicalTrials.gov within 21 days after the enrollment of the first subject. When seeking informed consent from subjects, investigators must ensure that the informed consent document and process include a statement that the trial is registered with ClinicalTrials.gov, in accordance with the provisions of [21 CFR 50.25\(c\)](#). This statement is part of the U-M IRBMED Informed Consent template. For additional information, see the HRPP guidance on [Clinical Trials Registration & Results Reporting](#), and [Part 11](#) of this OM.

D. Noncompliance

Serious or continuing noncompliance with the obligations of a sponsor or sponsor-investigator may lead to University or FDA restrictions on the ability of the faculty member to enter into future agreements with the FDA. See [Part 12](#) of this OM.

E. Manufacturer of Investigational Articles

In the rare event that a U-M employee intends to manufacture an investigational article, advice must be sought from one or more of the following U-M offices at the earliest opportunity and prior to use of the article with humans (even for feasibility assessment): IRBMED, Office of the General Counsel (OGC), Office of the Vice President for Research (OVPR), UMMS Office of Regulatory Affairs, MIAP. These offices will alert other offices or units as applicable.

VIII. INVESTIGATOR AND IRB RESPONSIBILITIES FOR FDA-REGULATED RESEARCH

A. Ensuring Review by Appropriate IRB

The investigator conducting FDA-regulated research must ensure that an appropriate University IRB (or other IRB with which U-M has established a reliance agreement) is responsible for the initial and continuing review, and approval of modifications to the research, in accordance with the FDA requirements at 21 CFR 50 and 56. The U-M IRBs are registered with OHRP and the FDA and indicate which boards review FDA-regulated research. Changes may be made to a research protocol only after notifying the sponsor and receiving approval from the IRB, except when necessary to eliminate apparent immediate hazards to subjects. Research informed consent must be obtained from all prospective subjects prior to enrollment in the research, unless the IRB approved a waiver of informed consent.

B. Verification of IND or IDE Acquisition Prior to Release of Final IRB Approval

Through the eResearch IRB application, investigators answer a series of questions designed to determine whether or not an IND or IDE may be required for a research project. If it appears that an IND or IDE may be required, the reviewing IRB will require one of the following in order to verify IND or IDE acquisition prior to release of final IRB approval:

- Written FDA documentation that an IND or IDE has been granted (including the IND or IDE number), or that an existing IND or IDE has been amended, as appropriate, to cover the specific project in question; or
- Written documentation that the FDA's time for consideration of an IND application for the research project in question has lapsed without a notice of disapproval or conditional approval and without an unsatisfied request for additional information (the investigator must still provide the IRB with FDA documentation of the IND number assigned by the FDA when the FDA acknowledged receipt of the IND application); or
- Written documentation of the FDA's determination that an IND or IDE is not required.

As described in section II.B above, for research involving an investigational device, once the investigator demonstrates that the research meets the FDA criteria for a NSR device study, IRB approval of the research and documentation of the NSR decision is sufficient.

C. Oversight of FDA-Regulated Research

In addition to ensuring IRB review and approval, and in addition to general researcher responsibilities outlined in [Part 6](#) of this OM, a clinical investigator conducting FDA-regulated research must personally

conduct or supervise the study as specified in the signed investigator statement, the investigational plan (protocol), any applicable sponsor agreement, and the IRB-approved application and associated materials. Before initiating a research project, the clinical investigator must read and understand the information in the investigator's brochure or similar documentation, including the risks and potential benefits of the investigational article.

The principal investigator is responsible for ensuring that all sub-investigators and other research team members assisting in the conduct of the study are informed about their obligations and are adequately trained to carry out their responsibilities competently and appropriately. Investigator responsibilities are described in further detail at [21 CFR 312.60-312.69](#) (drugs and biologics); and [21 CFR 812.100-812.110](#) (devices). For more information, see FDA guidance on [Investigator Responsibilities - Protecting the Rights, Safety, and Welfare of Study Subjects](#).

D. Investigational Article Accountability

During the research project, the researcher is responsible for all aspects of protocol implementation, including proper receipt, storage, security, use, and disposal of the investigational article, and all related necessary documentation for the investigational product. In the eResearch application for IRB approval, the researcher must describe their plan to assure that investigational articles are used only in approved protocols and under the direction of approved researchers. Deviations from these plans are permitted only in emergency circumstances, consistent with FDA requirements and University policies on emergency use, or to avoid immediate harm to subjects. An IRB may not approve a proposed research project that does not include satisfactory plans for investigational article accountability. Test article accountability procedures are described in more detail in Part 3, Section III.C.6.i of this OM.

E. Charging for Investigational Articles

When the FDA-recognized sponsor or sponsor-investigator intends to charge subjects for investigational articles or related treatment or services, they must comply with all IRB policies (e.g., to ensure that the charges are appropriate and equitable, and to require disclosure of the charges in the informed consent document and process), institutional billing policies, and professional ethics. The charge may not exceed an amount that is necessary to recover the costs associated with the manufacture, research, development, and handling of the investigational article. FDA guidance on charging for investigational drugs, biologics and devices is available here: [Charging for Investigational Drugs Under an IND – Questions & Answers – Guidance for Industry](#) and [Investigational Device Exemption FAQs - Charging](#).

F. Records and Documentation

The researcher must ensure the creation and maintenance of complete and accurate research records, such as informed consent documentation, case report forms, correspondence files, and other relevant information for record keeping purposes and possible inspection by institutional officials, outside sponsors, and regulatory agencies. In addition, the names and commitment of study team members, as well as their responsibilities, qualifications, and study-specific training must be clearly documented, including, as appropriate, on FDA Form 1572 (drugs and biologics), investigator agreements (devices), and delegation logs.

1. Electronic Records

[FDA regulations regarding 21 CFR Part 11](#) set forth the criteria under which the agency considers electronic records, electronic signatures, and handwritten signatures executed to electronic records to be trustworthy, reliable, and generally equivalent to paper records and handwritten signatures executed on paper. [Part 11](#) is intended to ensure that information submitted to and considered by the FDA is readily accessible and auditable in order to validate its accuracy.

The University has conducted and documented a self-assessment of eResearch compliance with 21 CFR Part 11 ([Self-Assessment of eResearch Compliance](#)) and has issued an electronic signature certification statement ([Certification of Electronic Signatures](#)). Similar documentation of [Part 11](#) compliance of Michigan Medicine medical record systems is available at the UMMS Regulatory Affairs [Data Integrity and Sharing](#) intranet (UMMS Level 2 password required). For additional guidance regarding Part 11 compliance, see FDA Guidance: [Part 11, Electronic Records; Electronic Signatures - Scope and Application](#).

2. Record Retention

The FDA requires that records be retained in compliance with applicable laws, regulations, policies, and agreements. The required manner and duration of record retention, as specified in these rules, may vary widely and depend on the characteristics of the particular research project or other related activity. Clinical investigators are also advised to consult with the relevant FDA-recognized sponsor before disposing of records associated with a particular research project or related activity. U-M institutional guidance on record retention is available at [U-M Medical School Record Keeping Guidelines](#).

G. Required Reporting

The researcher must comply with FDA reporting requirements including timely submission of annual reports to the FDA. The researcher must also ensure that adverse events and other unanticipated problems involving risks to subjects or others are reported to the FDA sponsor and the IRB in a timely manner and be consistent with the IRB approved reporting plan in the study protocol. In addition, promptly after receipt, researchers must provide to the IRB copies of any audit or inspection reports, warning letters, debarment notices, or similar documents issued by sponsors, government regulators (such as, the FDA or NIH), internal oversight units, or other organizations with oversight responsibilities. More information on [adverse event and other reporting requirements is available in IRBMED Guidance](#).

H. ICH-E6 and Good Clinical Practice (GCP)

The ICH Efficacy Guideline (E6) on GCP is an international standard established to promote the ethical and scientifically sound design, conduct, recording, and reporting of human clinical trials. When a research protocol or agreement specifies that ICH GCP will be followed, the FDA and U-M oversight authorities will enforce compliance with GCP requirements. In addition, the NIH has established the expectation that researchers involved in the conduct, oversight, or management of NIH-funded clinical trials be trained in GCP per the following, [Policy on Good Clinical Practice Training for NIH Awardees Involved in NIH-funded Clinical Trials](#).

Additional information about GCP guidelines is available at: [E6\(R2\) Good Clinical Practice: Integrated Addendum to ICH E6\(R1\)](#) and in [Frequently Asked Questions: NIH Policy on Good Clinical Practice \(GCP\)](#).

Instructions for how to complete GCP training are available on the [HRPP Education Resources website](#).

I. FDA Inspections of FDA-Regulated Research and Related Activities

The FDA conducts routine and for-cause inspections of clinical trials, investigators, and IRBs, in order to validate data that is under FDA consideration, verify protection of research participants, confirm general compliance with FDA and other applicable regulations, policies, and agreements (including sponsor agreements), and investigate complaints and self-reports of non-compliance. FDA inspections are typically scheduled in advance, but may be conducted without advance notice.

When contacted by the FDA to schedule an inspection, or when the FDA has arrived without advance notice, the investigator or a member of the research team is expected to contact one of the following offices at the earliest opportunity for guidance and support: UMMS Office of Regulatory Affairs and the IRBMED. Depending on the nature of the inspection, it may also be appropriate to notify the Office of General Counsel (OGC) and the Office of the Vice President for Research (OVPR).

PART 9: Conflicts of Interest and Commitment

Describes how [conflicts of interest](#) (COI) and [conflicts of commitment](#) (COC) in research can adversely impact the integrity of research results and the confidence of prospective volunteers in the research enterprise. The University seeks to identify, disclose, and eliminate or manage conflicts to avoid these negative repercussions.

I. APPLICABLE POLICIES

The University follows several institutional, state, and federal regulations, policies, procedures, and practices concerning employees' outside activities, relationships and interests that could form the basis of a conflict. These include, but are not limited to:

- [U-M Standard Practice Guide \(SPG\) - 201.65-1](#) (applies to all U-M employees)
- [Policy for the Identification and Management of Conflicts of Interest in Research, Sponsored Projects, and Technology Transfer](#)
- [List of outside interest disclosure criteria](#)
- [U-M Policy for Institutional Conflicts of Interest in Research](#)
- [State of Michigan: Contracts of Public Servants with Public Entities \(Act 371 of 1968\)](#)
- [State of Michigan: Conflict of Interest \(Act 318 of 1968\)](#)
- [NIH \(PHS\) COI Policy](#)
- [NSF COI Policy](#)
- [DOE Interim COI Policy](#)
- [NASA COI Policy \(Grant Information Circular\)](#)

[School, college, and unit policies](#) on COI and COC augment these policies and may address the conditions that allow an individual with a significant financial interest to be a researcher. Michigan Medicine has an [Outside Interests and Conflicts of Interests Policy](#) (requires Level 2 access) that is of particular importance to the Human Research Protection Program (HRPP), as the researchers in Michigan Medicine conduct the majority of human subjects research that requires disclosure and COI management.

Generally, policies regulating outside interests seek to promote the following values:

- Objectivity and integrity in research;
- Open publication of research results;
- Appropriate use of sponsor or University funds;
- Maintenance of appropriate relationships with and fulfillment of obligations to colleagues, students, and other trainees;
- Fulfillment of administrative duties;
- Integrity of academic decision-making;

- Avoidance of "pipelining" University intellectual property to an outside entity outside of an appropriate research agreement; and
- Protection of and appropriate informed consent with research participants.

The University requires outside interest disclosure for study personnel as part of the IRB application for human subjects research. Study personnel listed on the IRB application are required to answer COI questions when they accept their role on the project. Refer to OM Part VI.I.E for roles and responsibilities of study team members.

II. CONFLICTS OF INTEREST OF INVESTIGATORS AND RESEARCH STAFF

There are three main steps to the COI review process for human subjects research:

1. Identification and disclosure of outside interests by researchers and research staff.
2. Review of outside interest disclosures by a U-M COI office to determine if a conflict of interest exists.
3. Risk/benefit analysis by an IRB.

A. Identification and Disclosure of Outside Interests Related to Human Research

Outside interests, activities and relationships ("outside interests") and potential conflicts of interest on the part of researchers and research staff (and their spouses, domestic partners, or dependents) relevant to the integrity of human subjects research include, but are not limited to, the following:

- Ownership (e.g., equity, shares, or stock options) in an outside company or other entity associated with the research (e.g., the company is sponsoring the research or providing drugs/devices used in the research);
- Compensation, other payments, or items of value from an outside entity (e.g., consulting fees);
- Proprietary interest related to the research including, but not limited to, an option or license agreement for technology used in the project; and
- Unpaid activities and relationships (e.g., serving in a leadership position for the company sponsoring the research, or serving on a scientific advisory board).

The University provides training for the disclosure of outside interests through [M-Inform, the University's outside interest disclosure system](#), and also through school/college/unit policies.

Information about relevant outside interests is identified from a number of transactions that include:

1. Sponsored Project Proposals

Every proposal for externally sponsored research requires submission of a completed eResearch Proposal Management (eRPM) Proposal Approval Form (PAF). This electronic form summarizes information about the proposal and is used for U-M administrative review and approval. The eResearch system requires all investigators listed on a PAF to complete a "Sign PAF" activity in the system. When completing this activity, investigators are required to indicate whether they (and/or their spouse, domestic partner, or dependents) have an outside activity related to the proposed research. In addition, the eRPM system prevents investigators from completing the "Sign PAF"

activity if an outside interest disclosure has not been completed in the M-Inform system within the previous 365 days.

2. IRB Application

As part of the eResearch IRB application, researchers and study team members indicate if they (and/or their spouses, domestic partners, or dependents) have an outside interest in a non-UM entity associated with the research in one of the following ways:

- Provides financial or non-financial support for the project;
- Supplies a product used in the project (e.g., an app, device, compound, drug, software, survey, evaluation) either for free or at a cost (e.g., purchased);
- Holds an option or license to intellectual property used in the project (e.g., a device, compound, drug, software, survey, evaluation, code, data, schematics, algorithms) that the researcher or a family member developed;
- Will perform work on the project (e.g., subcontract, service agreement, unfunded agreement);
or
- Has a financial stake in the outcome of the research.

If a related outside interest is identified based on a researcher's response to the question, formal disclosure from the individual is required in the M-Inform system.

Should a related interest arise during a research project, researchers must update both M-Inform and any related IRB applications within 30 days of the start of the new interest, via the amendment process.

3. Outside Interest Disclosures

All investigators listed on a PAF or award are required to disclose outside interests to U-M. U-M schools and colleges also have disclosure processes for reporting outside interests that are outlined in their respective [school, college, or unit COI/COC policies](#). These disclosures are reviewed by a central COI office for identification of potential COIs related to research or technology transfer not captured by other mechanisms.

4. Office of Research and Sponsored Project (ORSP) and Innovation Partnership Negotiations

To assist in complying with State of Michigan statutes, ORSP and Innovation Partnerships negotiators identify and forward to the COI offices proposed research or licensing agreements in which a University employee has a financial interest in, or management role with, the sponsor of the research or is the recipient of the license. The applicable COI committee (OVPR COI or MEDCOI) reviews these transactions and the associated outside interest disclosures to determine if a COI exists and requires management. The COI offices alert the appropriate IRB when they receive disclosures or are notified of situations associated with human subjects research.

B. Conflict of Interest Review and Management

When an IRB application includes an indication of a related outside interest, a U-M COI committee conducts

a risk review to:

- Ensure appropriate management of the conflict to eliminate or reduce risk to the integrity of the project, the researchers, and the University.
- Provide guidance on applicable informed consent language to notify and protect the study participants.

In conducting this review, the COI committee reviews the [outside interest disclosure](#), the IRB application, and applicable related transactions (e.g., research proposals and option and license agreements) to determine the extent to which:

- Researchers and study team members have outside interests or activities that are related to the research;
- Human participants are involved in the proposed research (e.g., human participant interaction, secondary data, specimens);
- Individuals in the oversight hierarchies of the key researchers have financial interests in the research; and/or
- The University itself has a financial interest in the research.

Representatives of the IRBs, ORSP, and Innovation Partnerships attend COI committee meetings as consultants, as appropriate. They provide source information regarding human subjects research, sponsored projects, contracts and agreements, and University financial interests in proposed sponsors of research or proposed licensees. The results of the committee review are documented in the study workspace within the IRB application in eResearch as an ancillary committee review. The IRB application and M-Inform are integrated and management plans are accessible to the IRB from the eResearch study workspace.

Individuals with a COI related to a research project are generally allowed to participate in that project, but some individuals with compelling circumstances may need to be presented to a COI committee for approval. COI management plans include specific management provisions to protect research participants. Additionally, in some cases, federal regulations might require management to include a retrospective review and mitigation report, if necessary.

The [Office of Research Compliance Review \(ORCR\)](#) conducts routine reviews for compliance with COI management plans.

C. IRB Risk/Benefit Analysis

The IRB has access to individual investigator COI and Institutional Conflict of Interest (ICOI) management plans established for study team members listed on the IRB application and for institutional interests related to the application. IRBs include COI/ICOI risk in their risk/benefit analysis and may place additional restrictions on the conflicted individuals or the research in its entirety, up to and including disapproving participation of a conflicted individual or disapproving the research. IRBs have the final authority to determine whether any disclosed interest and its management allows the research to receive IRB approval. IRBs typically require disclosure to potential research participants in the informed consent document if a key researcher, study team member, or the institution itself has a financial interest in the research. Should

the IRB determine conflict management imposed by any of the U-M COI committees should be altered (e.g., requiring additional measures or removing a requirement), the IRB will contact the appropriate COI office to request revision of the conflict management plan. If the IRB does not require any modifications to the proposed plan, they should ensure appropriate disclosures are included in the final approved informed consent document required by the COI committees and ensure compliance with other COI management plan conditions such as noting consenting restrictions.

III. CONFLICTS OF INTEREST OF IRB MEMBERS, CONSULTANTS AND STAFF

The IRBs have SOPs for identifying and avoiding COI when reviewing and approving research and in managing office functions. The SOP describes the process for re-assigning reviews to a non-conflicted member when an IRB member is assigned to a review in which they have a COI in the research.

An IRB member, consultant or staff member with the IRB will not be assigned to review an application if they (and/or their spouse, domestic partner, or dependents):

- Is a researcher or a team member of the study;
- Has a significant financial interest in the research, such as the [criteria listed in OM Part 9 II.A](#);
- Has other conflicts that the member/consultant, the IRB, the COI Committee, or The Office of the Vice President for Research (OVPR) believes might impact that individual's ability to perform an impartial review.

IRB members, consultants, and staff are also prohibited from participating, as applicable, in the following activities in which they have a conflict of interest:

- Serve as assigned board reviewer for the applicable eResearch application;
- Be present to count towards quorum;
- Be present for deliberations, or vote on the application, amendments, continuing review, AE/ORIO submissions;
- Review by expedited procedure;
- Review of unanticipated problems involving risks to research participants or others;
- Review of non-compliance with the regulations or the requirements of the IRB.

The IRB member, consultant, or staff may, however, be invited to attend the meeting to provide information relevant to the IRB's consideration of the application.

IV. INSTITUTIONAL CONFLICTS OF INTEREST

In support of the public interest, the University, acting as an organization, may form relationships with, enter into affiliations or agreements with, or invest in outside companies or organizations for mutual benefit. Through these relationships, the University can translate the knowledge of its faculty, staff, students, and trainees into socially useful applications, enrich education and research with practical experience, purchase goods and services, and secure financial returns to support the University's missions. These relationships may create institutional conflicts of interest (ICOI) for the University when accepting

grants from, making investments in, conducting research that utilizes licensed intellectual property, or engaging in activities with these outside companies or organizations that compromise or appear to compromise the University's fulfillment of its mission in an objective, unbiased manner.

The University's [Policy for Institutional Conflicts of Interest in Research](#) outlines the principles and procedures for the identification, review, and management of potential institutional conflicts of interest to ensure that research activities are conducted without untoward influence resulting from certain payments for the transfer of technology, university equity holdings outside the university's endowment, gifts to the university, or significant financial interests of covered official. This policy establishes the ICOI Committee, which is appointed by the President to review potential conflicts and make recommendations to the President for institutional decisions.

ICOIs include, but are not limited to:

- Licensing or technology transfer agreements;
- Income from University investments;
- Potential increase in the value of equity held by the University in a faculty start-up;
- The prospect or receipt of gifts to the University;
- Personal investments, intellectual property rights, or consulting or other activity of key University leaders;
- Other financial interests of the University.

Outside relationships or financial interests of the University's leadership ("covered officials") with outside companies or organizations may raise issues related to ICOI by virtue of the leaders' ability to influence decisions about the University's relationships, processes, policies, or functions of the University. These outside relationships or financial interests may interfere or appear to interfere with the obligation of covered officials to act in the University's best interests. The [Standard Practice Guide 201.65-1](#) applies to all employees of the University. Covered officials are required to report to their superiors (deans to the provost, executive officers to the President, and the President to the Regents) any outside activity and financial or other interest that could affect the performance of any of their leadership obligations. Interests are eliminated or managed as deemed appropriate by the office receiving the disclosure.

The following ICOI principles have been established to guide the development and refinement of strategies to ensure the highest level of integrity to maintain public trust. In all relationships and activities, the University and its leadership are expected to abide by the highest standards of conduct in education, research, and public service. The principles are intended to operate in conjunction with other University policies related to COI/COCs, including school, college, or unit-based policies on COI/COCs mandated by [Standard Practice Guide 201.65-1](#).

- The University and its leadership are responsible for furthering and collectively protecting the University's missions of education, research, and public service;
- Commercial collaborations and the transfer of technology between the University and industry are encouraged and play a critical role in furthering the University's missions by generating discoveries and facilitating the use of those discoveries for the public benefit;

- ICOIs that are not disclosed and remain unmanaged may interfere or appear to interfere with the obligations of the University and its leadership to further and protect the missions of the University;
- No outside relationship or financial interest of the University or its leadership should interfere with or compromise the missions of the University;
- The ICOI management process will ensure that the activities of the University and its leadership remain principled, capable of withstanding intense public scrutiny, and protective of the University's missions;
- The ICOI management process will be rational, well-publicized, transparent, and consistently applied.

Failure to abide by ICOI policies may subject offenders to potential sanctions ranging from verbal warning to termination of employment. For more information, see: [Regent Bylaw 5.08 and 5.09](#) and [Standard Practice Guide 201.12](#)

Conflicts of interest resulting from the interests of the institution itself are addressed by various institutional policies and practices.

When conducting reviews of research projects, the COI committees have access to information on any University financial interest and covered official interests in an outside organization associated with the research. From time to time, the COI committees may seek consultative advice from the ICOI Committee to manage a potential ICOI situation associated with significant outside interests.

The University's equity and right to equity or a liquidation fee in start-up companies is managed as part of the University's broader investment portfolio and, therefore, no different from other institutional investments. This helps avoid bias or favoritism. The Chief Financial Officer (CFO), not the Vice President for Research and Innovation (VPR), coordinates University investments by utilizing outside managers to assist with investment strategy. A determination to liquidate the University's investment in a holding is never a decision made by the VPR.

PART 10: Sponsored Research

Describes policies and procedures for administering sponsored project agreements for human research.

I. ROLE OF THE OFFICE OF RESEARCH AND SPONSORED PROJECTS

The [Office of Research and Sponsored Projects \(ORSP\)](#) enables and safeguards the conduct of research and other sponsored activities for the University of Michigan (U-M). ORSP applies specialized regulatory, statutory, and institutional policies to balance the University's mission, the sponsor's objectives, and the researcher's intellectual pursuits. ORSP assists faculty and staff members in all aspects of externally funded research projects and other scholarly activities, such as finding funding, preparing and submitting proposals, negotiating sponsor agreements, setting up financial accounts, managing and administering projects, and closing out projects.

II. AGREEMENTS WITH SPONSORS

ORSP submits sponsored research proposals to external agencies, negotiates the terms of agreements consistent with the mission and goals of the University and Human Research Protection Program (HRPP) and all applicable laws and policies, and arranges for establishing appropriate financial accounts when a project is awarded. ORSP uses the electronic [eResearch Routing and Proposal Management \(eRPM\) system](#) to obtain and record information about the proposed activity. The eRPM information system includes whether a research proposal involves human research as well as the status of the Institutional Review Board (IRB) determination. ORSP checks for IRB determination before setting up an account for a project and activating an award. When negotiating sponsor agreements, University policy requires agreements involving human research to include provisions addressing the following, when applicable:

- Assurance of compliance with human research protection requirements;
- Medical care for research-related injury;
- Communication of findings that could affect the safety of participants, or their willingness to participate, or influence the conduct of the research;
- Dissemination of research findings.

A. Assurance of Compliance with Human Research Protection Requirements

University policy requires that all sponsored activity at U-M comply with human research protection requirements mandated by federal regulatory agencies, State Laws, accreditation standards, and university policy.

In each sponsored agreement, the University includes a provision referencing the University's responsibility to conduct the research in accordance with applicable law and applicable organizational and industry ethical standards relating to protecting human research participants. In sponsored clinical trial agreements, the University includes additional provisions that incorporate, by reference, the written study protocol and allow the sponsor and regulatory authorities, such as the Food and Drug Administration (FDA), the right to inspect the University's property and documents related to the performance of a trial to ensure it is being

conducted in accordance with the protocol and applicable law.

B. Medical Care For Research-Related Injury

1. Provisions in Sponsor Agreements

Before any clinical research involving human research participants begins, arrangements for medical care for research-related injuries are defined, including who will provide such care and who will be responsible for paying for the care. Various University personnel including the PI, research administrator, clinical research coordinator, clinical research [Calendar Review and Analysis Office \(CRAO\)](#), clinical trials planning unit, or ORSP project representative, may discuss this issue with the sponsor. When contracting with sponsors, the University first attempts, when appropriate, to require the sponsor to be responsible for the payment of medical care provided for a research-related injury, illness, or adverse event.

2. Informed Consent Documents

For greater than minimal risk research, the Common Rule requires that researchers present information to research participants about medical and financial responsibility for research-related injuries in the informed consent document so that participants can consider this information before agreeing to participate. The informed consent document must specify financial and medical care responsibilities for research-related injuries and include instructions concerning where medical treatment should be sought if injury occurs and whom to contact in the event of a research-related injury.

The sponsor agreement generally sets forth information concerning research-related injuries consistent with the information provided to the research participant for research projects where this is applicable. CRAO compares the informed consent document and the contract provision to ensure that the language regarding research-related injuries is in agreement. For research not subject to CRAO review, the IRB considers the information regarding research-related injuries provided in the informed consent, seeking input from other institutional authorities, as indicated.

3. Billing Calendars

Faculty and staff conducting clinical trials containing billable items and services must submit a billing calendar as part of the IRB application process. All items and services to be utilized in the study as outlined in the protocol must be documented in the billing calendar at the designated time points with the appropriate designation.

CRAO reviews all human research protocols, informed consent documents, budgets, and contracts containing billable items and services irrespective of the payer, and each research protocol undergoes a Medicare Coverage Analysis to ensure billing compliance.

C. Communication of Findings that May Affect the Safety of Human Research Participants or Their Willingness to Participate, or Influence the Conduct of the Research

The University requires sponsors to provide written plans for communicating routine and urgent safety information that could:

- Affect the safety of participants;
- Affect the willingness of participants to continue participation;
- Influence the conduct of the research; or
- Alter the IRB’s approval to continue the study.

The sponsor must also agree to promptly report to the researcher any information that could directly affect the health or safety of past or current study participants or influence the conduct of the study, including but not limited to the study results and information in site monitoring reports and data and safety monitoring committee reports as required by the protocol. In each case, the researcher and the University shall be free to communicate these findings to each study participant and the IRB, per their reporting guidelines.

The above requirements may be addressed in a master agreement, a project-specific agreement, or any incorporated attachments such as a study protocol.

D. Dissemination of Findings from the Research

1. Policy on Disseminating Research Findings

The principles of open scholarly exchange and academic freedom are integral to U-M's mission. These principles are referred to as "*Openness in Research*" and are set forth by the Regents' policy, under the Standard Practice Guide ([SPG 303.01](#)). It ensures, in part, that U-M:

- reserves the right to publish and disseminate information resulting from sponsored research;
- can maintain the confidentiality of the sponsor’s confidential information, when necessary;
- does not conduct research that restricts the freedom to disclose the agreement’s existence.

[SPG 303.01](#) defines three types of restrictions on the dissemination of research findings: “Standard Restrictions,” “Non-Standard Restrictions,” and “Classified Research Restrictions.” “Standard Restrictions” include provisions giving a sponsor the right to review, comment, and protect confidential information and intellectual property. Sponsor-imposed restrictions within the above parameters are reviewed and approved through the regular Proposal Approval Form (PAF) process and do not require additional approvals. “Non-Standard Restrictions” and “Classified Research Restrictions” require explicit review and approval. Additional information is provided on [ORSP’s website](#).

2. Review/Comment and Delay Provisions

University policy permits a sponsor a reasonable period, usually not to exceed 180 days, to review a proposed publication or other dissemination of research results for:

- Comment (not for prior approval);
- Protection of sponsor’s confidential information;
- Possible participation in the protection of the sponsor’s intellectual property.

When the researcher wishes to disclose the results in a format other than submission to a journal,

(i.e., slides, posters, conference, etc.), negotiation with the sponsor typically provides for a reduced review period. Any publication delay of over 180 days must be reported to the [Office of the Vice President for Research \(OVPR\)](#), via an [Agreement Acceptance Request \(AAR\)](#).

During the review and comment period, a sponsor may recommend any changes to the publication it reasonably believes are necessary for scientific purposes.

3. Single Site Study Provisions

When the University is the only site participating in a sponsored research study, the publication protection of the research agreement will include the review/comment period, and the potential delay for confidential information and intellectual property, as well as the right of the sponsor to require the removal of confidential and proprietary information provided by the sponsor before publication or dissemination of findings.

4. Multi-Site Study Provisions

In multi-center studies, where numerous sites participate, the sponsor may require the pooling of the information from all the sites and an initial publication based on the aggregated data. University policy recognizes that multi-site publication may be the best way to ensure the integrity of multi-center trial results. The policy allows for a reasonable and determinate time delay for publication by the University of its site results following the initial multi-site publication or after the sponsor indicates that such publication will not occur.

The usual period of delay for the University to publish in such instances is between 12-18 months from the completion of the study at all sites. This delay period is often triggered once data collection from all trial sites is complete, and the overall study results database has been locked with the only remaining activity analysis of the aggregate data by the study sponsor. After this delay period has lapsed, the University researcher can present the results from their site to the sponsor for the review and comment period, and to determine if any confidential or proprietary information should be removed before publication or dissemination of findings. The sponsor is required to provide notice to the University when the study is completed to allow the University to compute the publication delay period.

5. Compliance with Federal Disclosure Requirements

Sponsor agreement provisions regarding dissemination of research findings must not prevent full compliance with federal disclosure provisions, such as those covered by the FDA Amendments Act requiring reporting of certain results in [ClinicalTrials.gov](#). See [Part 11 of this OM](#).

6. Dissemination to Research Participants

When participants request information concerning a completed study, they are provided with the information described in the IRB-approved consent form. In addition, if adverse events are experienced at the University or have occurred at other sites involved in the trial and are made known to the University via broadcasting of such instances from the sponsor or other sites, the University may revise the informed consent to include notice of any safety issues. It may also require re-consent of the research participants. In sponsor agreements, the University reserves the right to

use results, data, information, etc. for, among other things, patient care purposes.

III. FINDER FEES AND BONUS PAYMENTS

Research sponsors typically provide financial support commensurate with the work required to do the study. Although some sponsors may offer to pay “finders’ fees” or “bonus payments” to encourage participant recruitment efforts, University policy prohibits payment to or receipt by U-M researchers, including staff and students, of these types of payments.

A “finder’s fee” is a compensation of any type (e.g., cash, cash equivalent, office or medical supplies, educational stipends, gift certificates, travel cost above normal reimbursement costs, or anything else of value) made to the study team members in exchange for referral or recruitment of a participant to a research study (e.g., \$10 for every person recruited who signs the consent document to participate in the study).

“Bonus payment” is defined here as compensation tied to the rate or timing of recruitment, performance, or other aspects of a clinical study. Examples of bonus payments include the following: the sponsor announces that the highest enrolling site in the nation will receive a \$10,000 bonus; the sponsor offers to pay an additional \$10,000 beyond the budgeted study costs to any site that enrolls five participants within a week; the sponsor offers to pay an additional \$10,000 beyond the budgeted study costs to any site that fulfills its recruitment target by the end of the month; the sponsor offers to pay an additional \$1,000 beyond the budgeted study costs for any participant who agrees to enroll within one day of initial contact. It is not permissible to accept bonus payments at U-M.

The policy prohibiting “finders’ fees” and “bonus payments” does not prohibit renegotiation of contract fees when recruitment progresses much more slowly than anticipated, such that additional time and effort are required for recruitment activities than initially anticipated. The policy also does not prohibit compensation for recruitment and screening-related activities that are unrelated to whether the participant ultimately enrolls in or completes the research study (e.g., advertising, administrative, and personnel costs) or for the cost of services provided to those individuals who ultimately do enroll. This policy does not address payments to research participants, which are addressed in [Part 7. V of this OM](#).

Researchers should determine a reasonable budget amount directly related to the value of the services provided to the study and document how that amount was determined. Further, any payments to the University for personnel must be reflected in the study budget and in the written agreement that ORSP reviews.

IV. ADDITIONAL INFORMATION

Numerous applicable and helpful University websites provide information concerning University policies, Regental bylaws, and contracting procedures and requirements. Below are just a few of the links to such resources:

A. General Contracting Principles

- [ORSP: Working with a Private Team Sponsor](#)

B. Human Use in Research

- [SPG 303.05 - Policy for Research with Human Participants](#)
- [U-M Federalwide Assurance of Protection for Human Subjects](#)

PART 11: Laws, Regulations, and Standards

Describes selected laws and regulations commonly impacting human subjects research conducted at U-M by faculty, staff, students and other trainees.

I. FEDERAL, LAWS, REGULATIONS, AND REQUIREMENTS COMMONLY APPLICABLE TO RESEARCH

Numerous laws, regulations, formal and informal guidance documents, and other standards govern research activities. These requirements are implemented by government bodies (e.g., federal or state government), federal agencies (e.g., HHS), or other national or international institutions (e.g., International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use). These bodies may regulate the same or similar activities, which can result in conflicting guidance. Researchers must generally comply with the most restrictive requirements.

A. Federal Laws and Regulations Applicable to Research

A brief outline of federal laws applicable to research is provided below; other standards may also apply.

1. The "Common Rule"

The Federal Policy for the Protection of Human Subjects is known as the "Common Rule" because it has been adopted by a number of federal departments and agencies. HHS maintains a list of federal agencies that have adopted the Common Rule: [Federal Policy for the Protection of Human Subjects \('Common Rule'\)](#). Changes to regulations governing human subjects research, as outlined in the Common Rule, 45 CFR 46, were issued by HHS on January 18, 2017 and became effective on January 21, 2019. U-M applies the revised Common Rule to research approved on or after the effective date.

The Common Rule requirements are integrated throughout this OM and in the standard operating procedures (SOPs) of the University's IRBs and other review units.

Absent an interpretation from the sponsoring agency to the contrary, the guidance provided by the HHS and the requirements of all of the subparts of [45 CFR 46](#) apply to University research supported by Common Rule agencies. 45 CFR 46 includes several subparts that impose additional protections for identified vulnerable populations, specifically, pregnant women, fetuses, and neonates ([45 CFR 46 Subpart B](#)); prisoners ([45 CFR 46 Subpart C](#)); and children ([45 CFR 46 Subpart D](#)). Although many agencies have not adopted Subparts B, C, or D; unless guidance to the contrary, the University interprets the subparts to apply to all federally supported University research.

For research that is not federally supported, and in accordance with the University's [Federalwide Assurance \(FWA\)](#) with the OHRP, the University adheres to equivalent protections that are consistent with the requirements of 45 CFR 46 and the subparts, but that allow flexibility in IRB review of these projects.

2. Clinical Trials Disclosure Requirements

[The Food and Drug Administration Modernization Act](#) (FDAMA), the [Food and Drug Administration](#)

[Amendments Act](#) (FDAAA), and [NIH policy](#) mandate public registration of certain types of clinical trials. Failure to comply with these legal and policy requirements may result in administrative sanctions and civil penalties and, when applicable, withholding or even possible repayment of NIH funding.

Additionally, journals increasingly refuse to publish the results of trials that were not adequately registered in a comparable registry before enrollment of the first participant. [The International Committee of Medical Journal Editors](#) (ICMJE) generally requires registration of research projects that prospectively assign human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention (e.g., drug, surgical procedure, device, behavioral treatment, process-of-care change) and a health outcome (broadly defined, including pharmacokinetics).

Private funders may also have ClinicalTrials.gov related requirements that need to be followed.

Researchers conducting clinical trials subject to these requirements must identify the individual or entity that will act as the Responsible Party for registration and results reporting. Under federal regulations ([42 CFR 11](#)), the Sponsor – i.e., meaning the person or entity responsible for initiating the trial and for control of the protocol – is considered the Responsible Party unless that responsibility is designated to a Principal Investigator (PI). At the University of Michigan, for investigator-initiated research, the PI is expected to take on the role of the Responsible Party, with two exceptions:

- If there is an IND or IDE held by someone other than the PI, the IND or IDE holder is the Responsible Party, and
- Within the Oncology CTSU, the University of Michigan Rogel Cancer Center may retain Responsible Party status or may designate it to the PI.

Per FDAAA, 42 CFR §11, and NIH policy, the Responsible Party is required to:

- Register clinical trial information on ClinicalTrials.gov within the required time frame,
- Ensure that informed consent documents contain the applicable language related to clinical trial registration,
- Maintain the ClinicalTrials.gov record by making required updates to the record, and
- Report results, generally, within one year of the primary completion date.

3. Certificates of Confidentiality

a. Generally

[Certificates of Confidentiality](#) (CoCs) are issued by the NIH, the Centers for Disease Control and Prevention (CDC), the FDA, the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Health Resources and Services Administration (HRSA). CoCs protect the privacy of research participants by allowing PIs and institutions to avoid compulsory release of information that could be used to directly or indirectly identify individuals participating in a research project. CoCs are issued to institutions or universities where the research is conducted. When research is covered by a CoC, subject to certain permitted disclosure circumstances described later in this section, the researcher (and institution) shall not:

- Disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, the name of such individual or any such information, document, or biospecimen that contains identifiable, sensitive information about the individual and that was created or compiled for purposes of the research, unless such disclosure or use is made with the consent of the individual to whom the information, document, or biospecimen pertains; or
- Disclose or provide to any other person not connected with the research the name of such an individual or any information, document, or biospecimen that contains identifiable, sensitive information about such an individual and that was created or compiled for purposes of the research.

Generally, any research project that collects identifiable, sensitive information and that has been approved by an IRB that either 1) is operating under an approved FWA issued by the OHRP or 2) has the approval of the FDA is eligible for a CoC. Information is considered identifiable if it directly identifies an individual, or if for which there is at least a very small risk that some combination of that information, the request for that information, and other available data sources could be used to deduce the identity of an individual.

Information is considered sensitive if disclosing it could have adverse consequences for participants or damage their financial standing, employability, insurability, or reputation.

Usually, CoCs are issued for single, well-defined research projects following IRB approval. They may, however, be issued for multi-site and collaborative projects under limited circumstances.

CoCs are issued with expiration dates but may be extended if the research continues past those dates. The protection afforded by a CoC is permanent; all identifiable, sensitive information collected about participants in the study while the CoC is in effect is protected forever. Note, that if the CoC expires and the researcher continues to collect data from existing participants or enrolls new participants without formally extending the CoC, the data collected after the expiration date is not protected.

Effective October 1, 2017, Certificates of Confidentiality (CoCs) are automatically deemed to be issued for any NIH-funded research that collects or uses identifiable, sensitive information that was on-going on or after December 13, 2016. Institutions and their investigators are responsible for making the appropriate determination as to whether the research they are conducting involves the collection or use of identifiable, sensitive information and is subject to the CoC Policy and therefore deemed to be issued a Certificate. Examples of NIH-funded research automatically covered by a CoC include:

- Biomedical, behavioral, clinical or other research, including exempt research, except where the information obtained is recorded in such a manner that human participants cannot be identified or the identity of the human participants cannot readily be ascertained, directly or through identifiers linked to the subjects.
- The collection or use of biospecimens that are identifiable to an individual or for which there is at least a very small risk that some combination of the biospecimen, a request for the biospecimen, and other available data sources could be used to deduce the identity of an individual.

- The generation of individual level, human genomic data from biospecimens, or the use of such data, regardless of whether the data is recorded in such a manner that human subjects can be identified or the identity of the human subjects can readily be ascertained.
- Any other research that involves information about an individual for which there is at least a very small risk, as determined by current scientific practices or statistical methods, that some combination of the information, a request for the information, and other available data sources could be used to deduce the identity of an individual.

A project may receive protection under a CoC if the project is not sponsored or funded by NIH, as long as, in NIH's view, the subject matter of the study falls within a mission area of the NIH, including its Institutes, Centers, and the National Library of Medicine.

The CDC, FDA, SAMHSA, and HRSA only issue CoCs for research they sponsor or research that is subject to that agency's regulations.

b. Principal Investigator Responsibilities

Researchers conducting NIH-supported research covered by a CoC must ensure that if identifiable, sensitive information is provided to other researchers or organizations, the other researcher or organization must comply with applicable requirements, including with respect to the CoC, even if that other research is not itself federally funded. In addition, for NIH, CDC, and FDA-issued CoCs, the protections from the CoC flow down to collaborators who have a sub-award or sub-contract if the collaborators' research activities are funded from those agency funds.

The existence of a CoC, the protection it provides, and any limitations on that protection should be described in the informed consent document:

- For studies that were previously issued a CoC and notified participants of the protections provided by that CoC, NIH does not expect participants to be notified that the protections afforded by the CoC have changed, although IRBs may determine whether it is appropriate to inform participants.
- If part of the study cohort was recruited before issuance of the CoC, but are no longer actively participating in the study, NIH does not require participants who consented before the change in authority, or before the issuance of a CoC, to be notified as to the existence of a CoC, or that participants who were previously consented to be re-contacted to be informed of the CoC, although IRBs may determine whether it is appropriate to inform participants.

Refer to U-M IRB informed consent document templates for CoC language.

c. Disclosure

Certain disclosures are permitted even when a CoC has been issued. Disclosures are allowed if:

- Required by Federal, State, or local laws (e.g., as required by the Federal Food, Drug, and Cosmetic Act, or state laws requiring the reporting of communicable diseases to State and local health departments, or child or elder abuse and neglect reporting), excluding instances of disclosure in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding.

- Necessary for the medical treatment of the individual to whom the information, document, or biospecimen pertains and made with the consent of such individual;
- Made with the consent (which can be in the informed consent document itself or in a subsequent grant of permission) of the individual to whom the information, document, or biospecimen pertains; or
- Made for the purposes of other scientific research that is in compliance with applicable Federal regulations governing the protection of human subjects in research.

The IO or their designee must sign the statement of CoC assurances before submission to NIH, FDA, HSRA, SAMHSA, or CDC.

For information on how to apply for a CoC and other guidance, refer to [U-M Guidance on Certificates of Confidentiality](#).

For additional information about CoCs, see:

- [NIH Certificates of Confidentiality](#)
- [FDA](#)
- [CDC](#)
- [HSRA](#)
- [SAMHSA](#)

4. The Health Insurance Portability and Accountability Act (HIPAA)

The U.S. Department of Health and Human Services, Office for Civil Rights (OCR) has issued privacy and security regulations under the [Health Insurance Portability and Accountability Act of 1996](#). These regulations protect against unauthorized use and disclosure of individually identifiable information created or received by health plans, health care clearinghouses, and most health care providers (covered entities). Components of the University that are covered entities and therefore directly regulated by HIPAA include:

- U-M Health System Hospitals & Health Centers (including the U-M Medical School);
- U-M Group Health Plans;
- Mary A. Rackham Institute (University Center for the Child and Family, University Center for Language and Literacy, and the Adult Psychological Clinic);
- School of Dentistry Provider Clinics; and
- University Health Service.

In general, a covered entity may allow protected health information under its control to be used or disclosed for research only with an individual's written authorization. This authorization is described in [45 CFR 164.508](#). To be valid, the authorization must include at least the following information:

- A description of the information to be used or disclosed that identifies the information in a specific and meaningful way;
- The names or other identification of the specific people or categories of people (e.g., "your primary care physician" or "your health care providers") who can make the use or disclosure;

- The names or other identification of the specific people or categories of people who may receive the information (e.g., "the U-M," "the researchers," "the IRB and other University officials," "study sponsors," "government oversight agencies");
- A description of each purpose of the authorized disclosure (e.g., "to conduct the study," "to analyze any adverse reactions to the study intervention," "for study oversight,");
- An expiration date (e.g., January 1, 2016) or expiration event (e.g., "one year from signing" or "at the end of the study" or "none");
- Signature of the individual (or the person's legally authorized representative) and date;
- A statement of the individual's right to revoke their authorization in writing and any exceptions to that right;
- Whether treatment or payment will be conditioned on granting the authorization; and
- The potential for the information used or disclosed for the research to be redisclosed and no longer protected by HIPAA.

This authorization must be written in plain language. This information may be incorporated into a research consent form or provided separately to prospective participants, depending on the requirements of the IRB overseeing the research. U-M standard informed consent document templates incorporate the requirements for HIPAA authorization. In limited cases described in [45 CFR 164.512](#), an IRB or Privacy Board may waive these authorization requirements. See this [OM Part 3](#) for waiver criteria.

5. The Genetic Information Nondiscrimination Act (GINA)

[GINA](#) is a Federal law that prohibits discrimination in health coverage and employment based on genetic information. GINA, together with the nondiscrimination provisions of HIPAA, generally prohibit health insurers or health plan administrators from requesting or requiring genetic information of an individual or an individual's family members, or using such information for decisions regarding coverage, rates, or preexisting conditions. GINA also prohibits most employers from using genetic information for hiring, firing, or promotion decisions, and for any decisions regarding terms of employment.

Since GINA has implications regarding the actual or perceived risks of genetic research and an individual's willingness to participate in such research, OHRP has provided [guidance](#) for PIs and IRBs so that they are aware of the protections provided by GINA, as well as the limitations in the law's scope and effect. IRBs should consider the provisions of GINA when assessing whether genetic research satisfies the criteria required for IRB approval of research, particularly whether the risks are minimized and reasonable in relation to anticipated benefits and whether there are adequate provisions in place to protect the privacy of subjects and maintain the confidentiality of their data.

GINA is also relevant to informed consent. When PIs develop, and IRBs review, consent processes and documents for genetic research, they should consider whether and how the protections provided by GINA should be reflected in the consent document's description of risks and provisions for ensuring the confidentiality of the data.

6. Substance Use Disorder

Federal law ([42 CFR 2](#)) imposes restrictions upon the disclosure and use of alcohol and drug abuse

patient records that are maintained in connection with the performance of any federally assisted alcohol and drug abuse treatment program (a “Part 2 Program”). These regulations prohibit the disclosure and use of patient records unless certain circumstances exist. If a patient consents to a disclosure of their records, a Part 2 Program may disclose their records in accordance with that consent to any individual or organization named in the consent. The consent must include the following nine elements:

- The specific name or general designation of the program or person permitted to make the disclosure;
- The name or title of the individual, or name of the organization, to whom the disclosure is to be made;
- The name of the patient;
- The purpose of the disclosure;
- How much and what kind of information is to be disclosed;
- The patient signature (or signature of legally authorized representative);
- The date of signature;
- A statement that authorization may be revoked at any time except to the extent it already has been relied on to make a disclosure; and
- The date, event, or condition upon which authorization will expire if not revoked (the authorization may not last longer than reasonably necessary to serve the purpose for which it is given).

Further, per federal law ([42 CFR 2.52](#)), patient-identifying information may be used or disclosed for the purpose of conducting scientific research if certain requirements are met, specifically::

- If the part 2 Program Director or designee determines:
 - The recipient of the patient identifying information is a HIPAA covered entity or business associate that has obtained and documented authorization from the patient, or a waiver or alteration of authorization, consistent with HIPAA; or
 - The recipient of the patient identifying information is subject to HHS regulations regarding protection of human subjects ([45 CFR 46](#)), and provides documentation that either the researcher is in compliance with the requirements of the HHS regulations, including the requirements related to informed consent or a waiver of consent or that the research qualifies for exemption under the HHS regulations.
 - The recipient of the patient identifying information is both a HIPAA covered entity or a business associate and subject to the HHS regulations regarding protection of human subjects, both requirements above apply.

Or

- If the part 2 program or other lawful holder of the data is a HIPAA covered entity or business associate, and the use or disclosure is made in accordance with the requirements of HIPAA.

Additional obligations and restrictions apply to researchers using patient identifying information obtained pursuant to 42 CFR 2.52, including restrictions on re-disclosure and security procedures.

Furthermore, additional restrictions and obligations apply if researchers seek to link data sets or

establish data repositories containing personally identifiable information from a Part 2 Program, including ensuring that patient identifying information is not provided to law enforcement agencies or officials.

B. Federal Agencies and Additional Federal Requirements Applicable to Human Research

Several federal agencies conduct or support human research. A number of these federal agencies have created additional, agency-specific regulations for the research they support. Each IRB is responsible for ensuring that PIs and research staff meet these additional regulations when conducting human research supported by a particular agency. In addition, U-M researchers are responsible for complying with additional regulations when conducting human research supported by a particular agency.

An outline of federal agencies, as well as an overview of the laws and standards they oversee, is provided below.

1. Department of Health and Human Services

[HHS](#) and its [various offices and operating divisions](#) regulate human research supported with HHS federal funds or involving the use of investigational drugs, biologics, and devices. An overview of some of these offices/divisions and the laws these organizations oversee is provided below.

a. Office for Human Research Protections ([OHRP](#))

The OHRP is part of the Office for the Assistant Secretary of Health under HHS. The OHRP provides guidance and regulatory oversight of biomedical and social-behavioral research to protect the rights, welfare, and well-being of human research participants. OHRP has oversight of the [Common Rule](#) and additional rules for research involving pregnant women, fetuses, and neonates ([45 CFR 46 Subpart B](#)); prisoners ([45 CFR 46 Subpart C](#)); and children ([45 CFR 46 Subpart D](#)).

U-M maintains a Federalwide Assurance with HHS. Refer to [Part 1](#) of this OM for additional information.

b. Food and Drug Administration

The U.S. [Food and Drug Administration](#) (FDA) enforces the Federal, Drug, Food, and Cosmetic (FD&C) Act and associated regulations, including regulations covering human subjects protections ([21 CFR part 50](#)), IRBs ([21 CFR part 56](#)), investigational drugs ([21 CFR part 312](#)), biologics ([21 CFR 312](#))), and investigational devices ([21 CFR part 812](#)). Additional information about and requirements for research regulated by the FDA is provided in [Part 8](#) of this OM and directly from the FDA.

c. National Institutes of Health, Office of Science Policy

The [Office of Science Policy](#) (OSP), through the Biosafety, Biosecurity, and Emerging Biotechnology Policy Division, oversees research involving recombinant DNA (rDNA). OSP develops and implements NIH policies and procedures for the safe conduct of rDNA activities and human gene transfer (see [The NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules](#)). Its duties include the review and evaluation of the composition of institutional biosafety committees and the development of registries of activities related to rDNA and human gene transfer research. OSP-regulated research is subject to oversight by the

University's [Institutional Biosafety Committee](#).

d. Office of Research Integrity

The [Office of Research Integrity](#) (ORI) is located in the Office of the Assistant Secretary for Health under HHS. ORI promotes integrity in biomedical and behavioral research supported by the Public Health Service (PHS). ORI facilitates the responsible conduct of research through educational, preventive, and regulatory activities and monitors institutional investigations of [research misconduct](#). ORI's response to misconduct depends on the circumstances but may include government-wide debarment. ORI publishes all findings of misconduct. The University's policy on research misconduct is described in the [Standard Practice Guide 303.03](#).

e. Office for Civil Rights

The [Office for Civil Rights](#) (OCR) is responsible for the implementation and enforcement of privacy and security rules issued under [HIPAA](#), which protects individually identifiable health information. While the privacy and security rules do not directly regulate human research, they do govern the circumstances under which “covered entities” (health care providers, health plans, and health care clearinghouses) who control information necessary for many research activities may use, disclose, or provide access to that information. HIPAA is further discussed in Section I.A.4 of this part.

2. Department of Defense (DoD)

In addition to the Common Rule requirements adopted at [32 CFR Part 219](#), the DoD has additional requirements for human research it supports or conducts. See U-M HRPP Guidance: Additional Requirements for Department of Defense Sponsored Research.

3. Department of Justice (DOJ)

In addition to requirements adopted at [28 CFR 46](#), the DOJ has additional requirements for research conducted with the Bureau of Prisons and research involving the National Institute of Justice (NIJ). See U-M HRPP Guidance: Additional Requirements for Research Supported by the Department of Justice.

4. Environmental Protection Agency (EPA)

In addition to the Common Rule requirements adopted at [40 CFR 26](#), the EPA has additional requirements for human research it supports or conducts or for research that is otherwise intended for submission to the EPA. See U-M HRPP Guidance: Additional Requirements for Research Supported by the Environmental Protection Agency (EPA).

5. Department of Education (ED)

In addition to the Common Rule requirements adopted at [34 CFR 97](#), the ED has additional requirements for human research involving students or education records conducted at institutions receiving ED funding. These additional requirements include the Family Educational Rights and Privacy Act (FERPA) ([34 CFR 99](#)) and the Protection of Pupil Rights Amendment (PPRA) ([34 CFR 98](#)).

The U-M IRBs may provide guidance regarding complying with PPRA and/or FERPA requirements, but the school providing access to its students or student records for research purposes is responsible for

ensuring compliance with FERPA or PPRA. See U-M HRPP Guidance: Additional Requirements for Research Supported by the Department of Education (ED).

6. Department of Energy (DOE)

In addition to the Common Rule requirements adopted at [10 CFR 745](#), the DOE has additional requirements for human research it supports or conducts. See U-M HRPP Guidance: Additional Requirements for Research Supported by the DOE.

II. MICHIGAN STATE LAWS, REGULATIONS, AND REQUIREMENTS COMMONLY APPLICABLE TO HUMAN RESEARCH

Studies conducted at the University or other in-state locations are subject to the laws and regulations of the State of Michigan. Studies performed in whole or in part in other states may be subject to different requirements. For example, different states may have different requirements for informed consent; confidentiality, privacy, and security standards; public health reporting mandates; limitations on participation of vulnerable populations in research; professional licensing requirements; etc. For human research conducted out-of-state, researchers are expected to comply with the requirements of those other states. Typically, University IRBs rely on local IRB or ethics board oversight to ensure project compliance with local laws and regulations. Where the design of the research does not anticipate local review, the PI may contact the U-M Office of the Vice President and General Counsel (OGC) to determine whether the protocol is likely to implicate state laws that are inconsistent with those of Michigan. Note that it may be necessary for OGC to consult with external legal counsel in such situations, which could entail additional expenses for the researcher.

Contracts signed with sponsors and funders of research and reliance agreements signed with research performance sites may also impose further restrictions. The PI is responsible for ensuring that the study complies with all of these requirements.

This section describes legal standards under Michigan law only. Researchers are required to determine the laws and standards applicable to their projects and follow them accordingly. Researchers may contact OGC for general assistance in determining which laws and standards may apply to their project. See also [OHRP's International Compilation of Human Research Standards](#) for additional guidance.

A. Informed Consent and Legally Authorized Representatives

Informed Consent is addressed in [Parts 3, 6, and 7 of this OM](#). This section contains a general overview of Michigan laws regarding informed consent that may be applicable to research. Michigan requirements regarding consent are largely consistent with federal law.

1. Who May Give Consent

Competent adults (those able to understand the nature and consequences of their actions) must consent on their own behalf to participate in research. Children and adults with diminished decision-making capacity, however, are considered vulnerable and susceptible to coercion and undue influence. In general, neither of those groups may provide legally effective informed consent.

a. Children

Michigan law ([MCL 722.1](#)) defines the “age of majority” as an individual who is eighteen or older. Parents or legal guardians (as defined by MCL [700.5201-700.5219](#)) must consent on behalf of children who are younger than eighteen.

The following exceptions to parental consent are allowed under Michigan law and the IRB will determine the applicability of these exceptions in the research setting:

- Emancipated minors (generally those who are validly married or are on active duty in the United States armed forces) ([MCL 722.4e\(1\)\(g\)](#));
- Children seeking confidential prenatal and pregnancy-related care (excluding abortions) ([MCL 333.9132](#));
- Children age 14 and above seeking confidential limited outpatient mental health services ([MCL 330.1707](#));
- Children seeking confidential substance abuse treatment ([MCL 330.1264](#)); and
- Children seeking confidential treatment for sexually transmitted diseases, including HIV/AIDS ([MCL 333.5127](#)).

b. Adults with Cognitive Impairment or Otherwise Impaired Decision-making Capacity

Federal law permits that a legally authorized representative consent to research participation on behalf of adults with impaired decision-making capacity. Under Michigan law, individuals who constitute a legally authorized representative are listed as follows, in descending order of priority:

- Patient Advocate named in a Durable Power of Attorney
- Guardian
- Spouse
- Adult child(ren)
- Parent(s)
- Adult sibling(s)

OGC can also assist with making determinations related to legally authorized representative issues.

2. Michigan Laws Requiring Special Consent

Michigan has adopted laws and regulations imposing specific consent requirements for certain types of clinical activities that may impact research. PIs are responsible for obtaining and documenting informed consent in compliance with applicable federal and state laws and institutional policies.

a. Electroconvulsive Therapy (ECT) ([MCL 330.1717](#))

Michigan law outlines specific requirements before administration of ECT (or any procedure intended to produce convulsions or coma). Depending on the relevant circumstances, these requirements may include concurrence by two psychiatrists (neither of whom may be the treating psychiatrist), notice to the patient of his/her right to object, and/or a potential petition to probate court.

A U-M PI who wishes to conduct clinical research that involves ECT should consult with the IRB and

OGC to ensure compliance with state and federal laws.

b. Genetic Testing ([MCL 333.17020](#) and [333.17520](#))

Per MCL 333.17020 and 333.17520, the term “genetic test” does not include procedures performed as a component of biomedical research that is conducted pursuant to federal regulations 21 C.F.R. 50 and 56 and 45 C.F.R. 46 (Common Rule Subpart A). However, they do establish best practice in Michigan and should be followed when appropriate in the context of an individual research project.

Best practices in Michigan include: requiring specific, written informed consent from the patient or the patient's legally authorized representative before a physician or other provider may perform a pre-symptomatic or predictive genetic test. The informed consent must confirm that the physician or provider has explained, and the patient or his legally authorized representative understands, all of the following, at a minimum:

- The nature and purpose of the genetic test;
- The effectiveness and limitations of the genetic test;
- The implications of taking the genetic test, including, but not limited to, the medical risks and benefits;
- The future uses of the sample taken from the test subject to conduct the genetic test and the information obtained from the genetic test;
- The meaning of the genetic test results and the procedure for providing notice of the results to the patient; and
- Who will have access to the sample taken from the patient to conduct the genetic test and the information obtained from the genetic test, and the patient's right to confidential treatment of the sample and the information.

A copy of the informed consent document should be provided to the person who signed it. The original form, signed by the patient or his legally authorized representative, must be placed in the patient's medical record. The Michigan Department of Community Health (MDCH) has developed a [patient information brochure](#) and model informed consent document that it recommends for use with genetic testing.

c. HIV Testing ([MCL 333.5133](#))

Michigan law has specific requirements related to informed consent for HIV testing. However, if the HIV test is performed solely for research purposes and if the test is performed in such a manner that the identity of the test subject is not revealed to the researcher and the test results are not made known to the test subject, the requirements under Michigan law may not apply. The researcher still has the obligation to obtain informed consent as outlined in [Part 6](#) of this OM.

If the researcher will know the identity of the subject and the test results are made known to the subject, then Michigan law requires the physician to do the following prior to the HIV test:

- Inform the subject or his or her legally authorized representative (LAR) verbally or in writing that an HIV test will be performed unless the subject or his or her LAR declines the HIV test.

- Offer the subject or his or her LAR an opportunity to ask questions and decline the HIV test. If the subject or his or her LAR declines the HIV test, the decision must be documented in the subject's medical record.

Under Michigan law, if the HIV test is positive then the health facility must provide appropriate counseling regarding HIV infection and acquired immunodeficiency syndrome to the patient and referrals to expedite HIV treatment and services.

Note that Michigan law does not require separate consent for HIV testing, such that an individual that provides general informed consent for medical care is considered to have consented to an HIV test.

Separately, the OHRP has published [guidelines for AIDS research](#).

d. Pregnancy Termination ([MCL 333.17015](#))

Michigan has enacted various laws related to pregnancy termination. In the case of a minor seeking an abortion, the physician must also obtain written consent from one parent or the legal guardian of the minor unless such consent is waived by a court.

A U-M investigator who wishes to conduct clinical research that involves pregnancy termination should consult with the IRB and OGC to ensure compliance with state and federal laws.

B. Confidentiality of and Access to Research Records and Other Information

1. General Research Records

The "Confidential Research and Investment Information Act," [MCL 390.1551-390.1557](#), exempts from disclosure under the Michigan Freedom of Information Act (FOIA, [MCL 15.231-MCL 15.246](#)) intellectual property created by individuals employed or contracted by the University for research, education, and related activities until a reasonable opportunity has been provided to publish. In addition, the Act protects from disclosure confidential information received by the University from third parties for research, education, and related activities, provided that the information is designated as confidential before it is received by the University; the University, and the third party enter into an agreement to keep the information confidential; and other conditions are met. The law also protects copyrightable and patentable information, until a reasonable opportunity has been provided to obtain a copyright or patent.

In addition to the federal privacy and confidentiality standards, Michigan law ([MCL 333.20201](#)) generally provides that patients are entitled to the privacy of their medical information and prohibits hospitals and other health facilities from providing copies of patient medical records to third parties without prior authorization. Patients may refuse the release of their records outside a health facility except as required for transfer to another health facility, as required by law or third-party payment contract, or as permitted by HIPAA.

2. Information Pertaining to HIV/AIDS ([MCL 333.5131](#))

All reports, records, and data pertaining to testing, care, treatment, reporting, research, and information pertaining to partner notification under [MCL 333.5114a](#), that are associated with

infections of HIV infection and acquired immunodeficiency syndrome (AIDS) are confidential and can only be released under Michigan law only in the following situations:

- In response to a court order, but only if (1) the court determines that other ways of obtaining the information are not available or would not be effective; and (2) the public interest in and need for the disclosure outweigh the potential for injury to the patient. The court order must: limit disclosure to those parts of the patient's record that are determined to be essential to fulfill the objective of the order; limit disclosure to those individuals whose need for the information is the basis of the order; and include other measures necessary to limit disclosure for the protection of the patient.
- To the Michigan Department of Community Health, a local health department, or other health care provider (1) to protect the health of an individual; (2) to prevent further transmission of HIV; (3) to diagnose and care for a patient.
- By a physician or local health officer to a known contact of the individual who is HIV infected or has been diagnosed as having acquired AIDS, if the physician or local health officer determines that disclosure is necessary to prevent a reasonably foreseeable risk of further transmission of HIV. (In this case, the physician or local health official has a duty to disclose the information to the known contact or to refer the individual who is HIV infected or has been diagnosed as having AIDS to a local health department for assistance with partner notification. The referral shall include available contact information for known contacts of this individual.) To the extent released, the information should not identify the individual to whom the information pertains unless reasonably necessary to prevent a foreseeable risk of transmission.
- If the disclosure is expressly authorized in writing by the individual who is HIV infected or has been diagnosed as having acquired AIDS. Written authorization must be specific to HIV infection or acquired immunodeficiency syndrome; if an individual is a minor or incapacitated, written authorization may be executed by the parent or legal guardian of the individual.
- As otherwise required or permitted by law.

3. Mental Health Treatment ([MCL 330.1748](#))

Michigan law accords special protection to the privacy of mental health records, including special requirements for when mental health information may be disclosed as necessary for outside research, evaluation, accreditation, or statistical compilation. In this case, the individual subject should not be identified in the disclosed data set unless the identification is essential to achieve the purpose for which the information is sought or if preventing the identification would clearly be impractical. Under no circumstances may the information be disclosed if the subject is likely to be harmed by the identification.

In general, information in the record of a recipient of mental health services must be kept confidential and only may be disclosed with specific authorization of the recipient, with the following exceptions:

- If the recipient is a child, the authorization may be granted by the recipient's parent with legal custody.
- If the recipient is an incompetent adult, authorization may be granted by the recipient's legal guardian.

- If the recipient is deceased, the authorization may be granted by the personal representative or executor of the estate.

The law also significantly restricts any re-disclosure. Even when information is disclosed in accordance with Michigan law, the identity of the person to whom it pertains should be protected whenever feasible.

4. Substance Abuse Treatment ([42 CFR 2](#); [MCL 330.1260-330.1287](#))

Per Michigan law, substance abuse diagnosis, prognosis, and treatment records are confidential and may be disclosed only with the consent of the individual to whom the record pertains, unless one of the following applies:

- To medical personnel, to the extent necessary to meet a bona fide medical emergency;
- To qualified personnel, for the purpose of conducting scientific statistical research, financial audits, or program evaluation, but the personnel shall not directly or indirectly identify an individual in a report of the research audit or evaluation or otherwise disclose an identity in any manner; or
- By court order, as described in [MCL 330.1263](#).

The individual may withdraw consent at any time unless prohibited by federal law.

C. Mandatory Disclosure Requirements

Various Michigan laws require U-M personnel to report information that might otherwise be considered confidential. Researchers are also responsible for complying with the laws of other states, when applicable.

1. Michigan Freedom of Information Act

The Michigan FOIA ([MCL 15.231-15.246](#)) requires “public bodies” including U-M to allow people to inspect, copy, or receive copies of “public records.” A public record is defined as “a writing prepared, owned, used, in the possession of, or retained by a public body in the performance of an official function, from the time it is created.” Most records created by University faculty, staff, and trainees in the performance of their University functions, or retained on University property or in University electronic resources, are public records subject to disclosure under FOIA. However, under FOIA, the institution must deny requests for a number of specific reasons, including student education records subject to the protections of FERPA. The Michigan FOIA also permits withholding of health records subject to HIPAA protections. In addition, the [Confidential Research and Investment Information Act \(CRIIA\)\(MCLA 390.1551-1557\)](#) offers some exemptions from disclosure for some sensitive materials provided by research partners and sponsors. If research records protected by a CoC are requested under FOIA, the researcher should consult with HRPP and OGC about how to proceed to protect the records from disclosure.

2. Mandatory Reporting Abuse, Neglect, and Violence

Michigan has enacted laws designed to protect children and vulnerable adults from harm by requiring various professionals to report suspected abuse or neglect.

The following is a description of Michigan laws on mandatory abuse, neglect, and domestic violence reporting. When a researcher can reasonably anticipate that mandatory reporting requirements will

be triggered during a project (e.g., where the researcher is a mandatory reporter and (i) members of these vulnerable populations are likely to be recruited to participate in the study or (ii) the researcher plans to explicitly question subjects about any history of abuse, neglect, or domestic violence), the informed consent discussion and document should include a description of the researcher's mandatory reporting obligations.

a. *Child Abuse and Neglect (Michigan Child Protection Law [MCL 722.621-722.638](#))*

Under Michigan law, individuals in [certain professions](#) are considered to be mandatory reporters and are legally required to contact Child Protective Services if they suspect child abuse or neglect. Reporting resources are available through the [Michigan Department of Health and Human Services](#).

For any university-sponsored research in which there may be interaction with minors participating as subjects, the University requires adherence to [U-M SPG 601.34](#). The study team members to whom this applies includes the PI, all individuals (faculty, staff, students, or volunteers) who do or may have interaction with minors during the study, as well as their supervisors. This U-M SPG requires reporting actual or suspected child abuse or neglect to the appropriate authorities, regardless of whether the individual is a mandatory reporter under Michigan state law. Mandatory reporters as defined under Michigan state law must also adhere to their mandatory reporting obligations to the Michigan Department of Health and Human Services.

b. *Vulnerable Adults ([MCL 400.11a](#))*

Individuals in [certain professions](#) are considered to be mandatory reporters under Michigan law and are legally required to contact Adult Protective Services if they suspect abuse, neglect, or exploitation of a vulnerable adult. Reporting resources are available through the [Michigan Department of Health and Human Services](#). The term "vulnerable adults" refers to individuals who are unable to protect themselves because of mental or physical impairment or because of advanced age.

c. *The "Gun and Knife Law" ([MCL 750.411](#))*

Michigan law requires hospitals, pharmacies, and their managers to report immediately to law enforcement authorities any person brought to these facilities with a wound or other injury inflicted by means of a knife, gun, pistol, or other deadly weapon, or by other means of violence (which has been interpreted to include sexual assault). It likewise requires physicians treating patients with these types of injuries to report. See [Michigan Medicine Disclosure of PHI for Law Enforcement Purposes Policy, 01-04-313](#) (UMMS Level 2 login required for link).

3. Court Orders and Subpoenas

A court order, administrative agency record request, or subpoena may be issued to require an institution (such as a hospital or university) or an individual (such as a researcher) to give testimony or to provide documents related to a case or other controversy. These documents may require the release of confidential research records or clinical information. A University faculty, staff member, or trainee who receives a subpoena or court order related to University research should consult with OGC.

D. Additional Protections for Vulnerable Populations

1. Research Involving Prisoners and Other Detained Persons

Michigan law ([Mich. Admin. Code R. 791.733](#)) requires correctional facilities to implement policies to prohibit the use of inmates for “medical, pharmaceutical, or cosmetic experiments.” This prohibition does not apply to individual treatment of an inmate based on the need for a specific medical procedure that is not generally available outside of the research. An IRB should not approve research that would be prohibited under this regulation, even if a particular facility has failed to implement the required policies.

Refer to [Part 7](#) of this OM for additional information regarding research involving prisoners or other detained persons.

2. Research Involving Pregnant Women, Fetuses, and Neonates

Michigan law ([MCL 333.2685-333.2690](#)) prohibits the use of a live human embryo, fetus, or neonate for non-therapeutic research if the research “substantially jeopardizes” its life or health, based on the judgment of the researcher and the available knowledge at the time of the research. Non-therapeutic research is any scientific or laboratory research or other kind of experimentation or investigation not designed to improve the health of the research subject. Non-therapeutic research is prohibited if the researcher is aware that the embryo or fetus is subject to a planned abortion being performed for any purpose other than to protect the life of the mother. This prohibition does not apply to any diagnostic, assessment, or treatment procedures performed on the fetus with the purpose of either determining the life or status of the fetus or improving the health of either the fetus or the mother.

A dead embryo, fetus, or neonate is not considered a “human subject” for purposes of U-M HRPP oversight. However, Michigan law (MCL 222.2688) permits research on a dead embryo, fetus, or neonate only if the mother grants express written consent. This research is to be performed in accordance with the same standards applicable to research conducted according to the Uniform Anatomical Gift Law.

E. Human Stem Cell Research

In addition to the limitations on embryonic research described above, Michigan law ([MCL 333.16274](#) and [750.430a](#)) prohibits “human cloning,” defined as “the use of human somatic cell nuclear transfer technology to produce a human embryo.” “Human embryo” means a human egg cell with a full genetic composition capable of differentiating and maturing into a complete human being. “Human somatic cell” means a cell of a developing or fully developed human being that is not and will not become a sperm or egg cell. “Human somatic cell nuclear transfer” means transferring the nucleus of a human somatic cell into an egg cell from which the nucleus has been removed or rendered inert.

The Michigan Constitution ([Article 1, Section 27](#)) also describes conditions surrounding research involving human embryos. Generally, the Michigan Constitution permits any research that would be permitted under federal law with some additional limitations and requirements, including:

- No stem cells may be taken from a human embryo more than fourteen days after cell division begins (not including time during which an embryo is frozen);

- The human embryos were created for the purpose of fertility treatment and, with voluntary and informed consent, documented in writing, the person seeking fertility treatment chose to donate the embryos for research; and;
- The embryos were in excess of the clinical need of the person seeking the fertility treatment and would otherwise be discarded unless they are used for research; or the embryos were not suitable for implantation and would otherwise be discarded unless they are used for research.
- No person may, for valuable consideration, purchase or sell human embryos for stem cell research or stem cell therapies and cures.

F. Document Control and Record Retention and Destruction

Document retention obligations may vary depending on the nature of the research and the academic unit with which the PI is affiliated. Generally, the most restrictive requirement applicable to a particular research record should be applied. Record retention requirements that may apply to research records include the following:

- For any clinical research or other research involving the collection or use of protected health information (i.e., information subject to HIPAA requirements), the general rule of thumb is that records must be retained at least 6 years after the last intervention or interaction with subjects ([45 CFR 164.530\(j\)](#)).
- For FDA-regulated research, records must be retained for a period of:
 - 2 years following the date a marketing application is approved for the drug for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and FDA is notified ([21 CFR 312.57](#)).
 - 2 years after the latter of the following two dates: The date on which the investigation is terminated or completed, or the date that the records are no longer required for purposes of supporting a premarket approval application, a notice of completion of a product development protocol, a humanitarian device exemption application, a premarket notification submission, or a request for De Novo classification.
 - Note: the sponsor may have additional retention requirements ([21 CFR 812.140\(d\)](#))
- All federal grant-related administrative/financial records must be maintained at least 3 years following the end of the grant (or in the case of a repeating 5-year grant, 3 years following the end of the relevant segment) ([2 CFR 200.333](#)). Private sponsors may require longer periods, and this can be determined only by reviewing the sponsorship agreements on a case-by-case basis.
- IRB records should be maintained according to IRB record retention policies.
- Michigan law ([MCL 333.16213](#)) requires that licensed healthcare providers maintain patient records for seven years after the date of service unless a longer federal or state requirement applies. Note: [UMHS Medical Record Retention Policy 03-09-008](#) (UMMS Level 2 login required for link) requires retention of Medical Records for no less than 40 years.
- Because health care fraud and abuse laws allow the government to reach back up to 10 years ([31 U.S.C. 3729](#)), a 10-year retention period is recommended, but not mandated, where feasible for research that may be regulated by these laws.
- For other research, records should be retained for at least 3 years after termination of the study.

G. State Professional Licensing Laws and Institutional Credentialing Policies

Michigan laws limit who may practice in the various health professions, define the scope of practice of various types of licensees (e.g., physicians, nurses, dentists, psychologists, social workers, etc.), and describe whether and to what extent licensed professionals may delegate their functions to unlicensed individuals. Similarly, U-M credentialing and privileging policies and determinations restrict who may practice at U-M and the specific procedures or treatments they are authorized to perform.

Generally, research investigators and research staff may not perform functions for clinical trials that they are not otherwise eligible to perform for non-research purposes. Specific state licensing laws should be consulted if there is any question as to the appropriateness of an individual's functions in the context of a research study. For questions about licensing issues regarding a research project, contact the Office of General Counsel. Note that it may be necessary for OGC to consult with external legal counsel in such situations, which could entail additional expenses for the researcher.

III. INTERNATIONAL RESEARCH

U-M facilitates the conduct of international human research by its faculty, students, and staff. International research frequently poses special concerns for IRBs and PIs to consider when evaluating risks and benefits to subjects and the appropriateness of study procedures. IRB SOPs must describe procedures for obtaining local IRB or ethics committee approval or must describe alternative procedures for seeking input on subject protection when an IRB or ethics board is not available or not necessary based on the research design. Additional requirements may be mandated by research sponsors, U.S. government agencies, and international agencies, depending on the specific location of the research and the nature of the study. The HHS Office of Human Research Protections maintains an online [compilation of international laws](#) and regulations pertaining to human research protections.

PIs are responsible for complying with the ethical and legal aspects of conducting human research in an international setting. This includes compliance with federal laws related to export controls that govern how technology, technical data, technical assistance, and items or materials (from software to satellites and more) are physically or electronically exported, shipped, transmitted, transferred, or shared from the U.S. to foreign countries, persons, or entities. Federal export laws also apply when research participants are residents of embargoed countries, even if the PI or other study team members are not physically located in the embargoed country.

A. World Medical Association (WMA)

The World Medical Association (WMA) is an international organization created to ensure the independence of physicians. A central objective of the WMA is to establish and promote the highest possible standards of ethical behavior and care by physicians. In pursuit of this goal, the WMA has adopted global policy statements, many of which are recognized internationally as the global ethical standards for the topics they address, on a range of issues related to medical professionalism, patient care, research on human subjects, and public health.

One of the WMA's most important policy statements is the [Declaration of Helsinki](#), which outlines ethical principles for medical research involving human subjects, including research on identifiable human material

and data.

B. International Council for Harmonisation Good Clinical Practice (ICH-GCP)

GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting clinical trials that involve human participants. Compliance with the standard provides public assurance that the rights, safety, and well-being of trial participants are protected; consistent with the principles of the Declaration of Helsinki, and that the clinical trial data are credible.

The objective of the [ICH-GCP Guideline](#) is to provide a unified standard for the European Union (EU), Japan, and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions. ICH-GCP is not the law in the United States but has been adopted as guidance by the FDA.

"A sponsor may require, as part of the protocol and study SOPs, compliance with ICH-GCP Guidelines."

If a PI in the research contract agrees to conduct an investigation in full compliance with the investigator obligations under ICH-GCP, any compliance review conducted by the U-M Office of Research Compliance Review (ORCR) will be done against the complete set of ICH-GCP requirements. Investigator obligations under ICH-GCP can be found in U-M HRPP Guidance: ICH-GCP.

C. The General Data Protection Regulation (GDPR)

GDPR is a data privacy regulation intended to protect the personal information of persons physically located within the European Union (EU). GDPR may apply to the collection of personal data during the conduct of a research project if the data are collected from an individual who is physically located within the EU at the time of data collection. GDPR may also apply to the transfer of personal data originally collected under GDPR from an EU country to a non-EU country. U-M researchers should consult with the IRB to determine if GDPR applies to a particular research project. Additional information regarding U-M and GDPR compliance can be found on the [U-M Safe Computing Website](#).

IV. ACCESS TO LEGAL COUNSEL

Members and staff of IRBs and other review units have access to legal advice concerning the application of the laws and regulations that affect human research through U-M's Office of the Vice President and General Counsel (OGC).

PART 12: Quality Assurance, Quality Improvement, and Research Compliance

Describes the Human Research Protection Program (HRPP) quality assurance and quality improvement activities and objectives, reportable events, and research compliance oversight.

I. QUALITY ASSURANCE AND IMPROVEMENT

Quality assurance (QA) is an evaluation of whether or not activities meet defined standards. Quality improvement (QI) is a process initiated to improve a practice or procedure and to institutionalize the practice. QA/QI activities comprise a critical component of the HRPP and play a vital role in protecting the rights and welfare of research participants. They assist in the institutionalization of sound, ethical research design and procedures; promote compliance with laws, regulations, and institutional policies governing the conduct of research; and are critical in the development of a culture that encourages and rewards ethical behavior.

A. Performance Measurement and Quality Assurance

The various University units and functions responsible for the operation of the HRPP identify and communicate legal and regulatory standards and best practices applicable to human research. These are reflected in and communicated throughout the University community in the [University's Standard Practice Guide 303.05](#), this Operations Manual, IRB Standard Operating Procedures, policies and procedures implemented at the individual unit level, mandatory educational modules, and a variety of ad hoc communications.

Performance measurement and quality assurance is an ongoing process and includes the following formal and informal activities:

- Initial and continuing IRB review and monitoring;
- Routine and for-cause study audits;
- Continuing analysis of regulatory developments and sponsor standards, analysis of their application to University research, and integration as appropriate into the HRPP;
- Solicitation, review, and analysis of research participant, researcher, HRPP staff, and other stakeholder feedback;
- Data collection and analysis to identify the cause and determine remediation of identified performance gaps;
- Development and implementation of corrective action plans in response to internal and external investigations and inspections;
- Receipt, investigation, and response to complaints;
- Risk assessment; and
- Accreditation.

B. Quality Improvement

Quality improvement occurs at all levels of the HRPP and includes the following activities:

- Education of the research community through in-person and online training, website development, and dissemination of formal and informal guidance;
- Policy development;
- Significant investment in technological improvements that facilitate workflow integration among and between HRPP entities and that provide "control points" for regulatory compliance; and
- Training and mentoring to provide qualified and experienced IRB staff and IRB membership, compliance and auditing staff, and research team personnel.

The effectiveness of the HRPP's quality improvement initiatives is measured at the study level through post-approval monitoring and at the system level through system-wide audits, accreditation, and other activities to evaluate the effectiveness of HRPP initiatives.

C. Research Compliance Review

To assist with both quality assurance and quality improvement activities, the University established the [Office of Research Compliance Review \(ORCR\)](#). ORCR's mission is to facilitate safe, ethical, efficient, and high-quality human research. ORCR activities include conducting compliance reviews of research studies, IRBs, and other HRPP components, participating in and leading various HRPP working groups, and coordinating accreditation efforts.

ORCR compliance reviews are divided broadly into routine and for-cause reviews of research studies and are described in the [ORCR SOPs](#). Generally, ORCR activities are conducted according to a work plan that is developed annually and outlines compliance measures and objectives.

Through the various activities, ORCR conducts objective analysis and evaluation of research activity compliance for studies and the HRPP as a whole. Outcomes of ORCR reviews inform quality assurance and drive systemic improvements.

In addition, ORCR issues an annual report that includes a summary of quality assurance activities and recommendations for quality improvement. Identified performance gaps and priorities for quality improvement are discussed at HRPP leadership meetings.

II. REPORTABLE EVENTS: ADVERSE EVENTS, UNANTICIPATED PROBLEMS, NONCOMPLIANCE, SUSPENSIONS, AND TERMINATIONS OF IRB APPROVAL

A. Background

It is a condition of the [University of Michigan Federalwide Assurance of Protection for Human Subjects \(FWA\)](#) that the institution have written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, the head (or designee) of any federal department or agency conducting or supporting the research, and any applicable regulatory bodies, including the HHS OHRP, or the FDA for research subject to FDA oversight, of any:

- Unanticipated problems involving risks to research participants or others;
- Serious and/or continuing noncompliance with the federal regulations or the requirements or determinations of the IRB(s); and

- Suspension or termination of IRB approval.

B. Definitions

1. Adverse Events (AEs)

OHRP defines an AE as “any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject's participation in research, whether or not considered related to the subject's participation in the research.” Further, “adverse events encompass both physical and psychological harms. They occur most commonly in the context of biomedical research, although on occasion, they can occur in the context of social and behavioral research.”

In the context of multi-site studies, OHRP further defines internal and external AEs from the perspective of a particular engaged institution, where internal AEs are those AEs experienced by participants enrolled by researcher(s) at that institution, and external AEs are those AEs experienced by participants enrolled by researcher(s) at other institutions engaged in the study ([OHRP, Unanticipated Problems Involving Risks & Adverse Events Guidance, 2007](#)).

The FDA defines an AE as "any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related" ([21 CFR 312.32](#)). Part 812 uses the term unanticipated adverse device effect for device studies, defined in 21 CFR 812.3(s).

2. Unanticipated Problems (UAP)

OHRP considers unanticipated problems, in general, to include any incident, experience, or outcome that meets all of the following criteria:

It is “unexpected” in terms of its nature, severity, or frequency given 1) the research procedures described in the protocol-related documents, such as IRB-approved research protocol and informed consent documentation; and 2) the characteristics of the subject population being studied;

It is “related” or “possibly related” to the participation in the research; meaning there is a reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research; and

It suggests that the research places subjects or others at greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. ([OHRP, Unanticipated Problems Involving Risks & Adverse Events Guidance, 2007](#))

The FDA indicates an AE observed during the conduct of a study should be considered an unanticipated problem involving risk to human subjects, and be reported to the IRB, only if it is unexpected, serious, and would have implications for the conduct of the study (e.g., requiring a significant, and usually safety-related, change in the protocol such as revising inclusion/exclusion criteria or including a new monitoring requirement, or revisions to the informed consent or investigator's brochure). An individual AE occurrence ordinarily does not meet these criteria because, as an isolated event, its implications for the study cannot be understood. ([FDA, Guidance for Clinical Investigators, Sponsors, and IRBs - Adverse Event Reporting to IRBs, 2009](#))

Although all unanticipated problems are either AEs or Other Reportable Information or Occurrence (ORIOs), not all AEs and ORIOs are unanticipated problems.

3. Unanticipated Adverse Device Effect (UADE)

The FDA's Investigational Device Exemption (IDE) regulations define an UADE as "any serious adverse effect on the health or safety or any life-threatening problem or death caused by, or associated with, a device, if that problem or death was not previously identified in nature, severity or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects." ([21 CFR 812.3\(s\)](#))

4. Suspension

Suspension of an IRB-approved protocol is when an approved protocol is partially or completely halted by the IRB pending future action by the IRB or other regulatory entity to protect research participants. If the IRB is undertaking further inquiry, a voluntary "hold" during this fact-finding period does not constitute a suspension of IRB approval for purposes of the HRPP reporting to external agencies or sponsors.

5. Termination

Termination of an IRB approval is defined as an ending of all activities related to human participant research or a PI's privilege of conducting human participant research except for the continuation of follow-up activities necessary to protect human participant safety as a result of direct action by the IRB. A request from a PI to terminate IRB approval at the end of a study's defined approval period, or any other earlier point during the approval period, does not constitute a termination of IRB approval for the purposes of the HRPP reporting to external agencies or sponsors.

6. Noncompliance

The failure of a person or organization to act in accordance with the requirements of a law, regulation, policy, or the requirements and/or determination of an IRB.

7. Serious Noncompliance

Noncompliance that materially increases risks or causes substantive harm to research participants or materially compromises the rights or welfare of participants, including consideration of the following:

- Harm to participants;
- Exposure of participants to a significant risk of substantive harm;
- Compromised privacy and confidentiality of participants;
- Willful or knowing research misconduct on the part of the researcher;
- A violation of ethical principles for human research; or
- Damage caused to the scientific integrity of the data collected.

8. Continuing Noncompliance

Noncompliance that recurs after a researcher has been notified of a similar or related noncompliance

concern pertaining to one or more protocols.

9. Allegation of Noncompliance

An unconfirmed report of noncompliance.

C. Roles and Responsibilities for Required Reporting of Reportable Event

This section outlines the general roles and responsibilities related to reportable events. Additional descriptions of reporting procedures related to noncompliance are included in section III of this part.

1. Researchers

The PI of any research project is responsible for tracking, documenting, and reporting AEs and ORIOs, including self-identified noncompliance to the IRB overseeing that project, and must understand the nature and significance of unanticipated problems. PIs must follow IRB reporting guidelines of U-M IRBs and external IRBs (non-U-M) overseeing the research.

Information that must be reported to the U-M IRB, along with the timelines for reporting, is posted on each U-M IRB's website. All reportable information is submitted by researchers through the eResearch Regulatory Management (eRRM) system for review by the U-M IRB, and must include a detailed description of the events, the researchers' assessment, any actions taken, and supporting documents.

In addition, PIs must forward to the U-M IRB any inspection, audit, or investigation reports issued by internal or external sponsors or oversight authorities as required by U-M IRB policies or by a study-specific reporting plan approved by the U-M IRB. The key responsibilities of researchers are described in more detail in [Part 6](#) of this manual.

When a non-U-M IRB is overseeing the project, the PI must also follow the reporting requirements of the non-U-M IRB. The following section describes the roles and responsibilities of U-M IRBs related to reportable events.

2. The IRBs

IRBs must require, through SOPs or other policies or guidelines, the reporting of specified AEs and ORIOs in accordance with a defined process and timetable.

The IRB SOPs explain the timing and methods by which all reports submitted by researchers are reviewed. Generally, IRB staff members conduct the initial review of a report to ensure completeness and to make a preliminary assessment of whether the report meets the OHRP's or FDA's definition of potential unanticipated problem (including those reports not characterized by the researcher or sponsor as an unanticipated problem), or when the report represents a serious, unexpected, and related adverse event. Reports of concern are forwarded for prompt review to an IRB member with expertise for assessment or to the IRB Chair, who may act on behalf of the IRB for such a review.

The IRB Chair is authorized to take immediate action to protect the health and safety of research participants. Such action may take the form of: (i) asking the researcher to voluntarily impose a hold on the recruitment of participants to facilitate further inquiry by the IRB and/or institutional officials; (ii) asking the researcher to voluntarily impose a hold on the recruitment and research intervention to

facilitate further inquiry by the IRB and/or institutional officials; (iii) suspending recruitment or enrollment; (iv) altering or suspending current interventions; or (v) terminating the IRB's approval of the project.

Any such action of the IRB chair will be documented in the IRB research record immediately. If the IRB Chair imposes a partial or complete suspension, the IRB Chair will promptly (i.e., no later than three business days) report the suspension to the HRPP Director. The IRB Chair shall report any such action taken to the convened IRB at its next regularly scheduled meeting.

While the IRB is undertaking further inquiry, any voluntary "hold" during the fact-finding period does not constitute a suspension of IRB approval for purposes of the HRPP reporting to external agencies or sponsors.

A convened IRB will review reportable events occurring on studies under its direct oversight as well as reportable events that are potential UAPs (internal and external), potential serious adverse events, and potential serious and/or continuing noncompliance from studies that are otherwise reviewed via the expedited procedure. The IRB may endorse the interim action by the chair, if any, or may take a different action or additional actions. In the event immediate action is not required to protect the health and safety of research participants, any of the above actions must be approved in advance by a vote of the IRB.

3. Institution

If the IRB determines that a submitted report is a UAP, the IRB will follow the methods for prompt reporting described in their SOPs. Generally, required reports to federal agencies for unanticipated problems will be made promptly (i.e., not to exceed one month, absent special circumstances, such as the need for extensive data gathering or analysis).

If the IRB makes a determination of suspension or termination, it will promptly (i.e., no later than three business days) inform the HRPP Director. The HRPP Director will promptly (i.e., not to exceed one month, absent special circumstances, such as the need for extensive data gathering or analysis) notify federal agencies and sponsors as required by regulations or agreements and provide notification to the Institutional Official (IO), the IRB, the Associate Vice President for Research, the PI, and other institutional and external entities as needed. The following information will be included when making required reports to federal agencies:

- Title of the research project and/or grant proposal in which the problem occurred;
- Name of the PI on the protocol;
- Number of the research project assigned by the IRB and the number of any applicable federal awards (e.g., grants, contracts, or cooperative agreements);
- A detailed description of the problem; and
- Actions the University is taking or plans to take to address the problem (e.g., revise the protocol, suspend subject enrollment, terminate the research, revise the informed consent document, inform enrolled participants, increase monitoring of participants, etc.)
- Reports are shared with other sites involved in research, when appropriate.

III. COMPLIANCE OVERSIGHT

A. Background

The HRPP promotes an organizational culture that encourages a commitment to compliance with the legal, regulatory, and ethical principles that govern human research. The program relies on a system of self-regulation and integrated oversight to accomplish this objective. The IO strives to promote and enforce the program consistently throughout the organization and ensure its acceptance. This is achieved by maintaining the utmost respect for individuals, clearly communicating expected behaviors, fostering principled reasoning based on shared values, and recognizing shared responsibilities.

The following section describes the circumstances under which allegations of noncompliance may and must be reported and the process for reporting, the protections afforded individuals who make reports, and the process for investigating and responding to reports. Although all complaints and concerns related to the HRPP or the conduct of individual studies are reviewed, they may not all involve noncompliance.

B. Noncompliance Review Procedures

1. Process Summary

Generally, reports of potential noncompliance related to specific research projects are first reviewed by the responsible IRB and its compliance staff. IRBs may take interim actions as noted in their SOPs, including suspension of research to protect research participants while a concern is under review. Any suspension or termination of research is reported to the HRPP Director, so that the required external reports can be made. If, after initial review, the IRB decides that the report may represent serious and/or continuing noncompliance, it reports the case to the HRPP Director. The HRPP Director may conduct additional fact-finding using the resources of the [Office of Research Compliance Review \(ORCR\)](#) and additional faculty input as needed. When the IRB makes a final determination of serious and/or continuing noncompliance, it reports the determination to the HRPP Director, so that the HRPP Director may make the required external reports.

The review procedures described in this section are followed for all complaints or allegations of noncompliance, including reports of attempts to exercise undue influence over IRB staff or members or HRPP administrator, described in [Part 1.V](#) of this manual.

Complaints that are not related to a specific research project may be directed to the IRB Chair, the HRPP Director, or the nearest organizational entity. All inquiries are taken seriously and are directed to the appropriate personnel while following procedures to promote a fair and objective outcome.

2. Policy Against Retaliation for Reporting

Consistent with the requirements and spirit of the [Michigan Whistleblowers Protection Act](#), a University employee may not be discharged, threatened, or otherwise discriminated against (with respect to compensation, terms, conditions, location or privileges of employment) because the employee made a report (or is preparing to make a report) of a violation or suspected violation of applicable human research laws or regulations, University policy, or IRB requirements, unless the employee knew the report was false or materially misleading. Any violation of this policy must be reported to the University. The [University's Compliance Hotline](#) is one option that permits confidentiality of the reporter to be maintained.

C. How Compliance Concerns are Brought Forward

All researchers, research review units, and their staff are responsible for maintaining the integrity of the HRPP. Accordingly, all are expected to report identified compliance concerns, including concerns of coercion or undue influence.

Complaints or allegations of noncompliance may be made by participants or their representatives, faculty, staff, or others engaged in research or responsible for related University oversight activities. Written informed consent documents provide a contact phone number that research participants or their representatives may call to discuss concerns or complaints regarding research studies. The [University's HRPP](#) website and individual IRB websites also provide the telephone numbers and email contacts for IRB staff members. In addition, the University provides anonymous reporting through the [Compliance Hotline](#). As described in detail in [Section D below](#), faculty and staff are obligated to report noncompliance concerns.

Allegations of noncompliance are normally reportable directly to the IRB with jurisdiction over the relevant research protocol but may be transmitted directly to the HRPP Director, the IO, ORCR, the Office for the Vice President and General Counsel (OGC), the Director of University Audits, the [Compliance Hotline](#), or to other institutional officials (such as the appropriate dean, director, or department head). The recipient of any allegation, complaint, or other concern must forward this information to the IRB with jurisdiction over the study or studies. If the concern relates to the conduct of an HRPP subsystem that is not affiliated with a specific IRB, the concern should be forwarded to the HRPP Director. The IRB SOPs will contain, at a minimum, expected timeframes for addressing allegations of noncompliance and provisions for exceptions to these timeframes in extenuating circumstances.

Allegations of noncompliance may also emerge through audits by the IRBs or ORCR, site visits, or audits by regulatory agencies, such as FDA or research sponsors or their agents. If a complaint or allegation is received by any of these methods, it must be forwarded promptly to the responsible IRB for prompt initiation of established IRB-level review procedures. The HRPP Director will decide on the appropriate initial review location for concerns about noncompliance by the IRBs themselves or by other HRPP components.

Any complaint or concern identified by OHRP about human research conducted at or by the University will, per OHRP policy, be directed in the first instance to the IO. The HRPP Director is delegated primary responsibility for assuring appropriate internal investigation and response to any such report and will seek the assistance of the IRBs and ORCR in fulfilling this responsibility.

D. Receipt and Initial Handling of Allegations of Noncompliance

The IRB, through appropriate members and/or staff (and consistent with locally adopted SOPs, if any), will initiate a fact-finding review. The IRB Director determines whether the complaint or allegation of noncompliance is reportable immediately to the IRB Chair(s) for a determination of potential serious and/or continuing noncompliance. If the IRB Director concludes that the concern is clearly without merit or that the conduct in question (i) does not constitute serious and/or continuing noncompliance; and/or (ii) can be addressed through minor corrective action agreed to by the PI or other involved parties, the matter may be appropriately addressed and closed.

Noncompliance that does not rise to the level of potentially serious or continuing is handled by the IRB

following their SOPs.

The following Sections E to H describe the process for handling noncompliance that is potentially serious or continuing.

E. Chair and Board Considerations and Determinations

Potential noncompliance, particularly if the conduct in question might constitute serious and/or continuing noncompliance, is referred to the IRB Chair(s) for additional review. The IRB Chair(s) must perform or make arrangements for any additional fact-finding necessary to make an initial determination. In reviewing the alleged noncompliance, the Chair(s) may request a meeting with the PI and others to discuss the allegations and provide an opportunity for the study team to answer any questions.

While the investigation is taking place, the Chair(s) may request a researcher to voluntarily "hold" new research participant accrual or research-related interventions during the fact-finding period, unless doing so would place participants at risk of immediate harm or otherwise jeopardize their course of treatment. Such a voluntary hold does not constitute a suspension of IRB approval for purposes of the HRPP reporting to external agencies or sponsors. Any Chair, consultant, IRB member, or staff person with an actual or apparent conflict of interest associated with the research or must recuse themselves from involvement in the matter.

After reviewing any relevant information gathered about the alleged noncompliance, the Chair(s) must make a preliminary assessment as to whether or not it has caused injury to a subject, represents an unanticipated problem involving risks to participants or others, or whether or not it constitutes potentially serious and/or continuing noncompliance with IRB determinations, applicable regulations, or HRPP policies. If the Chair(s) determines that the conduct does not represent serious or continuing noncompliance, the Chair(s) may determine the relevant parties to develop an appropriate corrective action plan.

If the Chair(s) determines that the conduct represents potentially serious and/or continuing noncompliance, the matter (together with sufficient background to facilitate an informed discussion and decision) must be referred to the convened IRB for review and discussion of the findings, recommendations regarding corrective actions (examples described below), and vote to approve the recommended actions. The convened IRB may request additional information for consideration before proceeding to a vote. The results of the convened IRB meeting will be provided to OVPR within one month, absent extenuating circumstances.

F. Actions of the HRPP Director as Delegated by the IO

When the HRPP Director receives a report from an IRB (or from another source regarding an issue outside a U-M IRB's jurisdiction), he or she will review the report and determine whether additional investigation is needed. If so, the HRPP Director will, directly or through a designee, conduct the investigation or require that one be completed through the relevant academic unit, research review unit, or the ORCR. Upon completion of such an investigation, a report must be drafted (with specific recommendations for corrective action, if merited) within a time specified by the HRPP Director. Upon receipt of the report, the HRPP Director together with the DIO, IO and in consultation, as appropriate, with the relevant IRB and other interested parties, may determine that no further action is needed; or may take any other action appropriate under the circumstances.

References to the HRPP Director in [Part 12](#) of the Operations Manual also encompass any qualified individual designated in this role during the unavailability of the HRPP Director.

G. Response to Determinations of Noncompliance

Each IRB, as well as the IO and other institutional authorities, has the authority at any time to suspend or terminate approval of human research that is not being conducted in accordance with applicable laws and regulations, institutional policy, or an IRB's requirements, or that has been associated with unexpected serious harm to participants or others, or that for any other reason is believed to impose unreasonable risks on participants or others.

Other sanctions or corrective actions may be imposed on the conduct of the research or study team in response to findings of noncompliance, depending on the severity and nature of the noncompliance. Examples include the following:

- Development and implementation of case-specific corrective action and mitigation plans;
- Protocol modification or termination;
- Modification of the continuing review schedule;
- Monitoring of the consent process;
- Notifications to or re-consenting of participants;
- Recommended or mandatory education or mentoring requirements;
- One-on-one mentoring;
- Regular or remedial IRB courses;
- Additional online training modules;
- Additional professional certification;
- Attendance at regional/national meetings/seminars;
- Increased monitoring or oversight; and
- Random or targeted audits.

The IO may institute any or all of the following additional sanctions:

- Embargo or destruction of research data;
- Refunding improperly billed/incurred costs;
- Notification to publishers with present or past submissions of circumstances of noncompliance and status of data;
- Faculty or staff suspension from engagement in University research; and
- Other disciplinary sanctions up to and including dismissal (in consultation, where required by University policy, with other appropriate institutional authorities and subject to any additional University due process requirements).

H. Institutional Notification and Reporting Requirements

In the event the U-M IRB votes that the alleged noncompliance constitutes serious and/or continuing noncompliance, the IRB must ensure the prompt (i.e., no later than 3 business days) reporting of this information to the HRPP Director. The HRPP Director must ensure prompt (i.e., not to exceed one month, absent special circumstances, such as the need for extensive data gathering or analysis) reporting to

government authorities with jurisdiction and to sponsors to the extent required by any relevant regulations, grants, or contracts. In addition, reports are made to other entities including accrediting bodies as required. The HRPP Director will provide notification of external reporting to the IO, DIO, the IRB, the VPR, the PI, and other institutional entities as indicated.

If the IRB determines that alleged noncompliance is neither serious and/or continuing, the IO may accept the IRB determination, may reject the determination and report externally as required, or conduct an additional investigation of the allegation.

Part 13: Education and Training

Describes educational resources available at the University and outreach activities to research participants and their communities.

I. EDUCATION IN GENERAL

The University of Michigan (U-M) and its faculty, staff, and trainees are committed to complying with the laws and regulations governing the review and conduct of human research and upholding the highest ethical standards. To help achieve this and ensure the protection of research participants, the University requires a basic level of human research protection education and provides a variety of educational activities designed to enhance the understanding of protection for research participants at all levels including leadership, IRB members, staff, researchers, research staff, and communities.

A. Required Education

U-M has developed an online Program for Education and Evaluation in Responsible Research and Scholarship ([PEERRS](#)) required for designated University faculty and staff, students, and collaborators involved in human research. PEERRS offers a Human Subjects Research Protections eLearning course that fulfills regulatory requirements for training in the protection of research participants in research. This course is modeled on the Collaborative Institutional Training Initiative (CITI) Human Subjects Research modules. Certification in the PEERRS course is granted for three years from the last date the user passes a certification test. Completion of this course for all designated study team members is a requirement for initial IRB approval, and the status of PEERRS certification is monitored through the IRB process, with reminders of lapsed or missing certification provided by the IRB.

Good Clinical Practice (GCP) training is required for all researchers and research staff involved in the conduct, oversight, or management of NIH-funded clinical trials and for studies conducted under GCP requirements. GCP training must be completed every three years or sooner if required for the conduct of a specific study.

Individuals may be required to complete additional training depending on the scope and nature of the specific research. Additional information on training requirements and resources is available on the [Human Research Protection Program \(HRPP\) website](#).

II. TRACKING AND COMMUNICATING NEW DEVELOPMENTS

University officials responsible for regulatory compliance are made aware of new legal and policy developments through a variety of sources, which include: membership in professional associations; participation in and assumption of leadership roles with professional organizations; participation in relevant electronic listservs; access to electronic regulatory, legislative, and analytical resources; and attendance at regional and national educational conferences. Government Relations representatives keep regulatory compliance staff apprised of relevant pending legislation and regulatory activities, and the Office of the Vice President for Research and General Counsel assists in providing analysis of these developments.

University officials, in turn, notify the research community of relevant developments through multiple

mechanisms, including policy revisions, changes to application forms and guidelines, newsletters, educational sessions, web postings, and other communications, as necessary to promote ongoing compliance.

HRPP leadership is linked to institutional functionality through membership on committees such as the Conflict of Interest Review Committees and the Human Pluripotent Stem Cell Research Oversight (HPSCRO) Committee. IRB leadership and staff representatives also serve on committees and provide direction regarding eResearch initiatives. This integrative approach facilitates communication of new legal and policy developments throughout the HRPP organization.

III. IRB CHAIRS, MEMBERS, AND STAFF EDUCATION

IRB Chairs, members, and staff are trained through a detailed orientation procedure to provide them with the knowledge and skills to effectively discharge their duties and uphold the federal and local laws, University policies, and ethical standards on research with research participants. Continuing education for IRB staff and members is also required and is provided in the form of workshops, presentations, national webinars, and printed and electronic materials that are shared on an ongoing basis.

The IRB SOPs describe the initial orientation procedure, continuing education requirements, and evaluations of IRB Chairs, members, and staff.

IV. RESEARCHERS AND RESEARCH STAFF EDUCATION

A. IRB Educational Activities

The U-M IRBs are committed to providing educational activities that supplement required training for human research protection and are tailored to meet the ongoing educational needs of the research community. The activities are designed to improve the understanding of regulatory requirements, IRB application completion, and special topics related to research with research participants. Websites of the U-M [IRBMED](#) and [IRB-HSBS](#) provide detailed descriptions of the educational offerings as well as access to online materials.

B. MICHR Educational Activities

[MICHR](#) (Michigan Institute for Clinical & Health Research), the university's NIH-funded clinical and translational science award, supports clinical research at the University through education and study management services. MICHR offers an extensive selection of courses, workshops, and seminars to the U-M research community, designed to meet the needs of students, faculty, and staff. The educational offerings include: pre-doctoral, post-doctoral, and study coordinator programs; mentoring; and general education.

The MICHR website has a full description of the offerings and a [calendar of events](#).

C. Additional Educational Activities

Ongoing educational activities and events are available through individual colleges, schools, departments, and institutes of the University. Such activities promote compliance and continually enhance the

knowledge of human research protections of the U-M research community. Individual schools and departments maintain a list of educational activities and events on their websites and/or in newsletters.

V. RESEARCH PARTICIPANTS AND THEIR COMMUNITIES: ENGAGEMENT, EDUCATION, AND OUTREACH ACTIVITIES

A. General Research Communications

The U-M HRPP is committed to promoting public awareness and trust in research through outreach efforts designed to enhance the understanding of research by participants, prospective participants, and their communities. The HRPP website presents [Information to the Public](#), including key considerations in protections for research participants, frequently asked questions, and a list of resources and related links. Information about progress in research is regularly distributed through the [U-M news service](#), including the [University Record](#), [Michigan Today](#), [Michigan Radio](#), and [Michigan Medicine News](#). In addition, continuous campus events showcase research for local, national, and international audiences.

B. Research-Specific Communications

When participant consent is not feasible in the context of research involving imminent life-threatening circumstances, the IRB may approve Emergency Research with Exception from Informed Consent (EFIC) under [21 CFR 50.24](#). Community Consultation Plans (including, where appropriate, consultation carried out by the IRB) are reviewed and approved in the course of the IRB review of EFIC research and may include consultation with representatives of the communities in which the clinical investigation will be conducted and participants will be drawn.

C. MICHR's Community Engagement Program

Several initiatives have been established by MICHR to foster the involvement of community members in human research activities at the U-M.

[The Community Engagement Program](#) was established with the specific goal of involving the community's expertise and knowledge in improving the quality of U-M clinical health research and producing outcomes that measurably benefit the health of the local communities. Involving the community in the design and conduct of programs helps ensure that research participants understand intervention content and that research questions are reliable and valid.

The Community Engagement Program focuses on facilitating the ability of research teams to:

- Develop and maintain robust partnerships emphasizing power-sharing processes to ensure research priorities directly reflect community and practitioner needs;
- Partner with community members, community-based organizations, and practice networks to stimulate and sustain a robust program of community-based participatory research and implementation/translation science; and
- Accelerate the dissemination and implementation of research results across healthcare systems, practitioners, and communities.

MICHR achieves these goals through programs that train researchers, practitioners, and community

partners in community engagement, community-based participatory research methods, cultural sensitivity, and implementation science.

D. UMHealthResearch.org

MICHR has also established the [U-M Health Research website](#) to educate the community on research opportunities at the U-M and facilitate participant recruitment in clinical research. Interested study participants may use the tool to search for open research studies at the U-M using various parameters, express interest in studies, communicate securely with study teams, and receive personalized study recommendations. Study teams, in turn, may use the tool to search for eligible study participants.

The U-M Health Research website is also described in a brochure that is distributed in U-M health clinics, at various outreach events, and by community partners.

E. Additional Community Engagement Initiatives

Colleges, schools, departments, and other units throughout the University and the Health System have initiatives geared toward increasing and improving community involvement in research with research participants. Individual schools and departments maintain a list of educational activities and events on their websites and/or in newsletters.

F. Evaluation of Community Outreach Programs

While each of the programs listed above has internal processes for evaluating their outreach activities, the HRPP also utilizes evaluations and surveys to solicit feedback from both the broader research community and research participants.

HRPP OM Revision Table

Date Updated	Part(s) Updated	Summary of Changes
7/28/2020	Part 1, 2, 5, 8	<ul style="list-style-type: none"> Updated references to Flint IRB panel. DIO title was updated. Language referencing FDA Part 11 (Electronic Records) in Part 8 was updated.
10/7/2021	Part 2, 3, 6, 7, 12, 13	References to IRB Council were changed to HRPP Advisory Council in Parts 2, 3, 12 and 13.
1/28/2022	Part 2 and 9	<ul style="list-style-type: none"> Changes in HRPP organization and leadership were updated in Part 2. Reference to The Office of Technology Transfer (OTT) were updated to Innovation Partnerships in Part 9.
6/9/2022	Part 4	U-M Exemption Category 5 language was updated.
4/13/2023	Part 4 and 8	Clarification about Agency Fund Activities. Updated to describe IRB process for emergency use of investigational article.
3/31/2025	Part 2	<ul style="list-style-type: none"> Revised language regarding roles of DIO and HRPP Director due to restructuring. Added information about the Coordinated Services and Practice Unit. Removed reference to HRPP Advisory Council as the current committee was sunnedowned.
3/31/2025	Part 3	Added additional examples as to who is considered “affiliated” and “unaffiliated” for IRB membership.
3/31/2025	Part 5	<ul style="list-style-type: none"> Reorganized section to better identify responsibilities of U-M IRB when serving as sIRB.

		<ul style="list-style-type: none"> Added new information about research with U-M Health Network of Care Sites.
3/31/2025	Part 6	<ul style="list-style-type: none"> Clarification regarding eResearch roles for study team members. Clarification of external collaborator roles on U-M research, including collaborators from U-M Health Network of Care Sites. Added requirements regarding storage of informed consent documents and signature/date requirements for informed consent documents.
3/31/2025	Part 7	Clarification that additional protections for adults with cognitive impairment or impaired decision making only apply when the participant lacks the capacity to provide informed consent.
3/31/2025	Part 8	Update to reflect oversight of expanded access moved from MIAP to Research Pharmacy.
3/31/2025	Part 11	Clarified language regarding mandated reporting for child abuse and neglect.
11/14/2025	Part 2	Added additional information on resourcing for the HRPP.
11/14/2025	Part 3	Updated to include link to OHRP guidance on informed consent requirements in Emergency Research.
11/14/2025	Part 5	<ul style="list-style-type: none"> Clarification that all applicable federal human subjects research regulations or policies apply to the review of IRB submissions at all sites. Included language specifying what requirements apply to an external organization when U-M cedes non-IRB review functions.
11/14/2025	Part 9	<ul style="list-style-type: none"> Updated to include where results of committee reviews are

		<p>documented.</p> <ul style="list-style-type: none">• Language was added to specify that federal regulations might require management to include a retrospective review and mitigation report.
11/17/2025	Part 4	<ul style="list-style-type: none">• Clarification added regarding requirements for 'Not Regulated' projects conducted outside of the University.